

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046966
Article Type:	Original research
Date Submitted by the Author:	15-Nov-2020
Complete List of Authors:	<p>Zhao, Nan; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Xu, Jing-can; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Qihong; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha</p> <p>Li, Xinyi; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Nursing School of Central South University</p> <p>Chen, Jiarui ; Central South University Xiangya School of Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Jing; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing</p> <p>Zhou, Feng; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Hospital Central South University, Department of Emergency</p> <p>Liang , Jinghong; Sun Yat-Sen University, 6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen</p>
Keywords:	Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Diabetic foot < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

AUTHORS' INFORMATION

Zhao Nan^{1,2}, Xu Jingcan^{1,2}, Zhou Qihong^{1,4}, Li Xinyi^{1,3}, Chen Jiarui^{2,3}, Zhou Jing¹, Zhou Feng^{1,5}, Liang Jinghong⁶

Zhao Nan 187811023@csu.edu.cn

Xu Jingcan 983556951@qq.com

Zhou Qihong 928555448@qq.com

Li Xinyi 905492390@qq.com

Chen Jiarui chenjr@csu.edu.cn

Zhou Jing zhou-jing62@hotmail.com

Zhou Feng 316925782@qq.com

Liang Jinghong liangjh78@mail2.sysu.edu.cn

1. Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, 410008, China

2. Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group, Changsha, 410013, China

3. Xiangya Nursing School of Central South University, Changsha, 410013, China

4. Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha, 410008, China

5. Department of Emergency, Xiangya Hospital, Central South University, Changsha, 410008, China

6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China

Corresponding author: Xu Jingcan, 983556951@qq.com; Zhou Qihong, 928555448@qq.com

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

ABSTRACT

Objective: Diabetic peripheral neuropathy (DPN) is one of the most important risk factors of diabetic foot ulcers (DFU), and early screening and treatment of DPN is crucial. The Ipswich Touch Test (IPTT) is a new method for screening for DPN and, compared with traditional methods, is more simple to operate and requires no equipment. However, the screening accuracy of IPTT in DPN patients has not been well characterized. We aim to conduct a systematic review and meta-analysis to characterize the sensitivity and specificity of IPTT compared to tradition methods and to understand the potential screening value of IPTT.

Design: Systematic review and meta-analysis.

Data sources: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedical Literature Database (CBM) up to April 16, 2020.

Methods: Sensitivity, specificity, and other measures of accuracy of IPTT for screening DPN were pooled. Subgroup and sensitivity analysis were performed to identify the sources of heterogeneity. The protocol was registered with PROSEPRO (42020168420).

Results: Of 441 records retrieved, seven studies were evaluated for the screening value of IPTT. Five studies with 10g-MF as the reference standard were included in the meta-analysis, and the pooled sensitivity and specificity were 0.78 (95 % CI 0.65–0.87) and 0.95(95 % CI 0.89–0.98), respectively, and AUC was 0.93. Subgroup analysis results showed that the sample size and ethnicity were not the main sources of heterogeneity.

Conclusions: Compared with 10g-MF, IPTT displays high specificity and acceptable sensitivity as a screening tool for DPN. It can be used clinically, especially in remote areas and in primary medical

1
2
3 institutions, and by self-monitoring patients. More high-quality studies are needed to assess and
4
5 promote more effective screening practices.
6
7

8 **Prospero:** Registration Number is CRD (42020168420)
9

10 **Strengths and limitations of this study**

11
12

- 13
14 • This is the first meta-analysis to explore the potential screening value of IPTT in DPN.
15
16
- 17 • The current evidence shows that the discrepancy between previous studies is due to the use of
18 different reference standards by the researchers. With 10g-MF as the reference standard, IPTT
19 displays acceptable sensitivity and a high specificity.
20
21
- 22 • Our research results are likely to have a positive impact on the screening of DPN by different
23 medical institutions, such as in remote areas lacking equipment and personnel, and by self-
24 monitoring patients with diabetes.
25
26
- 27 • By facilitating the identification of patients at-risk for foot ulceration, we can Effectively prevent
28 the occurrence of DFU, and reduce the social and economic burden of this disease.
29
30
- 31 • Although we conducted sensitivity and subgroup analysis to explore the heterogeneity analysis,
32 we were unable to determine the source of heterogeneity.
33
34
35
36
37
38
39
40
41

42 **Keywords:** Ipswich Touch Test, Diabetic peripheral neuropathy, Meta-analysis
43
44

45 **INTRODUCTION**

46
47

48 Diabetic peripheral neuropathy (DPN) is a common long-term complication and the most important
49 risk factor for the occurrence of diabetic foot ulcers (DFU).¹⁻⁴ DPN affects up to 50% of people with
50 diabetes,^{5,6} with chronic painful neuropathy affecting up to 26%.⁷ In the early stage of DPN, the
51 symptoms lack specificity, and about half of patients with diabetes cannot recognize the injury to
52 the lower extremities.^{8,9} Once the patient has symptoms such as limb numbness and pain, it signals
53 that pathological changes have occurred in the peripheral nerves and have advanced into the
54
55
56
57
58
59
60

1
2
3 irreversible stage. If not treated promptly, serious tissue damage, such as foot ulcers, amputation,
4 and even death, may occur.^{10,11} Studies have shown that early screening and detection of peripheral
5 neuropathy can not only slow down the DPN process, but also effectively prevent DFU.¹² Therefore,
6 early screening and treatment of DPN is very important.
7
8
9

10
11
12 At present, the screening value of 10g monofilament (10g-MF), Vibration perception threshold
13 (VPT), and 128Hz tuning fork in DPN has been widely recognized.¹³ Compared with VPT and
14 128Hz tuning forks, 10g-MF is the most widely used screening tool because it is more simple,
15 objective, and easy to carry, although it requires a calibration facility to confirm that the vertical
16 pressure of the monofilament used when bending is 10g.¹⁴⁻¹⁶ Commercially available 10g-MF
17 devices exhibit significant variability within and between devices of different manufacturers and
18 their actual bending force varies widely from their designated 10g value. When used they have a
19 short service life where the instrument is within 10% of their initial bending force which is not
20 usually the stated 10g of force.^{17,18} Meanwhile, medical personnel are required to be trained before
21 using the device, and screening is limited to hospitals or clinics. For clinics and communities in
22 remote areas, medical personnel may lack the device or the training to screen patients for DPN,
23 resulting in a missed opportunity for patients to receive the best treatment. In recent years, Dr.
24 Rayman proposed the Ipswich Touch Test (IPTT), which only requires the physician's index finger.
25 During this test, the patient is required to close their eyes while the physician lightly rests their finger
26 on each of the patient's first, third, and fifth toes for 1 to 2 seconds. Patients are instructed to respond
27 with a "yes" when they feel the physician's touch. Compared with the current methods, IPTT
28 requires no equipment, and is more convenient and effective.¹⁹ Doctors, nurses, and even family
29 caregivers can perform the test after training.¹⁹ It can be applied to inpatients, outpatients,
30 community patients, self-monitoring patients at home, and to areas lacking more advanced
31 equipment.^{20,21} Currently, IPTT has been applied in some countries, and previous studies have
32 reported differences in the results of the screening value of DPN. However, neither a meta-analysis
33 nor a systematic review has been conducted on the screening value of IPTT.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56
57 In this study, we aimed to conduct a comprehensive and systematic literature review to
58 systematically evaluate the potential screening value of IPTT in DPN, and provide evidence and
59
60

1
2
3 guidance for the clinical application value of IPTT.
4
5

6 **METHODS**

7

8
9 The Joanna Briggs Institute (JBI) protocol²² has been registered with PROSPERO, the International
10 Prospective Register of Systematic Reviews hosted by the Centre for Reviews and Dissemination
11 (Registration Number is CRD (42020168420). We followed the Preferred Reporting Items for
12 Systematic Reviews and Meta-Analyses (PRISMA)²³ statements for reporting our systematic
13 review.
14
15
16
17
18

19 **Patient and public involvement**

20

21 No patient involved
22

23 **Data Sources and Searches**

24

25
26 We systematically searched PubMed, Embase, Cochrane Library, Web of Science, China National
27 Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Biomedical Literature Database (CBM)
28 for reports published before to April 16, 2020. For included studies with insufficient data, we
29 emailed the authors to ask if they would provide data for our study. With this strategy, we combined
30 search terms for applied technique (Ipswich touch test, touch test, IPTT) and disease (Diabetic
31 peripheral neuropathy, diabetic foot, diabetic foot ulcer, Diabetes Mellitus, diabetic complications).
32 The study design and published language was not limited. In addition, we conducted a manual search,
33 including searching through conference papers and gray literature, and the references of all included
34 studies were examined. All search strategies were determined by multiple pre-searches, and the
35 search formulas were adjusted according to the characteristics of each database. A detailed search
36 strategy is provided in Appendix S1. All analyses were based on previously published studies; thus,
37 no ethical approval and patient consent were required.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Inclusion and Exclusion Criteria**

54

55
56 Previously published studies were included in this meta-analysis if: (1) the study was designed as a
57 diagnostic test and systematic reviews; (2) all the research subjects were patients with diabetes, and;
58
59
60

1
2
3 (3) IPTT was included as an index test. Studies were excluded from the meta-analysis if the studies
4 had incomplete data sets or were other than original reports (commentaries/reviews). The age, sex,
5 region, and race of the subjects were not restricted. The published language was not limited.
6
7
8
9

10 **Data Extraction**

11
12
13 We imported initial search records from databases into NoteExpress V3.2.0.7535 literature
14 management software. Two reviewers independently screened titles and abstracts of all the included
15 literature, following the inclusion and exclusion criteria. After screening the abstract, the full text
16 was read in detail. Any discrepancies were resolved by discussion. The following information was
17 extracted from the eligible studies: study characteristics (author, publication year, study period,
18 country, reference standard, setting, operators), participant characteristics (sample number, range),
19 and outcome indicators (sensitivity, specificity, true positive number (TP), false positive number
20 (FP), false negative number (FN), true negative number (TN)). Missing data were supplemented by
21 contacting authors wherever possible. Data extraction was performed independently by the two
22 reviewers. Differences were reconciled by discussion until a consensus was reached on the item in
23 question. The methodological quality of the included studies was assessed with the Quality
24 Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2), as the subject of this meta-analysis is
25 determining diagnostic accuracy.²⁴
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Data Synthesis**

41
42
43 The sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and
44 corresponding 95% confidence intervals (95% CIs) were calculated using the TP, FP, FN and TN
45 values, which were extracted from each study prior to data pooling. The likelihood ratio is an
46 independent indicator to assess authenticity, which can simultaneously reflect sensitivity and
47 specificity. When the PLR is >10 or the NLR is <0.1, the probability of diagnosing or excluding a
48 certain disease increases significantly. The likelihood ratio is more clinically significant than
49 summary receiver operating characteristic curve (SROC) and diagnostic odds ratio (DOR) value.²⁵
50
51 The SROC was constructed based on a bivariate regression approach and the pooled estimate for
52 sensitivity and specificity was subsequently calculated. The DOR with 95% CI was also calculated.
53
54
55
56
57
58
59
60

1
2
3 For each summary statistic, a 95% confidence interval was computed. The random effects models
4 in meta-analysis were used to estimate variance between studies by using STATA, version15.1
5 (Stata Corp, College Station, TX).²⁶
6
7
8
9

10 In addition, Fagan nomograms were generated to evaluate the clinical utility of the two screening
11 methods. Heterogeneity among the reports was assessed by the χ^2 test (Cochran Q test) and the I^2
12 statistic, where $p \leq 0.05$ or an $I^2 \geq 50\%$ indicated the existence of significant heterogeneity.²⁷
13 Sensitivity and subgroup analysis were performed to further determine the source of heterogeneity
14 and to determine whether the results are stable and credible.²⁸ Publication bias was assessed with
15 Egger's test. Egger's linear regression test was used to evaluate asymmetry, and $p < 0.05$ was
16 considered to be statistically significant. All statistical tests were 2-sided.²⁹
17
18
19
20
21
22
23
24

25 RESULTS

26 Study Selection

27
28
29 Our initial search resulted in a total of 441 records: 437 from database searching and four records
30 from manual searches of references. After duplicates were removed, 242 records were identified,
31 and 220 records were excluded as irrelevant.³⁰⁻³⁴ After reading the full-text articles, 7 studies met
32 the inclusion criteria (Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-
33 Analyses (PRISMA) flow diagram.). Two studies were excluded for lacking necessary data for
34 meta-analysis. Finally, five studies with 6 datasets were included in the final meta-analysis,
35 involving a total of 1162 patients.
36
37
38
39
40
41
42
43
44
45

46 Characteristics and Quality of the Included Studies

47
48
49 The characteristics of the included studies are presented in Table 1. The 7 studies included a total of
50 1,510 participants with diabetes and were published between 2011 and 2020. 10g-MF, VPT, NDS,
51 pin prick, tuning fork 128Hz, and ankle reflex were used as the reference standard to explore the
52 accuracy of IPTT in DPN. The research setting included homes of patients, clinics, care centers, and
53 outpatient centers, and the assessors included doctors, nurses, and family caregivers.
54
55
56
57
58
59
60

Table 1. Basic characteristics of the included studies.

Study	Year	Country	n	Setting	operators	Reference standard	TP	FP	FN	TN	Se(%)	Sp (%)
Sharma 30	2012	UK	130	home	families	10g-MF	24	4	6	96	80.0	96.0
Sharma 31	2014	UK	331	home	families	10g-MF	65	15	18	233	78.3	93.9
				clinic	doctors/ nurses	10g-MF	67	9	16	239	81.2	96.4
Amal Madanat 32	2015	Saudi Arabia	351	care centers	doctors/ nurses	10g-MF	29	6	28	288	51.0	98.0
						VPT	48	24	9	270	85	92
						NDS	30	9	27	285	53	97
I.S, Basir 33	2020	Spain	100	care centers	doctors/ nurses	10g- MF	4	30	1	65	80.0	68.0
						Pin prick	4	1	11	84	80.0	88.0
						Tuning fork 128Hz	2	3	69	26	40.0	27.0
						Ankle reflex	1	4	2	93	20.0	97.0
Dutra 34	2020	Brasília	250	outpatient centre	doctors/ nurses	10g-MF	30	5	6	209	83.3	97.7
Rayman 19	2011	UK	265	clinic	-	VPT	-	-	-	-	76.0	90.0
Bowling 35	2012	UK	83	clinic	doctors/ nurses	VPT	-	-	-	-	100	96.6
						NDS	-	-	-	-	100	90.3

Se, Sensitivity; Sp, Specificity

We assessed the methodological quality of the studies using QUADAS-2. The risk of bias and applicability concerns were analyzed using Revman5.3. The QUADAS-2 assessment results of the research methodological quality of each study are presented in Figures 2 (Figure 2. Assessment for the risk of bias) and Figure 3 (Figure 3. Assessment for the risk of bias in the included studies).

Overall, risk of bias in both groups of studies was affected by the reference standard. Different studies chose different reference standards, leading to a higher risk of bias. The second factor that led to a high risk of bias was patient selection, particularly where it was a convenience sample. In some studies, patient selection and inclusion criteria were poorly defined or unexplained. In addition, the index test is another factor resulting in a higher risk of bias, as some studies did not describe the target test in detail.

Screening Accuracy

In the included studies, the researchers used a variety of different test methods as the standard to observe the sensitivity and specificity of IPTT for screening for DPN, such as 10g-MF, VPT, NDS, tuning fork 128Hz, and ankle reflex. The differences in the sensitivity and specificity of IPTT obtained by using different test methods as reference standards are presented in Table 1. In general, when 10g-MF and VPT were used as reference standards, the sensitivity and specificity of IPTT were relatively high. For the 5 studies comprising 6 data pools that used 10g-MF as the reference standard, the sensitivity ranged from 51.0% to 83.3%,³⁰⁻³⁴ and the specificity ranged from 68.0 to 98.0%. For the 3 studies that used VPT as a reference standard, the sensitivity ranged from 76.0 to 100.0%, and the specificity ranged from 90.0 to 96.6%. Using neuropathy disability scores (NDS) as the reference standard, Madanat et al. calculated the sensitivity of IPTT to be 0.53, and the specificity to be 0.97. Using pin prick, tuning fork 128Hz, and ankle reflex as reference standards, Basir et al calculated sensitivities of 0.80, 0.40, and 0.20, respectively, and specificities of 0.88, 0.27 and 0.97, respectively (Table 1).

Meta-analysis Results Using 10g-MF as the Reference Standard

Screening Accuracy

Six datasets were included to evaluate the overall effect of IPTT in the screening of DPN. The combined sensitivity and specificity were 0.78 (95 % CI 0.65–0.87) and 0.95 (95 % CI 0.89–0.98), respectively. A visual inspection of the forest plots shows large deviations and heterogeneity (sensitivity: $I^2=73.57\%$, specificity: $I^2=95.88\%$, $p<0.01$) (Figure 4. Sensitivity and specificity of IPTT in the diagnosis of DPN). In addition, the PLR was 15.5 (95 % CI 7.2–33.4), the NLR was 0.23 (95 % CI 0.14–0.38), and the DOR was 67 (95 % CI 32–141). The SROC analysis for the studies yielded an overall weighted area under the curve of 0.93 (95%CI 0.90-0.95) (Figure 5. The SROC curve for quantitative analysis of IPTT in the diagnosis of DPN).

Subgroup Analysis and Sensitivity Analysis

The results of subgroup analysis show that sample size ($n<300$ or $n\geq 300$) and ethnicity (Asian or non-Asian) are not the main sources of heterogeneity (Table 2 or Supplementary Files 2). Sensitivity analysis determined a combined DOR value of 13.12, 95%CI: 10.32-16.66. After excluding each study, the difference between the combined effect and the value before exclusion was minor, suggesting the results of this study are stable (Supplementary Files 3). Fagan's analysis shows that the post-test probability of PLR can be increased by 50%, and when the pre-test probability was 94%, the NLR was reduced to 23%. The above results demonstrate that there is good diagnostic value of IPTT for DPN (Figure 6. Fagan nomogram for assessment of IPTT screening probability).

Table 2. Subgroup analysis results.

Variables	No.	Sensitivity (95%CI)	Weight(%)	Specificity (95% CI)	Weight (%)
Total	6	0.72 (0.68–0.76)	100	0.95 (0.94–0.97)	100
Race					
Asian	2	0.61 (0.34–0.87)	23.51	0.97 (0.54–1.13)	27.89
non-Asian	4	0.80 (0.75–0.86)	76.49	0.96 (0.94–0.98)	72.11
Size					
Total<300	3	0.82 (0.72–0.91)	39.43	0.89 (0.78–1.00)	42.53
Total>300	3	0.70 (0.55–0.87)	60.57	0.97 (0.94–0.99)	57.47

Publishing Bias

The publication bias was visually presented using Egger's test. Egger's test shows $p = 0.289$ (95%CI:

1
2
3 343.8-133.42). This indicated there was no publication bias (Supplementary Files 4 Egger's test for
4 the assessment of potential publication bias).
5
6
7

8 **DISCUSSION**

9

10
11 DPN is the most important risk factor for the occurrence of DFU and one of the more common
12 chronic complications associated with diabetes. However, it is often ignored. Once the patient
13 develops DPN, it is likely to cause diabetic foot ulcers, gangrene, and even amputation, and many
14 patients experience numbness and tingling in their limbs. Early identification of DPN can greatly
15 reduce the burden of chronic diseases on society. In this study, we systematically reviewed the
16 relevant literature on the identification of DPN by IPTT. A total of 7 studies were included,
17 involving 1,510 participants with diabetes to explore the value of IPTT screening. Previous studies
18 have disputed the diagnostic value of IPTT, mainly due to the use of different test methods, such as
19 VPT, NDS, pinprick, tuning fork 128Hz, and ankle reflex, as the reference standard.³³ Compared
20 with NDS, acupuncture, 128Hz tuning fork, and ankle reflex, IPTT has higher screening accuracy
21 when 10g-MF and VPT were used as the reference standard.^{10,19,20} Basir et al. observed that when
22 128Hz tuning fork was used as a reference standard, the sensitivity and specificity of IPTT was only
23 40% and 27%, respectively. This may be due to the fact that the predictive level of a tuning fork is
24 less than that of the monofilament. However, Miller et al observed that combining a tuning fork
25 with monofilament would result in a more effective evaluation.²¹ Regarding the quality of the
26 current studies, some studies lacked rigor in study design, such as the interval between target tests
27 and unclear reference standard tests, and most studies failed to describe the reference methods in
28 detail. The overall quality of the included studies was rated as low to medium quality.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 The results of the meta-analysis found the combined sensitivity and specificity of IPTT to be 0.78
49 (95%CI 0.65–0.87) and 0.95 (95%CI 0.89–0.98), respectively, and AUC to be 0.93 (95%CI 0.90-
50 0.95). The results indicated that IPTT had a moderate to high level of sensitivity and a high level of
51 specificity for diagnosing DPN. In our analysis, a DOR equal to 1 indicated that a test was unable
52 to distinguish between patients with or without the disease. Our study yielded a DOR value of 67
53
54
55
56
57
58
59
60

1
2
3 (95%CI 32–141), indicating that NLR had a certain accuracy in the diagnosis of patients with DPN.
4
5

6 We also drew Fagan's plot, including pre-test and post-test probabilities, which describes the change
7
8 to the IPTT screening of DPN. The results show that IPTT has a certain potential to improve the
9
10 screening efficiency of DPN.
11
12

13 Heterogeneity is an important factor of this meta-analysis. To further explore the source of
14
15 heterogeneity, subgroup analysis was performed based on ethnicity and sample size. However, we
16
17 found that these were not a major source of heterogeneity (Table 2). Sensitivity analysis showed
18
19 that the results of this study are stable, and that high heterogeneity may be a result of other factors,
20
21 such as differences in research methodology, operator, and other factors. We were limited in our
22
23 ability to more fully explore the sources of heterogeneity in the studies due to the underreporting of
24
25 clinical variables, the limited number of reported IPTT studies, the limited overall sample size, and
26
27 the presence of unclear risk of bias.
28
29

30 Studies have shown that routine foot examinations and rapid risk stratification are often difficult
31
32 to implement in busy primary care institutions. Additionally, the lack of awareness of standardized
33
34 testing for DPN amongst healthcare professionals is a concern, which may be due to a shortage of
35
36 material and personnel resources in primary care institutions. This is concerning because identifying
37
38 foot neuropathy and the patients at risk for ulceration has been shown to prevent the incidence of
39
40 foot ulcers.³⁵⁻³⁷ IPTT is a new method for screening DPN that does not require any tools and can be
41
42 carried out after minimal training. It is not affected by time, venue, or its operators.²⁰ The
43
44 advancement of IPTT is of great significance for the early screening of DPN to impede the
45
46 progression of diabetic foot ulcers, as it can be used to quickly and reliably screen and manage
47
48 patients at high-risk for ulceration, especially in remote areas or places lacking screening tools.^{38,39}
49
50 Kerry et al. reported that, in the first year IPTT was introduced as a screening tool, the relative risk
51
52 reduction (RRR) of DFU was 64%, and in the second year, the RRR was 70%, thereby reducing
53
54 hospital-acquired foot ulcers in patients with diabetes by two-thirds and negating the excess risk
55
56 associated with diabetes.⁴⁰⁻⁴³ Meanwhile, it can effectively improve patients' disease-related
57
58 knowledge, which plays a positive role in promoting the self-management of patients and their
59
60

1
2
3 families. At the same time, IPTT has a predictive effect on diabetic foot ulcers and reduces delays
4
5 in patient visits.²¹ However, more thorough studies are needed for verification.
6
7

8 Most of the literature on IPTT is focused on screening tests and some commentary-type studies,
9
10 and the number of studies is small. These studies were carried out in the United Kingdom, Spain,
11
12 Brazil, and Saudi Arabia, and although they achieved satisfactory results, have not been carried out
13
14 globally. However, it has not been applied in developing countries such as China. China is a country
15
16 with a large population and a relatively small number of medical personnel, especially in some
17
18 remote areas where the medical allocation is in short supply. In these areas, the application and
19
20 promotion of IPTT can effectively alleviate the allocation of medical resources and play an
21
22 important role in the management of patients with diabetes. IPTT has also recently been approved
23
24 for use in a number of countries.^{21,32-34} However, Kempegowda et al. reported that 88.4% of
25
26 physicians are not familiar with IPTT. Therefore, we suggest that IPTT be further promoted amongst
27
28 physicians and medical staff, especially in remote areas and areas lacking screening tools.³⁶ Future
29
30 large-scale, high-quality, and multi-center studies on populations of different ethnicities will verify
31
32 the potential applicability of IPTT alone or in combination with other DPN screening methods.
33
34

35 **Conclusion**

36
37
38 In summary, IPTT is a simple, novel, and straightforward method for screening DPN with high
39
40 specificity and acceptable sensitivity. It can be used clinically, especially in remote areas and
41
42 primary medical institutions, and self-monitoring patients. This is also the first meta-analysis of the
43
44 accuracy of IPTT identification of DPN, and a systematic quantitative evaluation of its screening
45
46 value, which can provide evidence for the clinical application of IPTT in the future. However, due
47
48 to a limited number of studies of low or medium quality from limited geographical areas, more high-
49
50 quality studies are needed to promote more effective screening practices.
51
52

53 **Funding sources**

54
55
56 This research was supported by the Natural Science Foundation of Hunan Province (2019JJ80087)
57
58

59 **Conflict of interest**

60

1
2
3 The authors state that they have no conflict of interest.
4
5

6 **Author contributions**

7

8 ZN conducted the database search, screened and extracted data for the meta-analysis, prepared
9 extracted data for the procedures, and had primary responsibility in writing this article. LXY, ZJ
10 and ZJ performed statistical analysis and interpretation of data. XJC, ZQH, and LJH contributed to
11 the discussion and editing. XJC and CJR critically revised the draft manuscript. All authors
12 contributed toward data analysis, drafting and critically revising the paper and agree to be
13 accountable for all aspects of the work.
14
15
16
17
18
19

20 **Acknowledgments**

21

22 Thanks all authors and patients of the previous research for providing data for our article.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018;138:271-281
2. Armstrong DG, Boulton A, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* 2017;376(24):2367-2375
3. Standards of medical care in diabetes--2014. *Diabetes Care* 2014;37 Suppl 1:S14-80
4. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. *Curr Neurol Neurosci Rep.* 2014;14(8):473
5. Strachan MW, Reynolds RM, Marioni RE, et al. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. *Nat Rev Endocrinol.* 2011;7(2):108-14
6. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep* 2019;19(10):86
7. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. *J Vasc Surg* 2014;60(5):1247-54.
8. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40(1):136-154
9. Javed S, Hayat T, Menon L, Alam U, Malik RA. Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. *Diabet Med* 2020;37(4):573-579
10. Feldman EL, Nave KA, Jensen TS, et al. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron* 2017;93(6):1296-1313
11. Saluja S, Anderson SG, Hambleton I, et al. Foot ulceration and its association with mortality in diabetes mellitus: a meta-analysis. *Diabet Med* 2020;37(2):211-8.
12. Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. *J Am Podiatr Med Assoc* 2011;101(2):93-115.
13. International Diabetes Federation. Diabetic foot screening pocket chart. Brussels: IDF 2017. <https://www.idf.org/our-activities/advocacy-aware>
14. Standards of Medical Care in Diabetes-2017: Summary of Revisions. *Diabetes Care* 2017;40(Suppl 1):S4-5.
15. Craig AB, Strauss MB, et al. Foot sensation testing in the patient with diabetes: introduction of the quick & easy assessment tool. *Wounds* 2014;26(8):221-31.
16. Slater RA, Koren S, Ramot Y, et al. Interpreting the results of the Semmes-Weinstein monofilament test: accounting for false-positive answers in the international consensus on the diabetic foot protocol by a new model. *Diabetes Metab Res Rev* 2014;30(1):77-80.
17. Lavery LA, Lavery DE, Lavery DC, et al. Accuracy and durability of Semmes-Weinstein monofilaments: what is the useful service life? *Diabetes Res Clin Pract* 2012;97(3):399-404.
18. Spruce MC, Bowling FL. Diabetic foot screening: new technology versus 10g monofilament. *Int J Low Extrem Wounds* 2012 2012-03-01;11(1):43-8.

19. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. *Diabetes Care* 2011;34(7):1517-8.
20. Vas PR, Sharma S, Rayman G. Distal Sensorimotor Neuropathy: Improvements in Diagnosis. *Rev Diabet Stud* 2015;12(1-2):29-47.
21. Miller JD, Carter E, Shih J, et al. How to do a 3-minute diabetic foot exam. *J Fam Pract* 2014;63(11):646-56.
22. Atlantis E, Cochrane B. The association of dietary intake and supplementation of specific polyunsaturated fatty acids with inflammation and functional capacity in chronic obstructive pulmonary disease: a systematic review *Int J Evid Based Healthc* 2016;14(2):53-63.
23. McInnes M, Moher D, Thoms BD, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018;319(4):388-96.
24. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Ann Intern Med* 2011;155(8):529-36.
25. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. *BMJ*. 2004;329(7458):168-9.
26. The Nordic Cochrane Centre (2014) Review manager. Cochrane Collab 1-43
27. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58.
28. Lo K, Stephenson M, Lockwood C. Analysis of heterogeneity in a systematic review using meta-regression technique. *Int J Evid Based Healthc* 2019.
29. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34.
30. Sharma S, Kerry C, Rosier J, et al. The Ipswich Touch Test (IpTT): Screening for diabetic neuropathy at home. *Diabet Med* 2012;29:20.
31. Sharma S, Kerry C, Atkins H, et al. The Ipswich Touch Test: a simple and novel method to screen patients with diabetes at home for increased risk of foot ulceration. *Diabet Med* 2014;31(9):1100-3.
32. Madanat A, Sheshah E, Badawy E, et al. Utilizing the Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration among diabetics: The Saudi experience. *Prim Care Diabetes* 2015;9(4):304-6.
33. Basir IS, Syam Y, Yusuf S, et al. Accuracy of Ipswich Touch Test (IpTT) to detect small fiber neuropathy and large fiber neuropathy as a risk factor of diabetic foot ulcers in public health centers. *Enferm Clin* 2020;30 Suppl 2:308-12.
34. Dutra L, Moura MC, Do PF, et al. Is it possible to substitute the monofilament test for the Ipswich Touch Test in screening for peripheral diabetic neuropathy? *Diabetol Metab Syndr* 2020;12:27.
35. Bowling FL, Abbott CA, Harris WE, et al. A pocket-sized disposable device for testing the integrity of sensation in the outpatient setting. *Diabet Med* 2012;29(12):1550-2.

- 1
2
3 36. Kempegowda P, Saeed MA. Foot STAMP (Short-burst Teaching Aimed at Medical
4 Professionals): Impact of 'shortburst' teaching on the knowledge regarding the Ipswich Touch
5 Test. *Diabet Med* 2016;33:134.
6
7
8 37. Bailey TS, Yu HM, Rayfield EJ. Patterns of foot examination in a diabetes clinic. *Am Med J*
9 1985;78(3):371-4.
10
11 38. Baker N. An alternative to a 10-g monofilament or tuning fork? Two new, simple, easy-to-use
12 screening tests for determining foot ulcer risk in people with diabetes. *Diabet Med*
13 2012;29(12):1477-9.
14
15 39. O'Loughlin A, Dinneen SF. ACP Journal Club: the Ipswich Touch Test at home had 78%
16 sensitivity and 94% specificity for detecting loss of foot sensation. *Ann Intern Med*
17 2015;162(4):C10.
18
19 40. Kerry C. VPRR. Reduction in the incidence of hospital acquired foot pressure ulcers in people
20 with diabetes. *Diabetic Med* 2015;SUPPL. 1(32):26
21
22 41. Kerry CD, Sharma S, Rayman G. Reduction in hospital-acquired diabetes foot lesions using the
23 Ipswich Touch Test (IpTT). *Diabetic Med* 2013;30:141-2.
24
25 42. Vas PR, Sharma S, Rayman G. Distal Sensorimotor Neuropathy: Improvements in Diagnosis.
26 *Rev Diabet Stud* 2015;12(1-2):29-47.
27
28 43. Madanat A, Sheshah E, Badawy E, et al.: "P.R. Vas, S. Sharma, G. Rayman, Utilizing the
29 Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration
30 among diabetics: comment on the Saudi experience. *Prim Care Diabetes* 2015;9(5):401-2.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Assessment for risk of bias.

589x428mm (72 x 72 DPI)

	Q1	Q10	Q11	Q12	Q13	Q14	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
Sharma2012	?	?	?	?	?	?	?	?	?	?	?	?	?	?
Sharma2014a	-	+	+	+	-	?	+	+	+	+	+	+	+	-
Sharma2014b	+	+	+	+	-	?	+	+	+	+	+	+	+	-
Madanat2015	+	?	?	+	?	?	+	+	?	?	?	?	+	-
Basir2020	+	?	?	+	-	?	+	+	?	?	?	+	+	-
Dutra2020	+	?	?	+	?	+	+	+	?	+	+	?	+	+

Figure 3. Assessment for the risk of bias in included studies.

589x428mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure4. Sensitivity and specificity of IPTT in the diagnosis of DPN.

589x428mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. The SROC curve for quantitative analysis of IPTT in the diagnosis of DPN.

429x429mm (72 x 72 DPI)




Figure 6. The Fagan for assessment of IPTT screening probability.

286x429mm (72 x 72 DPI)

1
2
3
4 **Appendix S1**

5 **Search Strategy in PubMed, Embase, Cochrane Library, Web of Science, CNKI, CMB, Wanfang**
6 **database.**
7

8
9
10 **PubMed Search Strategy**
11

12
13 #1 Search: "Diabetes Mellitus"[Mesh] Sort by: Most Recent
14

15
16 #2 Search: (((Diabetes[Title/Abstract]) OR (Diabetes, Type 2[Title/Abstract])) OR (Type 2
17 Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus, Type II[Title/Abstract])) OR
18 (Diabetes Mellitus, Type I[Title/Abstract])
19

20
21 #3 Search: "Diabetic Neuropathies"[Mesh] Sort by: Most Recent
22

23
24 #4 Search: (((((((((((((((((((((((((((((Diabetic Neuropathy[Title/Abstract]) OR
25 (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic[Title/Abstract])) OR
26 (Diabetic Autonomic Neuropathy[Title/Abstract])) OR (Autonomic Neuropathies,
27 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathies[Title/Abstract])) OR
28 (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR (Autonomic Neuropathy,
29 Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic Autonomic[Title/Abstract])) OR
30 (Symmetric Diabetic Proximal Motor Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic
31 Proximal Motor Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric
32 Polyneuropathy[Title/Abstract])) OR (Asymmetric Polyneuropathies,
33 Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy, Diabetic[Title/Abstract])) OR
34 (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR (Polyneuropathies, Diabetic
35 Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic Asymmetric[Title/Abstract]))
36 OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
37 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
38 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
39 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicis[Title/Abstract])) OR
40 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicis,
41 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 (Simplices, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
5 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
6
7 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract])
8
9

10 #5 Search: "Diabetes Complications"[Mesh] Sort by: Most Recent

11
12
13 #6 Search:

14
15
16 #7 Search: "Diabetic Foot"[Mesh] Sort by: Most Recent

17
18
19 #8 Search: (((Foot, Diabetic[Title/Abstract]) OR (Diabetic Feet[Title/Abstract])) OR (Feet,
20 Diabetic[Title/Abstract])) OR (Foot Ulcer, Diabetic[Title/Abstract])
21
22

23
24 #9 Search: ((ipswich touch test[Title/Abstract]) OR (touch test[Title/Abstract])) OR
25 (IPTT[Title/Abstract])
26
27

28
29 #10 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((((Diabetes[Title/Abstract]) OR
30 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
31 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))))
32 OR ("Diabetic Neuropathies"[Mesh])) OR (((
33 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
34 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
35 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
36 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
37 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
38 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
39 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
40 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR
41 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
42 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
43 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
44 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
5 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
6 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicies[Title/Abstract])) OR
7 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicies,
8 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
9 (Simplicies, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
10 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
11 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
12 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
13 Complications[Title/Abstract]) OR (Diabetes Related Complications[Title/Abstract])) OR
14 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
15 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
16 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
17 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
18 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract]) OR (Diabetic
19 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
20 Diabetic[Title/Abstract]))

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 #11 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((Diabetes[Title/Abstract]) OR
39 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
40 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))
41 OR ("Diabetic Neuropathies"[Mesh])) OR (((((((((((((((((((((((((((((((((((((((Diabetic
42 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
43 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
44 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
45 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
46 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
47 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
48 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
49 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR
50
51
52
53
54
55
56
57
58
59
60

1
 2
 3
 4 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
 5 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
 6 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
 7 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 8 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
 9 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
 10 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicies[Title/Abstract])) OR
 11 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicies,
 12 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
 13 (Simplicies, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 14 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
 15 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
 16 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
 17 Complications[Title/Abstract])) OR (Diabetes Related Complications[Title/Abstract])) OR
 18 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
 19 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
 20 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
 21 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
 22 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract])) OR (Diabetic
 23 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
 24 Diabetic[Title/Abstract])) AND (((ipswich touch test[Title/Abstract])) OR (touch
 25 test[Title/Abstract])) OR (IPTT[Title/Abstract]))

Embase Search Strategy

#1 'diabetes mellitus'/exp

#2 'diabetes, type 2':ab,ti OR 'type 2 diabetes mellitus':ab,ti OR 'diabetes mellitus, type
ii':ab,ti OR 'diabetes mellitus, type 1':ab,ti

#3 #1 OR #2

1
2
3
4 #4 'diabetic neuropathy'/exp
5

6 #5 'diabetic neuropathy':ab,ti OR 'neuropathies, diabetic':ab,ti OR 'neuropathy, diabetic':ab,ti
7
8 OR 'diabetic autonomic neuropathy':ab,ti OR 'autonomic neuropathies, diabetic':ab,ti OR
9
10 'autonomic neuropathy, diabetic':ab,ti OR 'diabetic autonomic neuropathies':ab,ti OR
11
12 'neuropathies, diabetic autonomic':ab,ti OR 'neuropathy, diabetic autonomic':ab,ti OR
13
14 'symmetric diabetic proximal motor neuropathy':ab,ti OR 'asymmetric diabetic proximal
15
16 motor neuropathy':ab,ti OR 'diabetic asymmetric polyneuropathy':ab,ti OR 'asymmetric
17
18 polyneuropathies, diabetic':ab,ti OR 'asymmetric polyneuropathy, diabetic':ab,ti OR 'diabetic
19
20 asymmetric polyneuropathies':ab,ti OR 'polyneuropathies, diabetic asymmetric':ab,ti OR
21
22 'polyneuropathy, diabetic asymmetric':ab,ti OR 'diabetic mononeuropathy':ab,ti OR 'diabetic
23
24 mononeuropathies':ab,ti OR 'mononeuropathies, diabetic':ab,ti OR 'mononeuropathy,
25
26 diabetic':ab,ti OR 'diabetic mononeuropathy simplex':ab,ti OR 'diabetic mononeuropathy
27
28 simplices':ab,ti OR 'mononeuropathy simplex, diabetic':ab,ti OR 'mononeuropathy simplices,
29
30 diabetic':ab,ti OR 'simplex, diabetic mononeuropathy':ab,ti OR 'simplices, diabetic
31
32 mononeuropathy':ab,ti OR 'diabetic polyneuropathy':ab,ti OR 'diabetic polyneuropathies':ab,ti
33
34 OR 'polyneuropathies, diabetic':ab,ti OR 'polyneuropathy, diabetic':ab,ti
35

36 #6 #4 OR #5
37

38
39 #7 'diabetic complication'/exp
40

41
42 #8 'diabetes complication':ab,ti OR 'diabetes-related complications':ab,ti OR 'diabetes
43
44 related complications':ab,ti OR 'diabetes-related complication':ab,ti OR 'diabetic
45
46 complications':ab,ti OR 'diabetic complication':ab,ti OR 'complications of diabetes
47
48 mellitus':ab,ti OR 'diabetes mellitus complication':ab,ti OR 'diabetes mellitus
49
50 complications':ab,ti
51

52
53 #9 #7 OR #8
54

55
56 #10 'diabetic foot'/exp
57

58
59 #11 'diabetic foot':ab,ti OR 'diabetic feet':ab,ti OR 'feet, diabetic':ab,ti OR 'foot ulcer,
60

1
2
3
4 diabetic':ab,ti OR 'foot ulcer':ab,ti
5

6
7 #12 #10 OR #11
8

9
10 #13 #3 OR #6 OR #9 OR #12
11

12
13 #14 'ipswich touch test':ab,ti OR 'touch test':ab,ti OR 'iptt':ab,ti
14

15
16 #15 #13 AND #14
17

18 **Cochrane Library Search Strategy**

19
20
21 #1 MeSH descriptor: [Diabetes Mellitus] explode all trees 31055
22

23
24 #2 (Diabetes):ti,ab,kw OR (Diabetes, Type 2):ti,ab,kw OR (Type 2 Diabetes
25
26 Mellitus):ti,ab,kw OR (Diabetes Mellitus, Type II):ti,ab,kw OR (Diabetes Mellitus, Type 1)
27

28
29 #3 MeSH descriptor: [Diabetic Neuropathies] explode all trees
30

31
32 #4 (Diabetic Neuropathy):ti,ab,kw OR (Neuropathies, Diabetic):ti,ab,kw OR (Neuropathy,
33
34 Diabetic):ti,ab,kw OR (Diabetic Autonomic Neuropathy):ti,ab,kw OR (Autonomic
35
36 Neuropathies, Diabetic):ti,ab,kw OR (Autonomic Neuropathy, Diabetic):ti,ab,kw OR
37
38 (Diabetic Autonomic Neuropathies):ti,ab,kw OR (Neuropathies, Diabetic
39
40 Autonomic):ti,ab,kw OR (Neuropathy, Diabetic Autonomic):ti,ab,kw OR (Symmetric
41
42 Diabetic Proximal Motor Neuropathy):ti,ab,kw OR (Asymmetric Diabetic Proximal Motor
43
44 Neuropathy):ti,ab,kw OR (Diabetic Asymmetric Polyneuropathy):ti,ab,kw OR (Asymmetric
45
46 Polyneuropathies, Diabetic):ti,ab,kw OR (Asymmetric Polyneuropathy, Diabetic):ti,ab,kw OR
47
48 (Diabetic Asymmetric Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic
49
50 Asymmetric):ti,ab,kw OR (Polyneuropathy, Diabetic Asymmetric):ti,ab,kw OR (Diabetic
51
52 Mononeuropathy):ti,ab,kw OR (Diabetic Mononeuropathies):ti,ab,kw OR
53
54 (Mononeuropathies, Diabetic):ti,ab,kw OR (Mononeuropathy, Diabetic):ti,ab,kw OR
55
56 (Diabetic Mononeuropathy Simplex):ti,ab,kw OR (Diabetic Mononeuropathy
57
58 Simplicis):ti,ab,kw OR (Mononeuropathy Simplex, Diabetic):ti,ab,kw OR (Mononeuropathy
59
60 Simplicis, Diabetic):ti,ab,kw OR (Simplex, Diabetic Mononeuropathy):ti,ab,kw OR

(Simplices, Diabetic Mononeuropathy):ti,ab,kw OR (Diabetic Polyneuropathy):ti,ab,kw OR
 (Diabetic Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic):ti,ab,kw OR
 (Polyneuropathy, Diabetic):ti,ab,kw 3653

#5 MeSH descriptor: [Diabetes Complications] explode all trees

#6 (Diabetes-Related Complications):ti,ab,kw OR (Diabetes Related
 Complications):ti,ab,kw OR (Diabetes-Related Complication):ti,ab,kw OR (Diabetic
 Complications):ti,ab,kw OR (Diabetic Complication):ti,ab,kw OR (Complications of Diabetes
 Mellitus):ti,ab,kw OR (Diabetes Mellitus Complication):ti,ab,kw OR (Diabetes Mellitus
 Complications)

#7 MeSH descriptor: [Diabetic Foot] explode all trees

#8 (Diabetic Feet):ti,ab,kw OR (Feet, Diabetic):ti,ab,kw OR (Foot Ulcer, Diabetic)

#9 (ipswich touch test):ti,ab,kw OR (touch test):ti,ab,kw OR (IPTT)

#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

#11 #9 AND #10

Web of Science Search Strategy

#1 TS=(Diabetes Mellitus or Diabetes or Diabetes, Type 2 or Type 2 Diabetes Mellitus or
 Diabetes Mellitus, Type II or Diabetes Mellitus, Type 1)

#2 TS=(Diabetic Neuropathies or Diabetic Neuropathy or Neuropathies, Diabetic or
 Neuropathy, Diabetic or Diabetic Autonomic Neuropathy or Autonomic Neuropathies,
 Diabetic or Autonomic Neuropathy, Diabetic or Diabetic Autonomic Neuropathies or
 Neuropathies, Diabetic Autonomic or Neuropathy, Diabetic Autonomic or Symmetric
 Diabetic Proximal Motor Neuropathy or Asymmetric Diabetic Proximal Motor Neuropathy or
 Diabetic Asymmetric Polyneuropathy or Asymmetric Polyneuropathies, Diabetic or
 Asymmetric Polyneuropathy, Diabetic or Diabetic Asymmetric Polyneuropathies or

1
2
3
4 Polyneuropathies, Diabetic Asymmetric or Polyneuropathy, Diabetic Asymmetric or Diabetic
5
6 Mononeuropathy or Diabetic Mononeuropathies or Mononeuropathies, Diabetic or
7
8 Mononeuropathy, Diabetic or Diabetic Mononeuropathy Simplex or Diabetic
9
10 Mononeuropathy Simplicis or Mononeuropathy Simplex, Diabetic or Mononeuropathy
11
12 Simplicis, Diabetic or Simplex, Diabetic Mononeuropathy or Simplicis, Diabetic
13
14 Mononeuropathy or Diabetic Polyneuropathy or Diabetic Polyneuropathies or
15
16 Polyneuropathies, Diabetic or Polyneuropathy, Diabetic)

17
18 #3 TS=(Diabetes Complications or Diabetes Complication or Diabetes-Related
19
20 Complications or Diabetes Related Complications or Diabetes-Related Complication or
21
22 Diabetic Complications or Diabetic Complication or Complications of Diabetes Mellitus or
23
24 Diabetes Mellitus Complication or Diabetes Mellitus Complications)

25
26
27 #4 TS=(Diabetic Foot or Foot, Diabetic or Diabetic Feet or Feet, Diabetic or Foot Ulcer,
28
29 Diabetic)

30
31
32 #5 #4 OR #3 OR #2 OR #1

33
34
35 #6 TS=(ipswich touch test or touch test or IPTT)

36
37
38 #7 #6 AND #5

39 40 41 **China National Knowledge Infrastructure (CNKI) Search Strategy**

42
43
44 检索式 A: (((主题=糖尿病 或者 题名=糖尿病 或者 v_subject=中英文扩展(糖尿病)
45
46 或者 title=中英文扩展(糖尿病)) 或者 (主题=糖尿病足 或者 题名=糖尿病足 或者
47
48 v_subject=中英文扩展(糖尿病足) 或者 title=中英文扩展(糖尿病足))) 或者 ((主题=糖
49
50 尿病周围神经病变 或者 题名=糖尿病周围神经病变 或者 v_subject=中英文扩展(糖尿
51
52 病周围神经病变) 或者 title=中英文扩展(糖尿病周围神经病变)) 或者 (主题=糖尿病并
53
54 发症 或者 题名=糖尿病并发症 或者 v_subject=中英文扩展(糖尿病并发症) 或者 title=
55
56 中英文扩展(糖尿病并发症)))) 并且 (((((主题=中英文扩展(touch test) 或者 题名=中
57
58 英文扩展(touch test) 或者 v_subject=touch test 或者 title=touch test) 或者 (主题=中英
59
60 文扩展(Ipswich Touch Test) 或者 题名=中英文扩展(Ipswich Touch Test) 或者

v_subject=Ipswich Touch Test 或者 title=Ipswich Touch Test)) 或者 ((主题=伊普斯维奇触摸测试 或者 题名=伊普斯维奇触摸测试 或者 v_subject=中英文扩展(伊普斯维奇触摸测试) 或者 title=中英文扩展(伊普斯维奇触摸测试)) 或者 (主题=中英文扩展(IPTT) 或者 题名=中英文扩展(IPTT) 或者 v_subject=IPTT 或者 title=IPTT))) 或者 ((关键词=轻触 或者 keyword=中英文扩展(轻触)) 或者 (关键词=轻触测试 或者 keyword=中英文扩展(轻触测试)))) 或者 ((题名=触摸 或者 Title=中英文扩展(触摸)) 或者 (题名=触摸测试 或者 Title=中英文扩展(触摸测试)))) (模糊匹配)

Wan Fang Database Search Strategy

主题:(糖尿病)+主题:(糖尿病足)+主题:(糖尿病周围神经病变)+全部:(糖尿病并发症)*主题:((touch test)+主题:(IPTT)+主题:(Ipswich Touch Test)+全部:(伊普斯维奇触摸测试))

China Biology Medicine disc (CBM) Search Strategy

- #1 "糖尿病"[不加权:扩展]
- #2 "糖尿病足"[常用字段:智能]
- #3 "糖尿病神经病变"[常用字段:智能]
- #4 "糖尿病并发症"[常用字段:智能]
- #5 (#4) OR (#3) OR (#2) OR (#1)
- #6 "touch"[常用字段:智能] AND "test"[常用字段:智能]
- #7 "IPTT"[常用字段:智能]
- #8 "Ipswich"[常用字段:智能] AND "Touch"[常用字段:智能] AND "Test"[常用字段:智能]
- #9 "伊普斯维奇触摸测试"[常用字段:智能]
- #10 "轻触"[常用字段:智能]

1
2
3 #11 "轻触测试"[常用字段:智能]
4
5

6 #12 "触摸"[常用字段:智能]
7
8

9 #13 "触摸测试"[常用字段:智能]
10
11

12 #14 (#13) OR (#12) OR (#11) OR (#10) OR (#9) OR (#8) OR (#7) OR (#6)
13
14

15 #15 (#14) AND (#5)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	2
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	6-7



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6-7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9-10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2
For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046966.R1
Article Type:	Original research
Date Submitted by the Author:	05-May-2021
Complete List of Authors:	<p>Zhao, Nan; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Xu, Jing-can; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Qihong; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha</p> <p>Li, Xinyi; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Nursing School of Central South University</p> <p>Chen, Jiarui ; Central South University Xiangya School of Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Jing; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing</p> <p>Zhou, Feng; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Hospital Central South University, Department of Emergency</p> <p>Liang , Jinghong; Sun Yat-Sen University, 6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Neurology, Public health, Diabetes and endocrinology
Keywords:	Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Diabetic foot < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

AUTHORS' INFORMATION

Zhao Nan^{1,2}, Xu Jingcan^{1,2}, Zhou Qihong^{1,4}, Li Xinyi^{1,3}, Chen Jiarui^{2,3}, Zhou Jing¹, Zhou Feng^{1,5}, Liang Jinghong⁶

Zhao Nan 187811023@csu.edu.cn

Xu Jingcan 983556951@qq.com

Zhou Qihong 928555448@qq.com

Li Xinyi 905492390@qq.com

Chen Jiarui chenjr@csu.edu.cn

Zhou Jing zhou-jing62@hotmail.com

Zhou Feng 316925782@qq.com

Liang Jinghong liangjh78@mail2.sysu.edu.cn

1. Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, 410008, China

2. Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group, Changsha, 410013, China

3. Xiangya Nursing School of Central South University, Changsha, 410013, China

4. Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha, 410008, China

5. Department of Emergency, Xiangya Hospital, Central South University, Changsha, 410008, China

6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China

Corresponding author: Xu Jingcan, 983556951@qq.com; Zhou Qihong, 928555448@qq.com

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

ABSTRACT

Objective: Diabetic peripheral neuropathy (DPN) is one of the most important risk factors of diabetic foot ulcers (DFU), and early screening and treatment of DPN are crucial. The Ipswich Touch Test (IPTT) is a new method for screening for DPN and, compared with traditional methods, is more simple to operate and requires no equipment. However, the screening accuracy of IPTT in DPN patients has not been well characterized. We aim to conduct a systematic review and meta-analysis to characterize the sensitivity and specificity of IPTT compared to traditional methods and to understand the potential screening value of IPTT.

Design: Systematic review and meta-analysis.

Data sources: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedical Literature Database (CBM) up to April 16, 2020.

Methods: Stata version 15.1 software was used for analysis, and the screening value of IPTT in DPN was described using 10g-MF, NDS, Pin prick, 128Hz tuning fork, and ankle reflex as reference standards. Sensitivity, specificity, and other measures of accuracy of IPTT for screening DPN were pooled based on a quality effects model. The protocol was registered with PROSPERO (42020168420).

Results: Of the 441 records retrieved, seven studies were evaluated for the screening value of IPTT. Five studies with 10g-MF as the reference standard were included in the meta-analysis, and the pooled sensitivity and specificity were 0.78 (95 % CI 0.65–0.87) and 0.95(95 % CI 0.89–0.98), respectively, and AUC was 0.93. Compared with VPT, IPTT showed a sensitivity between 0.76 and 1, and a specificity between 0.90 and 0.97. Compared with NDS, IPTT showed a sensitivity between 0.53 and 1, and a specificity between 0.90 and 0.97. Compared with Pin prick, IPTT showed a

1
2
3 sensitivity and specificity of 0.8 and 0.88, respectively. Compared with 128Hz tuning fork, IPTT
4 showed a sensitivity and specificity of 0.4 and 0.27, respectively. Compared with ankle reflex, IPTT
5 had a sensitivity of 0.2 and a specificity of 0.97.
6
7
8
9

10 **Conclusions:** IPTT has a high degree of agreement in DPN screening with commonly used
11 screening tool for DPN. It can be used clinically, especially in remote areas and in primary medical
12 institutions, and by self-monitoring patients. More high-quality studies are needed to assess and
13 promote more effective screening practices.
14
15
16
17
18

19 **Prospero:** Registration Number is CRD (42020168420)
20
21

22 **Strengths and limitations of this study**

23

- 24 • This is the first meta-analysis to explore the potential screening value of IPTT in DPN.
- 25 • A quality effects model was used to achieve optimal error estimation in the data analysis.
- 26 • Based on the existing evidence, the value of IPTT in DPN screening is summarized, and it
27 provides evidence for medical staff to use IPTT for DPN screening.
- 28 • By facilitating the identification of patients at risk for foot ulceration, we can effectively prevent
29 the occurrence of DFU, and reduce the social and economic burden of this disease.
- 30 • Although we have systematically and comprehensively studied the current evidence of IPTT
31 screening in DPN, still the original studies are very limited, and the existing conclusions are only
32 based on these 7 original studies. Therefore, caution should be taken when popularizing them.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 **Keywords:** Ipswich Touch Test, Diabetic peripheral neuropathy, Meta-analysis
50
51

52 **INTRODUCTION**

53

54
55
56 Diabetic peripheral neuropathy (DPN) is a common long-term complication and the most important
57 risk factor for the occurrence of diabetic foot ulcers (DFU).¹⁻⁴ DPN affects up to 50% of people with
58 diabetes,^{5,6} with chronic painful neuropathy affecting up to 26%.⁷ In the early stage of DPN, the
59
60

1
2
3 symptoms lack specificity, and about half of patients with diabetes cannot recognize the injury to
4 the lower extremities.^{8,9} Once the patient has symptoms such as limb numbness and pain, it signals
5 that pathological changes have occurred in the peripheral nerves and have advanced into the
6 irreversible stage. If not treated promptly, serious tissue damage, such as foot ulcers, amputation,
7 and even death, may occur.^{10,11} Studies have shown that early screening and detection of peripheral
8 neuropathy can not only slow down the DPN process, but also effectively prevent DFU.¹² Therefore,
9 early screening and treatment of DPN is very important.
10
11
12
13
14
15
16

17
18 At present, the screening value of 10g monofilament (10g-MF), Vibration perception threshold
19 (VPT), and 128Hz tuning fork in DPN has been widely recognized.¹³ Compared with VPT and
20 128Hz tuning forks, 10g-MF is the most widely used screening tool because it is more simple,
21 objective, and easy to carry, although it requires a calibration facility to confirm that the vertical
22 pressure of the monofilament used when bending is 10g.¹⁴⁻¹⁶ Commercially available 10g-MF
23 devices exhibit significant variability within and between devices of different manufacturers and
24 their actual bending force varies widely from their designated 10g value. When used they have a
25 short service life where the instrument is within 10% of their initial bending force which is not
26 usually the stated 10g of force.^{17,18} Meanwhile, medical personnel are required to be trained before
27 using the device, and screening is limited to hospitals or clinics. For clinics and communities in
28 remote areas, medical personnel may lack the device or the training to screen patients for DPN,
29 resulting in a missed opportunity for patients to receive the best treatment. In recent years, Dr.
30 Rayman proposed the Ipswich Touch Test (IPTT), which only requires the physician's index finger.
31 During this test, the patient is required to close their eyes while the physician lightly rests their finger
32 on each of the patient's first, third, and fifth toes for 1 to 2 seconds. Patients are instructed to respond
33 with a "yes" when they feel the physician's touch. Compared with the current methods, IPTT
34 requires no equipment, is more convenient and effective, and can be performed by doctors, nurses,
35 and even family caregivers after training.¹⁹ IPTT can be applied to inpatients, outpatients,
36 community patients, self-monitoring patients at home, and to areas lacking more advanced
37 equipment.^{20,21} Currently, IPTT has been applied in the United Kingdom, Spain, Brazil, and Saudi
38 Arabia,^{19,22-26} and was approved by the American Diabetes Association in 2015.²⁰ The 2019
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 guidelines of the International Working Group on the Diabetic Foot also suggest that IPTT should
4 be used for DPN screening in patients with diabetes in the absence of 10g-MF.²⁷ Although these
5 studies have achieved satisfactory results, they have not been widely promoted and applied globally.
6
7 Previous studies have reported differences in the results of the screening value of DPN. However,
8
9 neither a meta-analysis nor a systematic review has been conducted on the screening value of IPTT.
10
11
12
13

14 In this study, we aimed to conduct a comprehensive and systematic literature review to
15 systematically evaluate the potential screening value of IPTT in DPN, and provide evidence and
16 guidance for the clinical application value of IPTT.
17
18
19

20 21 **METHODS**

22
23
24 The Joanna Briggs Institute (JBI) protocol²⁸ has been registered with PROSPERO, the International
25 Prospective Register of Systematic Reviews hosted by the Centre for Reviews and Dissemination
26 (Registration Number is CRD (42020168420). We followed the Preferred Reporting Items for
27 Systematic Reviews and Meta-Analyses (PRISMA)²⁹.
28
29
30
31

32 33 **Data Sources and Searches**

34 We systematically searched PubMed, Embase, Cochrane Library, Web of Science, China National
35 Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Biomedical Literature Database (CBM)
36 for reports published before April 16, 2020. For included studies with insufficient data, we emailed
37 the authors to ask if they would provide data for our study. With this strategy, we combined search
38 terms for applied technique (Ipswich touch test, touch test, IPTT) and disease (Diabetic peripheral
39 neuropathy, diabetic foot, diabetic foot ulcer, Diabetes Mellitus, diabetic complications). The study
40 design and published language were not limited. In addition, we conducted a manual search,
41 including searching through conference papers and gray literature, and the references of all included
42 studies were examined. All search strategies were determined by multiple pre-searches, and the
43 search formulas were adjusted according to the characteristics of each database. A detailed search
44 strategy is provided in “Supplementary files 1”. All analyses were based on previously published
45 studies; thus, no ethical approval and patient consent were required.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Inclusion and Exclusion Criteria

Previously published studies were included in this meta-analysis if: (1) the study was designed as a diagnostic test and systematic reviews; (2) all the research subjects were patients with diabetes, and; (3) IPTT was included as an index test. Studies were excluded from the meta-analysis if the studies had incomplete data sets or were other than original reports (commentaries/reviews). The age, sex, region, and race of the subjects were not restricted. The published language was not limited.

Data Extraction and Quality Assessment

We imported initial search records from databases into NoteExpress V3.2.0.7535 literature management software. Two reviewers independently screened titles and abstracts of all the included literature, following the inclusion and exclusion criteria. After screening the abstract, the full text was read in detail. Any discrepancies were resolved by discussion. The following information was extracted from the eligible studies: study characteristics (author, publication year, study period, country, reference standard, setting, operators), participant characteristics (sample number, range), and outcome indicators (sensitivity, specificity, true positive number (TP), false positive number (FP), false negative number (FN), true negative number (TN)). Missing data were supplemented by contacting authors wherever possible.

The quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS), it is a methodological quality assessment scale, and includes 14 items³⁰. Quality items were weighted equally with 1 point awarded for each of the 14 items. The quality score was then calculated by summing the points awarded for each question (maximum sum 14). This score was then normalized by dividing the sum by the highest score of the listed studies, thereby ranking the studies from 1 down to a minimum of 0.³¹ Data extraction and quality assessment was performed independently by two reviewers. Differences were reconciled through discussion until a consensus was reached on the item in question.

Data Synthesis

The sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and

1
2
3 corresponding 95% confidence intervals (95% CIs) were calculated using the TP, FP, FN, and TN
4 values, which were extracted from each study prior to data pooling. The likelihood ratio is an
5 independent indicator to assess authenticity, which can simultaneously reflect sensitivity and
6 specificity. When the PLR is >10 or the NLR is <0.1, the probability of diagnosing or excluding a
7 certain disease increases significantly. The likelihood ratio is more clinically significant than
8 summary receiver operating characteristic curve (SROC) and diagnostic odds ratio (DOR) value.³²
9 The DOR with 95% CI was also calculated. For each summary statistic, a 95% confidence interval
10 was computed. The quality effects model in meta-analysis was used to estimate variance between
11 studies by using STATA, version 15.1 (Stata Corp, College Station, TX).^{33,34} Relevant studies have
12 proven that this model is superior to the traditional random effects model and fixed effects model.³⁵⁻
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37 The quality scores were used to redistribute inverse variance weights based on study deficiencies
via the quality effects model.^{38,39}

In addition, Fagan nomograms were generated to evaluate the clinical utility of the two screening
methods. Heterogeneity among the reports was assessed by the χ^2 test (Cochran Q test) and the I^2
statistic, where $p \leq 0.05$ or an $I^2 \geq 50\%$ indicated the existence of significant heterogeneity.⁴⁰ If there
was significant heterogeneity ($p \leq 0.05$ or $I^2 \geq 50\%$), sensitivity analysis was conducted to assess
stability between studies.⁴¹ Publication bias was assessed with Doi plots and the Luis Furuya-
Kanamori (LFK) index quantified the asymmetry in the Doi plots. The Doi plot uses a rank-based
measure (Z score) of precision (instead of the standard error) and plots it against the effect size, and
the LFK index quantifies the extent of Doi plot asymmetry by averaging half of the sum of the Z
score plus the normalized effect size across the meta-analysis. The closer the value of the LFK index
is to zero, the more symmetrical the Doi plot.⁴² LFK index values outside the interval of -1 and +1
are deemed consistent with asymmetry.⁴²

Patient and public involvement

Patients and the public were not involved in this research.

RESULTS

Study Selection

Our initial search resulted in a total of 441 records: 437 from database searching and four records from manual searches of references. After duplicates were removed, 242 records were identified, and 220 records were excluded as irrelevant. After reading the full-text articles, 7 studies met the inclusion criteria (Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.). Two studies were excluded for lacking necessary data for meta-analysis. Finally, five studies with 6 datasets were included in the final meta-analysis, involving a total of 1162 patients.²²⁻²⁶

Characteristics and Quality of the Included Studies

The characteristics of the included studies are presented in Table 1. The 7 studies included a total of 1,510 participants with diabetes and were published between 2011 and 2020.^{19,22-27} 10g-MF, VPT, NDS, pin prick, tuning fork 128Hz, and ankle reflex were used as the reference standard to explore the accuracy of IPTT in DPN. The research setting included homes of patients, clinics, care centers, and outpatient centers, and the assessors included doctors, nurses, and family caregivers.

We assessed the methodological quality of the studies using QUADAS. The assessment results of the research methodological quality of each study are presented in Figures 2.⁴³

Table 1. Basic characteristics of the included studies.

Study	Year	Country	n	Setting	Operators	Quality score(Qi)	Reference standard	TP	FP	FN	TN	Se(%)	Sp (%)
Sharma ²²	2012	UK	130	home	families	0.074	10g-MF	24	4	6	96	80.0	96.0
Sharma ²³	2014	UK	331	home	families	0.714	10g-MF	65	15	18	233	78.3	93.9
				clinic	doctors/ nurses	0.786	10g-MF	67	9	16	239	81.2	96.4
Amal Madanat ²⁴	2015	Saudi Arabia	351	care centers	doctors/ nurses	0.357	10g-MF	29	6	28	288	51.0	98.0
							VPT	48	24	9	270	85	92
							NDS	30	9	27	285	53	97
							10g- MF	4	30	1	65	80.0	68.0
I.S, Basir ²⁵	2020	Spain	100	care centers	doctors/ nurses	0.429	Pin prick	4	1	11	84	80.0	88.0
							Tuning fork 128Hz	2	3	69	26	40.0	27.0
							Ankle reflex	1	4	2	93	20.0	97.0
Dutra ²⁶	2020	Brasilia	250	outpatient centre	doctors/ nurses	0.643	10g-MF	30	5	6	209	83.3	97.7
Rayman ¹⁹	2011	UK	265	clinic	-	-	VPT	-	-	-	-	76.0	90.0
Bowling ²⁷	2012	UK	83	clinic	doctors/ nurses	-	VPT	-	-	-	-	100	96.6
							NDS	-	-	-	-	100	90.3

Se, Sensitivity; Sp, Specificity

Screening Accuracy

In the included studies, the researchers used a variety of different test methods as the standard to observe the sensitivity and specificity of IPTT for screening for DPN, such as 10g-MF, VPT, NDS, tuning fork 128Hz, and ankle reflex. The differences in the sensitivity and specificity of IPTT obtained by using different test methods as reference standards are presented. In general, when 10g-MF and VPT were used as reference standards, the sensitivity and specificity of IPTT were relatively high. For the 5 studies comprising 6 data pools that used 10g-MF as the reference standard, the sensitivity ranged from 51.0% - 83.3%, and the specificity ranged from 68.0 - 98.0%.²²⁻²⁶ For the 3 studies that used VPT as a reference standard, the sensitivity ranged from 76.0 - 100.0%, and the specificity ranged from 90.0 - 96.6%. Using neuropathy disability scores (NDS) as the reference standard, the sensitivity of IPTT to be 0.53, and the specificity to be 0.97. Compared with the pin prick, the sensitivity and specificity of IPTT were 0.8 and 0.88, respectively.²⁴ Compared with 128Hz tuning fork, the sensitivity and specificity of IPTT were only 0.4 and 0.27, respectively.²⁵ Compared with ankle reflex, IPTT had a sensitivity of 0.2 and a specificity of 0.97 (Table 1).²⁵

Meta-analysis Results Using 10g-MF as the Reference Standard

Screening Accuracy

In the literature we retrieved, there were a total of 5 studies with IPTT as the target test and 10g-MF as the reference standard.²²⁻²⁶ Among these 5 studies, one study has two datasets because it was conducted in the patient's home and the clinic.²² Therefore, six datasets were included to evaluate the overall effect of IPTT in the screening of DPN.²²⁻²⁶ The combined sensitivity and specificity were 0.77 (95 % CI 0.69–0.84) and 0.96 (95 % CI 0.93–0.98), respectively. The results show I-squared is 40.5%. In addition, the DOR was 75.24(39.90-141.89). The SROC analysis for the studies yielded an overall weighted area under the curve of 0.90(0.86-0.92) (Figure 3; Supplementary Files 2).

Sensitivity Analysis and Fagan's analysis

1
2
3 After excluding each study, the difference between the combined effect and the value before
4 exclusion was minor, suggesting the results of this study are stable (Supplementary Files 3). Fagan's
5 analysis showed that the pre-test probability was 50%, the probability of a positive result for DPN
6 detected by IPTT was 94%, and the probability of a negative result for DPN detected was 23%.
7
8 Further, the positive likelihood ratio was 15, and the negative likelihood ratio was 0.23. The above
9 results demonstrate that there is a good diagnostic value of IPTT for DPN (Figure 4).
10
11
12
13
14

15 16 ***Publication Bias***

17
18 The LFK index was calculated to be -1.68, and the Doi plot and LFK index showed minor
19 asymmetry, which means that there is a slight publication bias (Figure 5).
20
21
22

23 24 **DISCUSSION**

25
26 DPN is the most important risk factor for the occurrence of DFU and one of the more common
27 chronic complications associated with diabetes. However, it is often ignored. Once the patient
28 develops DPN, it is likely to cause diabetic foot ulcers, gangrene, and even amputation, and many
29 patients experience numbness and tingling in their limbs. Early identification of DPN can greatly
30 reduce the burden of chronic diseases on society. In this study, we systematically reviewed the
31 relevant literature on the identification of DPN by IPTT. A total of 7 studies were included,
32 involving 1,510 participants with diabetes to explore the value of IPTT screening. Previous studies
33 have disputed the diagnostic value of IPTT, mainly due to the use of different test methods, such as
34 VPT, NDS, pinprick, tuning fork 128Hz, and ankle reflex, as the reference standard.³³ Compared
35 with NDS, acupuncture, 128Hz tuning fork, and ankle reflex, IPTT has higher screening accuracy
36 when 10g-MF and VPT were used as the reference standard.^{10,19,20} Basir et al. observed that when
37 128Hz tuning fork was used as a reference standard, the sensitivity and specificity of IPTT were
38 only 40% and 27%, respectively. This may be since the predictive level of a tuning fork is less than
39 that of the monofilament. However, Miller et al observed that combining a tuning fork with
40 monofilament would result in a more effective evaluation.²¹ Regarding the quality of the current
41 studies, some studies lacked rigor in study design, such as the interval between target tests and
42 unclear reference standard tests, and most studies failed to describe the reference methods in detail.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The overall quality of the included studies was rated as low to medium quality.
4
5

6 Compared with 10g-MF, the results of the meta-analysis found the combined sensitivity and
7 specificity of IPTT to be 0.77(95 % CI 0.69-0.84) and 0.96(95 % CI 0.93-0.98), respectively, and
8 AUC to be 0.90(95%CI 0.86-0.92). The results indicated that IPTT had a moderate to high level of
9
10 sensitivity and a high level of specificity for screening DPN. In our analysis, a DOR equal to 1
11 indicated that a test was unable to distinguish between patients with or without the disease. Our
12 study yielded a DOR value of 75.24(95 % CI 39.90-141.89), indicating that NLR had a certain
13 accuracy in the diagnosis of patients with DPN. We also found that when VPT is used as reference
14 standards, IPTT has higher sensitivity and specificity. At present, 10g-MF and VPT are the most
15 widely used clinical screening methods for DPN. Basir et al. explored the accuracy of using IPTT
16 in detecting neuropathy in patients with small fiber and large fiber neuropathy, the result shows that
17 there is no difference between the IPTT against the golden standard small fiber neuropathy large
18 fiber neuropathy, and they concluded that the IPTT can be used an alternative assessment.²⁵
19 Therefore, the current evidence shows that IPTT has a high screening value for DPN and can be
20 used for preliminary screening of DPN in areas lacking equipment.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 We also drew Fagan's plot, the results show that IPTT has a certain potential screening value of
39 IPTT in DPN. Previous studies have shown that the prevalence of DPN is 50%, when the pre-test
40 probability of 50% through the likelihood ratio of 15, the line intersects with the post-test probability
41 of about 94%, this means that the probability of the diabetic patient with DPN will increase from 50%
42 to 94% when he or she has had a positive result for Test IPTT, at this time, electromyography and
43 nerve conduction velocity tests may be recommended by the clinician to determine whether the
44 patient has DPN; Joining the pre-test probability of 50% to the likelihood ratio of 0.23 on the Fagan's
45 nomogram, we read a post-test probability of about 19%, this means that after a negative test, a
46 person in this population's chance of having DPN reduces from 50% to 19%, this means that if the
47 patient tests negative, her chance of having DPN would decrease from 50% to a very low risk of
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 19%. This may make the doctor decide not to recommend electromyography and nerve conduction
4 velocity tests (Figure 4).
5
6
7

8 Heterogeneity is an important factor of this meta-analysis. In this study, we chose the quality
9 effects model because it has been proven to be significantly better than the traditional random effects
10 model and fixed effects model at effectively avoiding the problem of high heterogeneity caused by
11 statistical analysis. When 10g-MF was used as the reference standard, the I^2 was only 40.5%,
12 indicating that there was good consistency among the five studies included in the meta-analysis. In
13 addition, the existence of heterogeneity may be related to some other factors, such as differences in
14 research methodology, operators, or other factors. Due to the limited number of included studies,
15 we did not analyze the heterogeneity through subgroup analysis in this study. In terms of
16 methodology, although we have systematically and comprehensively studied the current evidence
17 of IPTT screening in DPN, still the original studies are very limited, and the existing conclusions
18 are only based on these 7 original studies. Therefore, caution should be taken when popularizing
19 them. About using other test methods as the reference standard (except 10g-MF), we only described
20 the relevant indicators as there were too few related studies to merge data, this was also one of the
21 limitations of our study.
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36
37 Studies have shown that routine foot examinations and rapid risk stratification are often difficult
38 to implement in busy primary care institutions. Additionally, the lack of awareness of standardized
39 testing for DPN amongst healthcare professionals is a concern, which may be due to a shortage of
40 material and personnel resources in primary care institutions. This is concerning because identifying
41 foot neuropathy and the patients at risk for ulceration has been shown to prevent the incidence of
42 foot ulcers.⁴⁴⁻⁴⁶ IPTT is a new method for screening DPN that does not require any tools and can be
43 carried out after minimal training. It is not affected by time, venue, or its operators.²⁰ The
44 advancement of IPTT is of great significance for the early screening of DPN to impede the
45 progression of diabetic foot ulcers, as it can be used to quickly and reliably screen and manage
46 patients at high risk for ulceration, especially in remote areas or places lacking screening tools.^{47,48}
47 Kerry et al. reported that in the first year IPTT was introduced as a screening tool, the relative risk
48 reduction (RRR) of DFU was 64%, and in the second year, the RRR was 70%, thereby reducing
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 hospital-acquired foot ulcers in patients with diabetes by two-thirds and negating the excess risk
4 associated with diabetes.^{20,49-51} Meanwhile, it can effectively improve patients' disease-related
5 knowledge, which plays a positive role in promoting the self-management of patients and their
6 families. At the same time, IPTT has a predictive effect on diabetic foot ulcers and reduces delays
7 in patient visits.²¹ However, more thorough studies are needed for verification.
8
9
10
11
12

13
14 Most of the literature on IPTT is focused on screening tests and some commentary-type studies,
15 and the number of studies is small. These studies were carried out in the United Kingdom, Spain,
16 Brazil, and Saudi Arabia, and although they achieved satisfactory results, have not been carried out
17 globally. However, it has not been applied in developing countries such as China. China is a country
18 with a large population and a relatively small number of medical personnel, especially in some
19 remote areas where the medical allocation is in short supply. In these areas, the application and
20 promotion of IPTT can effectively alleviate the allocation of medical resources and play an
21 important role in the management of patients with diabetes. IPTT has also recently been approved
22 for use in some countries.^{21,24-26} However, Kempegowda et al. reported that 88.4% of physicians are
23 not familiar with IPTT. Therefore, we suggest that IPTT be further promoted amongst physicians
24 and medical staff, especially in remote areas and areas lacking screening tools.³⁶ Future large-scale,
25 high-quality, and multi-center studies on populations of different ethnicities will verify the potential
26 applicability of IPTT alone or in combination with other DPN screening methods.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **CONCLUSIONS**

42
43
44 In summary, IPTT has a high degree of agreement in DPN screening with commonly used screening
45 tool for DPN, it can be used clinically, especially in remote areas and primary medical institutions,
46 and self-monitoring patients. This is also the first meta-analysis of the accuracy of IPTT
47 identification of DPN, and a systematic quantitative evaluation of its screening value, which can
48 provide evidence for the clinical application of IPTT in the future. However, due to a limited number
49 of studies of low or medium quality from limited geographical areas, more high-quality studies are
50 needed to promote more effective screening practices.
51
52
53
54
55
56
57
58
59
60

Acknowledgments

1
2
3 Thanks all authors and patients of the previous research for providing data for our article.
4
5

6 **Funding sources** 7

8
9 This research was supported by the Natural Science Foundation of Hunan Province (Grant No.
10 2019JJ80087)
11
12

13 **Author contributions** 14

15
16 ZN conducted the database search, screened and extracted data for the meta-analysis, prepared
17 extracted data for the procedures, and had primary responsibility in writing this article. LXY, ZJ
18 and ZF performed statistical analysis and contributed to article screening, data collection and
19 extraction. XJC, ZQH, and LJH contributed to the discussion and editing. XJC and CJR critically
20 revised the draft manuscript. All authors contributed toward data analysis, drafting and critically
21 revising the paper and agree to be accountable for all aspects of the work.
22
23
24
25
26
27
28
29

30 **Competing interests** 31

32
33 The authors state that they have no conflict of interest.
34
35

36 **Patient consent for publication** 37

38
39 Not required. All analyses were conducted based on previously published studies. Accordingly,
40 there was no patient or public involvement in this study. Ethical approval is not needed as it is a
41 systematic review of published literatures.
42
43
44
45

46 **Data availability statement** 47

48
49 Data are available in a public, open access repository. There are no data in this work. Data are
50 available on reasonable request. Data may be obtained from a third party and are not publicly
51 available. No data are available. All data relevant to the study are included in the article or uploaded
52 as supplementary information.
53
54
55
56
57
58
59
60

REFERENCES

1. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018;138:271-281.
2. Armstrong DG, Boulton A, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* 2017;376(24):2367-2375.
3. Banik PC, Barua L, Moniruzzaman M et al. Risk of diabetic foot ulcer and its associated factors among Bangladeshi subjects: a multicentric cross-sectional study. *BMJ Open*. 2020 Feb 28;10(2):e034058.
4. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. *Curr Neurol Neurosci Rep*. 2014;14(8):473.
5. Strachan MW, Reynolds RM, Marioni RE, et al. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. *Nat Rev Endocrinol*. 2011;7(2):108-14.
6. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep* 2019;19(10):86.
7. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. *J Vasc Surg* 2014;60(5):1247-54.
8. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40(1):136-154.
9. Javed S, Hayat T, Menon L, et al. Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. *Diabet Med* 2020;37(4):573-579.
10. Feldman EL, Nave KA, Jensen TS, et al. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron* 2017;93(6):1296-1313.
11. Zhang Y, Li N, Zhao Y, Fan D. Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnts (PDN-SCOPE): protocol for a multicentre cross-sectional registry study of clinical characteristics and treatment in China. *BMJ Open*. 2019 Apr 8;9(4):e025722.
12. Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. *J Am Podiatr Med Assoc* 2011;101(2):93-115.
13. International Diabetes Federation. Diabetic foot screening pocket chart. Brussels: IDF 2017. <https://www.idf.org/our-activities/advocacy-aware>.
14. Standards of Medical Care in Diabetes-2017: Summary of Revisions. *Diabetes Care* 2017;40(Suppl 1):S4-5.
15. Craig AB, Strauss MB, Daniller A, et al. Foot sensation testing in the patient with diabetes: introduction of the quick & easy assessment tool. *Wounds* 2014;26(8):221-31.
16. Slater RA, Koren S, Ramot Y, et al. Interpreting the results of the Semmes-Weinstein monofilament test: accounting for false-positive answers in the international consensus on the diabetic foot protocol by a new model. *Diabetes Metab Res Rev* 2014;30(1):77-80.
17. Lavery LA, Lavery DE, Lavery DC, et al. Accuracy and durability of Semmes-Weinstein

- monofilaments: what is the useful service life? *Diabetes Res Clin Pract* 2012;97(3):399-404.
18. Spruce MC, Bowling FL. Diabetic foot screening: new technology versus 10g monofilament. *Int J Low Extrem Wounds* 2012 2012-03-01;11(1):43-8.
19. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. *Diabetes Care* 2011;34(7):1517-8.
20. Vas PR, Sharma S, Rayman G. Distal Sensorimotor Neuropathy: Improvements in Diagnosis. *Rev Diabet Stud* 2015;12(1-2):29-47.
21. Miller JD, Carter E, Shih J, et al. How to do a 3-minute diabetic foot exam. *J Fam Pract* 2014;63(11):646-56.
22. Sharma S, Kerry C, Rosier J, et al. The Ipswich Touch Test (IpTT): Screening for diabetic neuropathy at home. *Diabet Med* 2012;29:20.
23. Sharma S, Kerry C, Atkins H, et al. The Ipswich Touch Test: a simple and novel method to screen patients with diabetes at home for increased risk of foot ulceration. *Diabet Med* 2014;31(9):1100-3.
24. Madanat A, Sheshah E, Badawy E, et al. Utilizing the Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration among diabetics: The Saudi experience. *Prim Care Diabetes* 2015;9(4):304-6.
25. Basir IS, Syam Y, Yusuf S, et al. Accuracy of Ipswich Touch Test (IpTT) to detect small fiber neuropathy and large fiber neuropathy as a risk factor of diabetic foot ulcers in public health centers. *Enferm Clin* 2020;30 Suppl 2:308-12.
26. Dutra L, Moura MC, Do PF, et al. Is it possible to substitute the monofilament test for the Ipswich Touch Test in screening for peripheral diabetic neuropathy? *Diabetol Metab Syndr* 2020;12:27.
27. Schaper NC, van Netten JJ, Apelqvist J, et al. IWGDF Editorial Board. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). *Diabetes Metab Res Rev*. 2020 Mar;36 Suppl 1:e3266. doi: 10.1002/dmrr.3266. PMID: 32176447.
28. Atlantis E, Cochrane B. The association of dietary intake and supplementation of specific polyunsaturated fatty acids with inflammation and functional capacity in chronic obstructive pulmonary disease: a systematic review *Int J Evid Based Healthc* 2016;14(2):53-63.
29. McInnes M, Moher D, Thombs BD, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018;319(4):388-96.
30. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol*. 2003 Nov 10;3:25. doi: 10.1186/1471-2288-3-25.
31. Foxlee N, Stone JC, Doi SA. A comparison of univariate and bivariate models in meta-analysis of diagnostic accuracy studies. *Int J Evid Based Healthc*. 2015 Mar;13(1):28-34.
32. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. *BMJ*. 2004;329(7458):168-9.

- 1
- 2
- 3 33. The Nordic Cochrane Centre (2014) Review manager. Cochrane Collab 1–43.
- 4
- 5 34. Doi SA, Barendregt JJ, Khan S, et al. Advances in the meta-analysis of heterogeneous clinical
- 6 trials II: The quality effects model. *Contemp Clin Trials*. 2015 Nov;45(Pt A):123-9.
- 7
- 8 35. Doi SAR, Furuya-Kanamori L. Selecting the best meta-analytic estimator for evidence-based
- 9 practice: a simulation study. *Int J Evid Based Healthc*. 2020 Mar;18(1):86-94.
- 10
- 11 36. Furuya-Kanamori L, Kostoulas P, Doi SAR. A new method for synthesizing test accuracy data
- 12 outperformed the bivariate method. *J Clin Epidemiol*. 2021 Apr;132:51-58.
- 13
- 14 37. Doi SAR, Furuya-Kanamori L, Thalib L, et al. Meta-analysis in evidence-based healthcare: a
- 15 paradigm shift away from random effects is overdue. *Int J Evid Based Healthc*. 2017
- 16 Dec;15(4):152-160.
- 17
- 18 38. Doi SA. Evidence synthesis for medical decision making and the appropriate use of quality
- 19 scores. *Clin Med Res*. 2014 Sep;12(1-2):40-6.
- 20
- 21 39. Stone JC, Glass K, Munn Z, et al. Comparison of bias adjustment methods in meta-analysis
- 22 suggests that quality effects modeling may have less limitations than other approaches. *J Clin*
- 23 *Epidemiol*. 2020 Jan;117:36-45.
- 24
- 25 40. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*
- 26 2002;21(11):1539-58.
- 27
- 28 41. Lo K, Stephenson M, Lockwood C. Analysis of heterogeneity in a systematic review using meta-
- 29 regression technique. *Int J Evid Based Healthc* 2019.
- 30
- 31 42. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative
- 32 method for detecting bias in meta-analysis. *Int J Evid Based Healthc*. 2018 Dec;16(4):195-203.
- 33
- 34 43. Furuya-Kanamori L, Xu C, Hasan SS, et al. Quality versus Risk-of-Bias assessment in clinical
- 35 research. *J Clin Epidemiol*. 2021 Jan;129:172-175.
- 36
- 37 44. Bowling FL, Abbott CA, Harris WE, et al. A pocket-sized disposable device for testing the
- 38 integrity of sensation in the outpatient setting. *Diabet Med* 2012;29(12):1550-2.
- 39
- 40 45. Kempegowda P, Saeed MA. Foot STAMP (Short-burst Teaching Aimed at Medical
- 41 Professionals): Impact of 'shortburst' teaching on the knowledge regarding the Ipswich Touch
- 42 Test. *Diabet Med* 2016;33:134.
- 43
- 44 46. Bailey TS, Yu HM, Rayfield EJ. Patterns of foot examination in a diabetes clinic. *Am Med J*
- 45 1985;78(3):371-4.
- 46
- 47 47. Baker N. An alternative to a 10-g monofilament or tuning fork? Two new, simple, easy-to-use
- 48 screening tests for determining foot ulcer risk in people with diabetes. *Diabet Med*
- 49 2012;29(12):1477-9.
- 50
- 51 48. O'Loughlin A, Dinneen SF. ACP Journal Club: the Ipswich Touch Test at home had 78%
- 52 sensitivity and 94% specificity for detecting loss of foot sensation. *Ann Intern Med*
- 53 2015;162(4):C10.
- 54
- 55 49. Kerry C. VPRR. Reduction in the incidence of hospital acquired foot pressure ulcers in people
- 56 with diabetes. *Diabetic Med* 2015;SUPPL. 1(32):26.
- 57
- 58
- 59
- 60

- 1
2
3 50. Kerry CD, Sharma S, Rayman G. Reduction in hospital-acquired diabetes foot lesions using the
4 Ipswich Touch Test (IpTT). *Diabetic Med* 2013;30:141-2.
5
6 51. Madanat A, Sheshah E, Badawy E, et al.: "P.R. Vas, S. Sharma, G. Rayman, Utilizing the
7 Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration
8 among diabetics: comment on the Saudi experience. *Prim Care Diabetes* 2015;9(5):401-2.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2 quality assessment of the included studies

589x428mm (72 x 72 DPI)

	Q1	Q10	Q11	Q12	Q13	Q14	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
Sharma2012	?	?	?	?	?	?	?	?	?	?	?	?	?	?
Sharma2014a	-	+	+	+	-	?	+	+	+	+	+	+	+	-
Sharma2014b	+	+	+	+	-	?	+	+	+	+	+	+	+	-
Madanat2015	+	?	?	+	?	?	+	+	?	?	?	?	+	-
Basir2020	+	?	?	+	-	?	+	+	?	?	?	+	+	-
Dutra2020	+	?	?	+	?	+	+	+	?	+	+	?	+	+

Figure 2. quality assessment of the included studies

589x428mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Sensitivity and specificity of IPTT in the diagnosis of DPN
255x185mm (72 x 72 DPI)




Figure 4. The Fagan for assessment of IPTT screening probability.

286x429mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Doi plot and LFK index.

255x185mm (72 x 72 DPI)

1
2
3
4 (Simplices, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
5 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
6 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))

7
8
9
10 #5 Search: "Diabetes Complications"[Mesh] Sort by: Most Recent

11
12
13 #6 Search:

14
15
16 #7 Search: "Diabetic Foot"[Mesh] Sort by: Most Recent

17
18
19 #8 Search: (((Foot, Diabetic[Title/Abstract]) OR (Diabetic Feet[Title/Abstract])) OR (Feet,
20 Diabetic[Title/Abstract])) OR (Foot Ulcer, Diabetic[Title/Abstract]))

21
22
23 #9 Search: ((ipswich touch test[Title/Abstract]) OR (touch test[Title/Abstract])) OR
24 (IPTT[Title/Abstract]))

25
26
27
28
29 #10 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((((Diabetes[Title/Abstract]) OR
30 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
31 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))))
32 OR ("Diabetic Neuropathies"[Mesh])) OR (((
33 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
34 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
35 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
36 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
37 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
38 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
39 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
40 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR
41 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
42 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
43 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
44 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
5 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
6 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicis[Title/Abstract])) OR
7 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicis,
8 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
9 (Simplicis, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
10 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
11 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
12 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
13 Complications[Title/Abstract]) OR (Diabetes Related Complications[Title/Abstract])) OR
14 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
15 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
16 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
17 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
18 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract]) OR (Diabetic
19 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
20 Diabetic[Title/Abstract]))

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 #11 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((((Diabetes[Title/Abstract]) OR
39 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
40 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))
41 OR ("Diabetic Neuropathies"[Mesh])) OR (((((((((((((((((((((((((((((((((((((((Diabetic
42 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
43 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
44 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
45 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
46 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
47 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
48 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
49 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR
50
51
52
53
54
55
56
57
58
59
60

(Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicies[Title/Abstract])) OR
 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicies,
 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
 (Simplicies, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
 Complications[Title/Abstract])) OR (Diabetes Related Complications[Title/Abstract])) OR
 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract])) OR (Diabetic
 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
 Diabetic[Title/Abstract])) AND (((ipswich touch test[Title/Abstract])) OR (touch
 test[Title/Abstract])) OR (IPTT[Title/Abstract]))

Embase Search Strategy

#1 'diabetes mellitus'/exp

#2 'diabetes, type 2':ab,ti OR 'type 2 diabetes mellitus':ab,ti OR 'diabetes mellitus, type
 ii':ab,ti OR 'diabetes mellitus, type 1':ab,ti

#3 #1 OR #2

1
2
3
4 #4 'diabetic neuropathy'/exp
5

6
7 #5 'diabetic neuropathy':ab,ti OR 'neuropathies, diabetic':ab,ti OR 'neuropathy, diabetic':ab,ti
8 OR 'diabetic autonomic neuropathy':ab,ti OR 'autonomic neuropathies, diabetic':ab,ti OR
9 'autonomic neuropathy, diabetic':ab,ti OR 'diabetic autonomic neuropathies':ab,ti OR
10 'neuropathies, diabetic autonomic':ab,ti OR 'neuropathy, diabetic autonomic':ab,ti OR
11 'symmetric diabetic proximal motor neuropathy':ab,ti OR 'asymmetric diabetic proximal
12 motor neuropathy':ab,ti OR 'diabetic asymmetric polyneuropathy':ab,ti OR 'asymmetric
13 polyneuropathies, diabetic':ab,ti OR 'asymmetric polyneuropathy, diabetic':ab,ti OR 'diabetic
14 asymmetric polyneuropathies':ab,ti OR 'polyneuropathies, diabetic asymmetric':ab,ti OR
15 'polyneuropathy, diabetic asymmetric':ab,ti OR 'diabetic mononeuropathy':ab,ti OR 'diabetic
16 mononeuropathies':ab,ti OR 'mononeuropathies, diabetic':ab,ti OR 'mononeuropathy,
17 diabetic':ab,ti OR 'diabetic mononeuropathy simplex':ab,ti OR 'diabetic mononeuropathy
18 simplices':ab,ti OR 'mononeuropathy simplex, diabetic':ab,ti OR 'mononeuropathy simplices,
19 diabetic':ab,ti OR 'simplex, diabetic mononeuropathy':ab,ti OR 'simplices, diabetic
20 mononeuropathy':ab,ti OR 'diabetic polyneuropathy':ab,ti OR 'diabetic polyneuropathies':ab,ti
21 OR 'polyneuropathies, diabetic':ab,ti OR 'polyneuropathy, diabetic':ab,ti
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 #6 #4 OR #5
37
38

39 #7 'diabetic complication'/exp
40
41

42 #8 'diabetes complication':ab,ti OR 'diabetes-related complications':ab,ti OR 'diabetes
43 related complications':ab,ti OR 'diabetes-related complication':ab,ti OR 'diabetic
44 complications':ab,ti OR 'diabetic complication':ab,ti OR 'complications of diabetes
45 mellitus':ab,ti OR 'diabetes mellitus complication':ab,ti OR 'diabetes mellitus
46 complications':ab,ti
47
48
49
50
51

52
53 #9 #7 OR #8
54
55

56 #10 'diabetic foot'/exp
57
58

59 #11 'diabetic foot':ab,ti OR 'diabetic feet':ab,ti OR 'feet, diabetic':ab,ti OR 'foot ulcer,
60

1
2
3
4 diabetic':ab,ti OR 'foot ulcer':ab,ti
5

6
7 #12 #10 OR #11
8

9
10 #13 #3 OR #6 OR #9 OR #12
11

12
13 #14 'ipswich touch test':ab,ti OR 'touch test':ab,ti OR 'iptt':ab,ti
14

15
16 #15 #13 AND #14
17

18 **Cochrane Library Search Strategy**

19
20
21 #1 MeSH descriptor: [Diabetes Mellitus] explode all trees 31055
22

23
24 #2 (Diabetes):ti,ab,kw OR (Diabetes, Type 2):ti,ab,kw OR (Type 2 Diabetes
25 Mellitus):ti,ab,kw OR (Diabetes Mellitus, Type II):ti,ab,kw OR (Diabetes Mellitus, Type 1)
26

27
28 #3 MeSH descriptor: [Diabetic Neuropathies] explode all trees
29

30
31
32 #4 (Diabetic Neuropathy):ti,ab,kw OR (Neuropathies, Diabetic):ti,ab,kw OR (Neuropathy,
33 Diabetic):ti,ab,kw OR (Diabetic Autonomic Neuropathy):ti,ab,kw OR (Autonomic
34 Neuropathies, Diabetic):ti,ab,kw OR (Autonomic Neuropathy, Diabetic):ti,ab,kw OR
35 (Diabetic Autonomic Neuropathies):ti,ab,kw OR (Neuropathies, Diabetic
36 Autonomic):ti,ab,kw OR (Neuropathy, Diabetic Autonomic):ti,ab,kw OR (Symmetric
37 Diabetic Proximal Motor Neuropathy):ti,ab,kw OR (Asymmetric Diabetic Proximal Motor
38 Neuropathy):ti,ab,kw OR (Diabetic Asymmetric Polyneuropathy):ti,ab,kw OR (Asymmetric
39 Polyneuropathies, Diabetic):ti,ab,kw OR (Asymmetric Polyneuropathy, Diabetic):ti,ab,kw OR
40 (Diabetic Asymmetric Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic
41 Asymmetric):ti,ab,kw OR (Polyneuropathy, Diabetic Asymmetric):ti,ab,kw OR (Diabetic
42 Mononeuropathy):ti,ab,kw OR (Diabetic Mononeuropathies):ti,ab,kw OR
43 (Mononeuropathies, Diabetic):ti,ab,kw OR (Mononeuropathy, Diabetic):ti,ab,kw OR
44 (Diabetic Mononeuropathy Simplex):ti,ab,kw OR (Diabetic Mononeuropathy
45 Simpleses):ti,ab,kw OR (Mononeuropathy Simplex, Diabetic):ti,ab,kw OR (Mononeuropathy
46 Simpleses, Diabetic):ti,ab,kw OR (Simplex, Diabetic Mononeuropathy):ti,ab,kw OR
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(Simplices, Diabetic Mononeuropathy):ti,ab,kw OR (Diabetic Polyneuropathy):ti,ab,kw OR
 (Diabetic Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic):ti,ab,kw OR
 (Polyneuropathy, Diabetic):ti,ab,kw 3653

#5 MeSH descriptor: [Diabetes Complications] explode all trees

#6 (Diabetes-Related Complications):ti,ab,kw OR (Diabetes Related
 Complications):ti,ab,kw OR (Diabetes-Related Complication):ti,ab,kw OR (Diabetic
 Complications):ti,ab,kw OR (Diabetic Complication):ti,ab,kw OR (Complications of Diabetes
 Mellitus):ti,ab,kw OR (Diabetes Mellitus Complication):ti,ab,kw OR (Diabetes Mellitus
 Complications)

#7 MeSH descriptor: [Diabetic Foot] explode all trees

#8 (Diabetic Feet):ti,ab,kw OR (Feet, Diabetic):ti,ab,kw OR (Foot Ulcer, Diabetic)

#9 (ipswich touch test):ti,ab,kw OR (touch test):ti,ab,kw OR (IPTT)

#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

#11 #9 AND #10

Web of Science Search Strategy

#1 TS=(Diabetes Mellitus or Diabetes or Diabetes, Type 2 or Type 2 Diabetes Mellitus or
 Diabetes Mellitus, Type II or Diabetes Mellitus, Type 1)

#2 TS=(Diabetic Neuropathies or Diabetic Neuropathy or Neuropathies, Diabetic or
 Neuropathy, Diabetic or Diabetic Autonomic Neuropathy or Autonomic Neuropathies,
 Diabetic or Autonomic Neuropathy, Diabetic or Diabetic Autonomic Neuropathies or
 Neuropathies, Diabetic Autonomic or Neuropathy, Diabetic Autonomic or Symmetric
 Diabetic Proximal Motor Neuropathy or Asymmetric Diabetic Proximal Motor Neuropathy or
 Diabetic Asymmetric Polyneuropathy or Asymmetric Polyneuropathies, Diabetic or
 Asymmetric Polyneuropathy, Diabetic or Diabetic Asymmetric Polyneuropathies or

1
2
3
4 Polyneuropathies, Diabetic Asymmetric or Polyneuropathy, Diabetic Asymmetric or Diabetic
5 Mononeuropathy or Diabetic Mononeuropathies or Mononeuropathies, Diabetic or
6 Mononeuropathy, Diabetic or Diabetic Mononeuropathy Simplex or Diabetic
7 Mononeuropathy Simplicis or Mononeuropathy Simplex, Diabetic or Mononeuropathy
8 Simplicis, Diabetic or Simplex, Diabetic Mononeuropathy or Simplicis, Diabetic
9 Mononeuropathy or Diabetic Polyneuropathy or Diabetic Polyneuropathies or
10 Polyneuropathies, Diabetic or Polyneuropathy, Diabetic)

11
12
13
14
15
16
17
18 #3 TS=(Diabetes Complications or Diabetes Complication or Diabetes-Related
19 Complications or Diabetes Related Complications or Diabetes-Related Complication or
20 Diabetic Complications or Diabetic Complication or Complications of Diabetes Mellitus or
21 Diabetes Mellitus Complication or Diabetes Mellitus Complications)

22
23
24
25
26
27 #4 TS=(Diabetic Foot or Foot, Diabetic or Diabetic Feet or Feet, Diabetic or Foot Ulcer,
28 Diabetic)

29
30
31 #5 #4 OR #3 OR #2 OR #1

32
33
34 #6 TS=(ipswich touch test or touch test or IPTT)

35
36
37 #7 #6 AND #5

38 39 40 41 **China National Knowledge Infrastructure (CNKI) Search Strategy**

42
43
44 检索式 A: (((主题=糖尿病 或者 题名=糖尿病 或者 v_subject=中英文扩展(糖尿病)
45 或者 title=中英文扩展(糖尿病)) 或者 (主题=糖尿病足 或者 题名=糖尿病足 或者
46 v_subject=中英文扩展(糖尿病足) 或者 title=中英文扩展(糖尿病足))) 或者 ((主题=糖
47 尿病周围神经病变 或者 题名=糖尿病周围神经病变 或者 v_subject=中英文扩展(糖尿
48 病周围神经病变) 或者 title=中英文扩展(糖尿病周围神经病变)) 或者 (主题=糖尿病并
49 发症 或者 题名=糖尿病并发症 或者 v_subject=中英文扩展(糖尿病并发症) 或者 title=
50 中英文扩展(糖尿病并发症)))) 并且 (((((主题=中英文扩展(touch test) 或者 题名=中
51 英文扩展(touch test) 或者 v_subject=touch test 或者 title=touch test) 或者 (主题=中
52 英文扩展(Ipswich Touch Test) 或者 题名=中英文扩展(Ipswich Touch Test) 或者

v_subject=Ipswich Touch Test 或者 title=Ipswich Touch Test)) 或者 ((主题=伊普斯维奇触摸测试 或者 题名=伊普斯维奇触摸测试 或者 v_subject=中英文扩展(伊普斯维奇触摸测试) 或者 title=中英文扩展(伊普斯维奇触摸测试)) 或者 (主题=中英文扩展(IPTT) 或者 题名=中英文扩展(IPTT) 或者 v_subject=IPTT 或者 title=IPTT))) 或者 ((关键词=轻触 或者 keyword=中英文扩展(轻触)) 或者 (关键词=轻触测试 或者 keyword=中英文扩展(轻触测试))) 或者 ((题名=触摸 或者 Title=中英文扩展(触摸)) 或者 (题名=触摸测试 或者 Title=中英文扩展(触摸测试))) (模糊匹配)

Wan Fang Database Search Strategy

主题:((糖尿病)+主题:(糖尿病足)+主题:(糖尿病周围神经病变)+全部:(糖尿病并发症))*主题:((touch test)+主题:(IPTT)+主题:(Ipswich Touch Test)+全部:(伊普斯维奇触摸测试))

China Biology Medicine disc (CBM) Search Strategy

- #1 "糖尿病"[不加权:扩展]
- #2 "糖尿病足"[常用字段:智能]
- #3 "糖尿病神经病变"[常用字段:智能]
- #4 "糖尿病并发症"[常用字段:智能]
- #5 (#4) OR (#3) OR (#2) OR (#1)
- #6 "touch"[常用字段:智能] AND "test"[常用字段:智能]
- #7 "IPTT"[常用字段:智能]
- #8 "Ipswich"[常用字段:智能] AND "Touch"[常用字段:智能] AND "Test"[常用字段:智能]
- #9 "伊普斯维奇触摸测试"[常用字段:智能]
- #10 "轻触"[常用字段:智能]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

#11 "轻触测试"[常用字段:智能]

#12 "触摸"[常用字段:智能]

#13 "触摸测试"[常用字段:智能]

#14 (#13) OR (#12) OR (#11) OR (#10) OR (#9) OR (#8) OR (#7) OR (#6)

#15 (#14) AND (#5)

For peer review only


1
2
3
4 . diagma tp fp fn tn, qe(qi)

5
6 Input form: TP FP FN TN assumed
7 Note: Weights are from Doi's quality effects model
8 Studies included: 6
9 Participants included: 1493
10 Prevalence of disease: 19.7%
11 Heterogeneity (I-squared): 40.5%
12 Pub bias (LFK index): -1.7, minor asymmetry
13

	Estimate	95% Conf. Interval	
Sens	.77	.688	.836
Spec	.957	.928	.975
LR+	18.064	10.748	30.358
LR-	.24	.167	.346
DOR	75.239	39.898	141.887
AUC	.897	.863	.923

14
15
16
17
18
19
20
21
22
23
24
25 The results of sensitivity and specificity of IPTT in the diagnosis of DPN
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Supplementary Files 3. Sensitivity analysis

644x429mm (72 x 72 DPI)



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	2
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	6-7



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6-7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9-10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	13
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2
For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046966.R2
Article Type:	Original research
Date Submitted by the Author:	16-Jul-2021
Complete List of Authors:	<p>Zhao, Nan; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Xu, Jing-can; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Qihong; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha</p> <p>Li, Xinyi; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Nursing School of Central South University</p> <p>Chen, Jiarui ; Central South University Xiangya School of Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Jing; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing</p> <p>Zhou, Feng; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Hospital Central South University, Department of Emergency</p> <p>Liang , Jinghong; Sun Yat-Sen University, 6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Neurology, Public health, Diabetes and endocrinology
Keywords:	Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Diabetic foot < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

AUTHORS' INFORMATION

Zhao Nan^{1,2}, Xu Jingcan^{1,2}, Zhou Qihong^{1,4}, Li Xinyi^{1,3}, Chen Jiarui^{2,3}, Zhou Jing¹, Zhou Feng^{1,5}, Liang Jinghong⁶

Zhao Nan 187811023@csu.edu.cn

Xu Jingcan 983556951@qq.com

Zhou Qihong 928555448@qq.com

Li Xinyi 905492390@qq.com

Chen Jiarui chenjr@csu.edu.cn

Zhou Jing zhou-jing62@hotmail.com

Zhou Feng 316925782@qq.com

Liang Jinghong liangjh78@mail2.sysu.edu.cn

1. Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, 410008, China

2. Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group, Changsha, 410013, China

3. Xiangya Nursing School of Central South University, Changsha, 410013, China

4. Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha, 410008, China

5. Department of Emergency, Xiangya Hospital, Central South University, Changsha, 410008, China

6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China

Corresponding author: Xu Jingcan, 983556951@qq.com; Zhou Qihong, 928555448@qq.com

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

ABSTRACT

Objective: Diabetic peripheral neuropathy (DPN) is one of the most important risk factors of diabetic foot ulcers (DFU), and early screening and treatment of DPN are crucial. The Ipswich Touch Test (IPTT) is a new method for screening for DPN and, compared with traditional methods, is more simple to operate and requires no equipment. However, the screening accuracy of IPTT in DPN patients has not been well characterized. We aim to conduct a systematic review and meta-analysis to characterize the sensitivity and specificity of IPTT compared to traditional methods and to understand the potential screening value of IPTT.

Design: Systematic review and meta-analysis.

Data sources: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedical Literature Database (CBM) up to April 16, 2020.

Methods: Stata version 15.1 software was used for analysis, and the screening value of IPTT in DPN was described using 10g-MF, NDS, Pin prick, 128Hz tuning fork, and ankle reflex as reference standards. Sensitivity, specificity, and other measures of accuracy of IPTT for screening DPN were pooled based on a quality effects model. The protocol was registered with PROSPERO (42020168420).

Results: Of the 441 records retrieved, seven studies were evaluated for the screening value of IPTT. Five studies with 10g-MF as the reference standard were included in the meta-analysis, and the pooled sensitivity and specificity were 0.78 (95 % CI 0.65–0.87) and 0.95(95 % CI 0.89–0.98), respectively, and AUC was 0.93. Compared with VPT, IPTT showed a sensitivity between 0.76 and 1, and a specificity between 0.90 and 0.97. Compared with NDS, IPTT showed a sensitivity between 0.53 and 1, and a specificity between 0.90 and 0.97. Compared with Pin prick, IPTT showed a

1
2
3 sensitivity and specificity of 0.8 and 0.88, respectively. Compared with 128Hz tuning fork, IPTT
4 showed a sensitivity and specificity of 0.4 and 0.27, respectively. Compared with ankle reflex, IPTT
5 had a sensitivity of 0.2 and a specificity of 0.97.
6
7
8
9

10 **Conclusions:** IPTT shows a high degree of agreement with other commonly used screening tools
11 for DPN screening. It can be used clinically, especially in remote areas and in primary medical
12 institutions, and by self-monitoring patients. More high-quality studies are needed to assess and
13 promote more effective screening practices.
14
15
16
17
18

19 **Prospero:** Registration Number is CRD (42020168420)
20
21

22 **Strengths and limitations of this study**

23

- 24 • This is the first meta-analysis to explore the potential screening value of IPTT in DPN.
- 25 • A quality effects model was used to achieve optimal error estimation in the data analysis.
- 26 • A Doi plots and Luis Furuya-Kanamori (LFK) index were used to assess publication bias.
- 27 • Although we systematically and comprehensively studied the current evidence of IPTT screening
28 in DPN screening, the number of original studies was very limited, and the existing conclusions
29 were based on these 7 original studies. Therefore, readers should therefore proceed with caution.
30
31
32
33
34
35
36
37
38
39
40
41

42 **Keywords:** Ipswich Touch Test, Diabetic peripheral neuropathy, Meta-analysis
43
44

45 **INTRODUCTION**

46

47
48 Diabetic peripheral neuropathy (DPN) is a common long-term complication and the most important
49 risk factor for the occurrence of diabetic foot ulcers (DFU).¹⁻⁴ DPN affects up to 50% of people with
50 diabetes,^{5,6} with chronic painful neuropathy affecting up to 26%.⁷ In the early stage of DPN, the
51 symptoms lack specificity, and about half of patients with diabetes cannot recognize the injury to
52 the lower extremities.^{8,9} Once the patient has symptoms such as limb numbness and pain, it signals
53 that pathological changes have occurred in the peripheral nerves and have advanced into the
54
55
56
57
58
59
60

1
2
3 irreversible stage. If not treated promptly, serious tissue damage, such as foot ulcers, amputation,
4 and even death, may occur.^{10,11} Studies have shown that early screening and detection of peripheral
5 neuropathy can not only slow down the DPN process, but also effectively prevent DFU.¹² Therefore,
6
7 early screening and treatment of DPN is very important.
8
9

10
11
12 At present, the screening value of 10g monofilament (10g-MF), Vibration perception threshold
13 (VPT), and 128Hz tuning fork in DPN has been widely recognized.¹³ Compared with VPT and
14 128Hz tuning forks, 10g-MF is the most widely used screening tool because it is more simple,
15 objective, and easy to carry, although it requires a calibration facility to confirm that the vertical
16 pressure of the monofilament used when bending is 10g.¹⁴⁻¹⁶ Commercially available 10g-MF
17 devices exhibit significant variability within and between devices of different manufacturers and
18 their actual bending force varies widely from their designated 10g value. When used they have a
19 short service life where the instrument is within 10% of their initial bending force which is not
20 usually the stated 10g of force.^{17,18} Meanwhile, medical personnel are required to be trained before
21 using the device, and screening is limited to hospitals or clinics. For clinics and communities in
22 remote areas, medical personnel may lack the device or the training to screen patients for DPN,
23 resulting in a missed opportunity for patients to receive the best treatment. In recent years, Dr.
24 Rayman proposed the Ipswich Touch Test (IPTT), which only requires the physician's index finger.
25 During this test, the patient is required to close their eyes while the physician lightly rests their finger
26 on each of the patient's first, third, and fifth toes for 1 to 2 seconds. Patients are instructed to respond
27 with a "yes" when they feel the physician's touch. Compared with the current methods, IPTT
28 requires no equipment, is more convenient and effective, and can be performed by doctors, nurses,
29 and even family caregivers after training.¹⁹ IPTT can be applied to inpatients, outpatients,
30 community patients, self-monitoring patients at home, and to areas lacking more advanced
31 equipment.^{20,21} Currently, IPTT has been applied in the United Kingdom, Spain, Brazil, and Saudi
32 Arabia,^{19,22-26} and was approved by the American Diabetes Association in 2015.²⁰ The 2019
33 guidelines of the International Working Group on the Diabetic Foot also suggest that IPTT should
34 be used for DPN screening in patients with diabetes in the absence of 10g-MF.²⁷ Although these
35 studies have achieved satisfactory results, they have not been widely promoted and applied globally.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Previous studies have reported differences in the results of the screening value of DPN. However,
4
5 neither a meta-analysis nor a systematic review has been conducted on the screening value of IPTT.
6
7

8 In this study, we aimed to conduct a comprehensive and systematic literature review to
9
10 systematically evaluate the potential screening value of IPTT in DPN, and provide evidence and
11
12 guidance for the clinical application value of IPTT.
13
14

15 **METHODS**

16
17
18 The Joanna Briggs Institute (JBI) protocol²⁸ has been registered with PROSPERO, the International
19
20 Prospective Register of Systematic Reviews hosted by the Centre for Reviews and Dissemination
21
22 (Registration Number is CRD (42020168420). We followed the Preferred Reporting Items for
23
24 Systematic Reviews and Meta-Analyses (PRISMA)²⁹.
25
26

27 **Data Sources and Searches**

28
29 We systematically searched PubMed, Embase, Cochrane Library, Web of Science, China National
30
31 Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Biomedical Literature Database (CBM)
32
33 for reports published before April 16, 2020. For included studies with insufficient data, we emailed
34
35 the authors to ask if they would provide data for our study. With this strategy, we combined search
36
37 terms for applied technique (Ipswich touch test, touch test, IPTT) and disease (Diabetic peripheral
38
39 neuropathy, diabetic foot, diabetic foot ulcer, Diabetes Mellitus, diabetic complications). The study
40
41 design and published language were not limited. In addition, we conducted a manual search,
42
43 including searching through conference papers and gray literature, and the references of all included
44
45 studies were examined. All search strategies were determined by multiple pre-searches, and the
46
47 search formulas were adjusted according to the characteristics of each database. A detailed search
48
49 strategy is provided in “Supplementary files 1”. All analyses were based on previously published
50
51 studies; thus, no ethical approval and patient consent were required.
52
53

54 **Inclusion and Exclusion Criteria**

55
56
57 Previously published studies were included in this meta-analysis if: (1) the study examined the
58
59 screening accuracy of the IPTT test for detecting DPN; (2) all the research subjects were patients
60

1
2
3 with diabetes, and; (3) IPTT was included as an index test. Studies were excluded from the meta-
4 analysis if the studies had incomplete data sets or were other than original reports
5 (commentaries/reviews). The age, sex, region, and race of the subjects were not restricted. The
6 published language was not limited.
7
8
9

10 11 12 **Data Extraction and Quality Assessment**

13
14
15 We imported initial search records from databases into NoteExpress V3.2.0.7535 literature
16 management software. Two reviewers independently screened titles and abstracts of all the included
17 literature, following the inclusion and exclusion criteria. After screening the abstract, the full text
18 was read in detail. Any discrepancies were resolved by discussion. The following information was
19 extracted from the eligible studies: study characteristics (author, publication year, study period,
20 country, reference standard, setting, operators), participant characteristics (sample number, range),
21 and outcome indicators (sensitivity, specificity, true positive number (TP), false positive number
22 (FP), false negative number (FN), true negative number (TN)). Missing data were supplemented by
23 contacting authors wherever possible.
24
25
26
27
28
29
30
31
32
33

34 The quality of the included studies was assessed using the Quality Assessment of Diagnostic
35 Accuracy Studies (QUADAS), it is a methodological quality assessment scale, and includes 14
36 items³⁰. Quality items were weighted equally with 1 point awarded for each of the 14 items. The
37 quality score was then calculated by summing the points awarded for each question (maximum sum
38 14). This score was then normalized by dividing the sum by the highest score of the listed studies,
39 thereby ranking the studies from 1 down to a minimum of 0.³¹ Data extraction and quality assessment
40 was performed independently by two reviewers. Differences were reconciled through discussion
41 until a consensus was reached on the item in question.
42
43
44
45
46
47
48
49
50

51 **Data Synthesis**

52
53
54 The likelihood ratio is an independent indicator to assess authenticity, which can simultaneously
55 reflect sensitivity and specificity. When the PLR is >10 or the NLR is <0.1, the probability of
56 diagnosing or excluding a certain disease increases significantly. The DOR with 95% CI was also
57
58
59
60

1
2
3 calculated. For each summary statistic, a 95% confidence interval was computed. The sensitivity,
4 specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and corresponding 95%
5 confidence interval (95% CI) were obtained using the quality effects model, it is the synthesis model
6 for diagnostic odds ratios within the split component synthesis method.^{32,33} Relevant studies have
7 proven that this model is superior to the traditional random effects model and fixed effects model.³⁴⁻
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

³⁶ The quality scores were used to redistribute inverse variance weights based on study deficiencies via the quality effects model,^{37,38} the software by using Stata, version 15.1 (Stata Corp, College Station, TX)

Since the number of studies included affects the Q test, we used the I^2 statistic to evaluate the magnitude of heterogeneity since the value of the I^2 statistic will not change with the number of studies included and the results of heterogeneity test are more reliable, An $I^2 \geq 50\%$ indicates the existence of significant heterogeneity.^{39,40} Publication bias was assessed with Doi plots and Luis Furuya-Kanamori (LFK) index, the Doi plot uses a rank-based measure (Z score) of precision (instead of the standard error) and plots it against the effect size, it can visualize asymmetry, and the LFK index quantifies the extent of Doi plot asymmetry by averaging half of the sum of the Z score plus the normalized effect size across the meta-analysis, which can detect and quantify the asymmetry in the Doi plots. The closer the value of the LFK index is to zero, the more symmetrical the Doi plot.⁴¹ LFK index values outside the interval of -1 and +1 are deemed consistent with asymmetry.⁴¹ Related studies have shown that these methods can markedly improve the ability of researchers to detect bias in a meta-analysis.⁴¹

Patient and public involvement

Since the data in this study were all from previously published studies, patients and the public were not involved in this research.

RESULTS

Study Selection

Our initial search resulted in a total of 441 records: 437 from database searching and four records

1
2
3 from mshuianual searches of references. After duplicates were removed, 242 records were identified,
4 and 220 records were excluded as irrelevant. After reading the full-text articles, 7 studies met the
5 inclusion criteria (Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
6 (PRISMA) flow diagram.). Two studies were excluded for lacking necessary data for meta-analysis.
7
8 Finally, five studies with 6 datasets were included in the final meta-analysis, involving a total of
9
10
11
12
13 1162 patients.²²⁻²⁶
14
15

16 **Characteristics and Quality of the Included Studies**

17
18
19 The characteristics of the included studies are presented in Table 1. The 7 studies included a total of
20
21 1,510 participants with diabetes and were published between 2011 and 2020.^{19,22-27} To explore the
22
23 accuracy of IPTT in DPN screening, 10g-MF, VPT, NDS, pin prick, 128Hz tuning fork, and ankle
24
25 reflex were used as the reference standard. The research setting included homes of patients, clinics,
26
27 care centers, and outpatient centers, and the assessors included doctors, nurses, and family
28
29 caregivers.
30
31

32 We assessed the methodological quality of the studies using QUADAS. The assessment results
33
34 of the research methodological quality of each study are presented in Figures 2.⁴²
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Basic characteristics of the included studies.

Study	Year	Country	n	Setting	Operators	Quality score(Qi)	Reference standard	TP	FP	FN	TN	Se(%)	Sp (%)
Sharma ²²	2012	UK	130	home	families	0.074	10g-MF	24	4	6	96	80.0	96.0
Sharma ²³	2014	UK	331	home	families	0.714	10g-MF	65	15	18	233	78.3	93.9
				clinic	doctors/ nurses	0.786	10g-MF	67	9	16	239	81.2	96.4
Amal Madanat ²⁴	2015	Saudi Arabia	351	care centers	doctors/ nurses	0.357	10g-MF	29	6	28	288	51.0	98.0
							VPT	48	24	9	270	85	92
							NDS	30	9	27	285	53	97
							10g- MF	4	30	1	65	80.0	68.0
I.S, Basir ²⁵	2020	Spain	100	care centers	doctors/ nurses	0.429	Pin prick	4	1	11	84	80.0	88.0
							Tuning fork 128Hz	2	3	69	26	40.0	27.0
							Ankle reflex	1	4	2	93	20.0	97.0
Dutra ²⁶	2020	Brasília	250	outpatient centre	doctors/ nurses	0.643	10g-MF	30	5	6	209	83.3	97.7
Rayman ¹⁹	2011	UK	265	clinic	-	-	VPT	-	-	-	-	76.0	90.0
Bowling ²⁷	2012	UK	83	clinic	doctors/ nurses	-	VPT	-	-	-	-	100	96.6
							NDS	-	-	-	-	100	90.3

Se, Sensitivity; Sp, Specificity

Screening Accuracy

In the included studies, the researchers used a variety of different test methods as the standard to observe the sensitivity and specificity of IPTT for screening for DPN, such as 10g-MF, VPT, NDS, tuning fork 128Hz, and ankle reflex. The differences in the sensitivity and specificity of IPTT obtained by using different test methods as reference standards are presented. In general, when 10g-MF and VPT were used as reference standards, the sensitivity and specificity of IPTT were relatively high. For the 5 studies comprising 6 data pools that used 10g-MF as the reference standard, the sensitivity ranged from 51.0% - 83.3%, and the specificity ranged from 68.0 - 98.0%.²²⁻²⁶ For the 3 studies that used VPT as a reference standard, the sensitivity ranged from 76.0 - 100.0%, and the specificity ranged from 90.0 - 96.6%. Using neuropathy disability scores (NDS) as the reference standard, the sensitivity of IPTT to be 0.53, and the specificity to be 0.97. Compared with the pin prick, the sensitivity and specificity of IPTT were 0.8 and 0.88, respectively.²⁴ Compared with 128Hz tuning fork, the sensitivity and specificity of IPTT were only 0.4 and 0.27, respectively.²⁵ Compared with ankle reflex, IPTT had a sensitivity of 0.2 and a specificity of 0.97 (Table 1).²⁵

Meta-analysis Results Using 10g-MF as the Reference Standard

Screening Accuracy

In the literature we retrieved, there were a total of five studies with IPTT as the target test and 10g-MF as the reference standard.²²⁻²⁶ Among these five studies, one study contained two datasets because it was conducted at the patient's homes and in the clinic.²² Therefore, six datasets were included to evaluate the overall effect of IPTT in the screening of DPN.²²⁻²⁶ The combined sensitivity and specificity were 0.77 (95% CI 0.69–0.84) and 0.96 (95% CI 0.93–0.98), respectively.

The results show I - squared is 40.5%. In addition, the DOR was 75.24(39.90-141.89). The SROC analysis for the studies yielded an overall weighted area under the curve of 0.897(0.86-0.92) (Figure 3; Supplementary Files 2; Table 2).

Table 2. Meta-analysis of screening accuracy under the quality effect model

Variables	Se (95% CI)	Sp (95% CI)	PLR (95% CI)	NLR (95% CI)	DOR (95% CI)	AUC (95% CI)
Pooled value	0.77(0.69-0.84)	0.96(0.93-0.98)	18.06 (10.75-30.36)	0.24(0.17-0.35)	75.24(39.90-141.89)	0.897(0.86-0.93)

Se, Sensitivity; Sp, Specificity; CI: Confidence Interval.

Publication Bias

Minor asymmetry was present in the Doi plot and the results of the LFK index also suggested minor negative asymmetry of the Doi plot (LFK index =-1.68), indicating the publication bias existed between the studies (Figure 4).

DISCUSSION

DPN is the most important risk factor for the occurrence of DFU and one of the more common chronic complications associated with diabetes. However, it is often ignored. Once the patient develops DPN, it is likely to cause diabetic foot ulcers, gangrene, and even amputation, and many patients experience numbness and tingling in their limbs. Early identification of DPN can greatly reduce the burden of chronic diseases on society. In this study, we systematically reviewed the relevant literature on the identification of DPN by IPTT. A total of 7 studies were included, involving 1,510 participants with diabetes to explore the value of IPTT screening. Previous studies have disputed the diagnostic value of IPTT, mainly due to the use of different test methods, such as VPT, NDS, pinprick, tuning fork 128Hz, and ankle reflex, as the reference standard, compared with NDS, acupuncture, 128Hz tuning fork, and ankle reflex, IPTT has higher screening accuracy when 10g-MF and VPT were used as the reference standard.^{10,19,20} Basir et al. observed that when the 128Hz tuning fork was used as a reference standard, the sensitivity and specificity of IPTT were only 40% and 27%, respectively. This may be due to the lower predictive level of the tuning fork compared to the monofilament. However, Miller et al observed that combining a tuning fork with a monofilament would result in a more effective evaluation.²¹ Regarding the quality of the current studies, some studies lacked rigor in study design, such as the interval between target tests and unclear reference standard tests, and most studies failed to describe the reference methods in detail.

1
2
3 The overall quality of the included studies was rated as low to medium quality.
4
5

6 Compared with 10g-MF, the results of the meta-analysis found the combined sensitivity and
7
8 specificity of IPTT to be 0.77(95%CI 0.69-0.84) and 0.96(95%CI 0.93-0.98), respectively, and the
9
10 AUC to be 0.897(95%CI 0.86-0.93). The results indicated that IPTT has a moderate to high level
11
12 of sensitivity and a high level of specificity for screening DPN. In our study, the PLR and the NLR
13
14 were 18.06 (95% CI 10.75-30.36) and 0.24(95% CI 0.17-0.35), respectively, it means that the
15
16 screening accuracy of IPTT in DPN patients was nearly 18 times of the healthy peoples, but with
17
18 24% error rate. A DOR equal to 1 indicated that a test was unable to distinguish between patients
19
20 with or without the disease. Our study yielded a DOR value of 75.24(95% CI 39.90-141.89),
21
22 indicating that IPTT had a certain accuracy in the diagnosis of patients with DPN. We also found
23
24 that when VPT is used as a reference standard, IPTT shows a higher sensitivity and specificity. At
25
26 present, 10g-MF and VPT are the most widely used clinical screening methods for DPN. Basir et
27
28 al. explored the accuracy of using IPTT in detecting neuropathy in patients with small fiber and
29
30 large fiber neuropathy, and found that there was no difference between IPTT and the gold standard,
31
32 indicating that IPTT can be used as an alternative assessment method.²⁵ Therefore, the current
33
34 evidence shows that IPTT has a high screening value for DPN and can be used for preliminary
35
36 screening of DPN in areas lacking more advanced equipment.
37
38
39
40
41

42 Heterogeneity is an important factor of this meta-analysis.⁴³ In this study, we chose the quality
43
44 effects model because it has been proven to be significantly better than the traditional random effects
45
46 model and fixed effects model at effectively avoiding the problem of high heterogeneity caused by
47
48 statistical analysis. When 10g-MF was used as the reference standard, the I^2 was only 40.5%,
49
50 indicating there was good consistency among the five studies included in the meta-analysis. In
51
52 addition, the existence of heterogeneity may be related to other factors, such as differences in
53
54 research methodology, operators, or other factors. Due to the limited number of included studies,
55
56 we did not analyze the heterogeneity through subgroup analysis in this study. In terms of
57
58 methodology, although we systematically and comprehensively studied the current evidence of
59
60

1
2
3 using IPTT for DPN screening, the number of original studies is very limited, and the current
4 conclusions are based only on these seven studies. Therefore, caution should be taken when
5 popularizing them. About using other test methods as the reference standard (except 10g-MF), we
6 only described the relevant indicators as there were too few related studies to merge data. In addition,
7 despite our efforts to conduct a thorough search for eligible studies, publication bias was detected.
8 Thus, the pooled effect may have been overstated, this was also one of the limitations of our study.
9
10
11
12
13
14
15

16 Studies have shown that routine foot examinations and rapid risk stratification are often difficult
17 to implement in busy primary care institutions. Additionally, the lack of awareness of standardized
18 testing for DPN amongst healthcare professionals is a concern, which may be due to a shortage of
19 material and personnel resources in primary care institutions. This is concerning because identifying
20 foot neuropathy and the patients at risk for ulceration has been shown to prevent the incidence of
21 foot ulcers.⁴⁴⁻⁴⁶ IPTT is a new method for screening DPN that does not require any tools and can be
22 carried out after minimal training. It is not affected by time, venue, or its operators.²⁰ The
23 advancement of IPTT is of great significance for the early screening of DPN to impede the
24 progression of diabetic foot ulcers, as it can be used to quickly and reliably screen and manage
25 patients at high risk for ulceration, especially in remote areas or places lacking screening tools.^{47,48}
26 Kerry et al. reported that in the first year IPTT was introduced as a screening tool, the relative risk
27 reduction (RRR) of DFU was 64%, and in the second year, the RRR was 70%, thereby reducing
28 hospital-acquired foot ulcers in patients with diabetes by two-thirds and negating the excess risk
29 associated with diabetes.^{20,49-51} Meanwhile, it can effectively improve patients' disease-related
30 knowledge, which plays a positive role in promoting the self-management of patients and their
31 families. At the same time, IPTT has a predictive effect on diabetic foot ulcers and reduces delays
32 in patient visits.²¹ However, more thorough studies are needed for verification.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Most of the literature on IPTT is focused on screening tests and some commentary-type studies,
52 and the number of studies is small. These studies were carried out in the United Kingdom, Spain,
53 Brazil, and Saudi Arabia, and although they achieved satisfactory results, have not been carried out
54 globally. However, it has not been applied in developing countries such as China. China is a country
55 with a large population and a relatively small number of medical personnel, especially in some
56
57
58
59
60

1
2
3 remote areas where the medical allocation is in short supply. In these areas, the application and
4 promotion of IPTT can effectively alleviate the challenges associated with the allocation of medical
5 resources and play an important role in the management of patients with diabetes. IPTT has also
6 recently been approved for use in a number of countries.^{21,24-26} However, Kempegowda et al.
7 reported that 88.4% of physicians are not familiar with IPTT. Therefore, we suggest that IPTT be
8 further promoted amongst physicians and medical staff, especially in remote areas and areas lacking
9 screening tools.³⁶ Future large-scale, high-quality, and multi-center studies on populations of
10 different ethnicities will verify the potential applicability of IPTT alone or in combination with other
11 DPN screening methods.
12
13
14
15
16
17
18
19
20
21

22 **CONCLUSIONS**

23
24
25 In summary, IPTT shows a high degree of agreement with commonly used screening tools for DPN,
26 it can be used clinically, especially in remote areas and primary medical institutions, and self-
27 monitoring patients. This is also the first meta-analysis of the accuracy of IPTT identification of
28 DPN, and a systematic quantitative evaluation of its screening value, which can provide evidence
29 for the clinical application of IPTT in the future. However, due to a limited number of studies of
30 low or medium quality from limited geographical areas, more high-quality studies are needed to
31 promote more effective screening practices.
32
33
34
35
36
37
38
39
40

41 **Acknowledgments**

42
43
44 Thanks all authors and patients of the previous research for providing data for our article.
45
46

47 **Funding sources**

48
49
50 This research was supported by the Natural Science Foundation of Hunan Province (Grant No.
51 2019JJ80087)
52
53
54

55 **Author contributions**

56
57 ZN conducted the database search, screened and extracted data for the meta-analysis, prepared
58 extracted data for the procedures, and had primary responsibility in writing this article. LXY, ZJ
59
60

1
2
3 and ZF performed statistical analysis and contributed to article screening, data collection and
4 extraction. XJC, ZQH, and LJH contributed to the discussion and editing. XJC and CJR critically
5 revised the draft manuscript. All authors contributed toward data analysis, drafting and critically
6 revising the paper and agree to be accountable for all aspects of the work.
7
8
9

10 11 12 **Competing interests**

13
14
15 The authors state that they have no conflict of interest.
16
17

18 19 **Patient consent for publication**

20
21
22 Not required. All analyses were conducted based on previously published studies. Accordingly,
23 there was no patient or public involvement in this study. Ethical approval was not required since it
24 was a systematic review of the published literature.
25
26
27

28 29 **Data availability statement**

30
31
32 Data are available in a public, open access repository. There are no data in this work. Data are
33 available on reasonable request. Data can be obtained from a third party and are not publicly
34 available. All data relevant to the study are included in the article or uploaded as supplementary
35 information.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018;138:271-281.
2. Armstrong DG, Boulton A, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* 2017;376(24):2367-2375.
3. Banik PC, Barua L, Moniruzzaman M et al. Risk of diabetic foot ulcer and its associated factors among Bangladeshi subjects: a multicentric cross-sectional study. *BMJ Open*. 2020 Feb 28;10(2):e034058.
4. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. *Curr Neurol Neurosci Rep*. 2014;14(8):473.
5. Strachan MW, Reynolds RM, Marioni RE, et al. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. *Nat Rev Endocrinol*. 2011;7(2):108-14.
6. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep* 2019;19(10):86.
7. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. *J Vasc Surg* 2014;60(5):1247-54.
8. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40(1):136-154.
9. Javed S, Hayat T, Menon L, et al. Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. *Diabet Med* 2020;37(4):573-579.
10. Feldman EL, Nave KA, Jensen TS, et al. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron* 2017;93(6):1296-1313.
11. Zhang Y, Li N, Zhao Y, Fan D. Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnts (PDN-SCOPE): protocol for a multicentre cross-sectional registry study of clinical characteristics and treatment in China. *BMJ Open*. 2019 Apr 8;9(4):e025722.
12. Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. *J Am Podiatr Med Assoc* 2011;101(2):93-115.
13. International Diabetes Federation. Diabetic foot screening pocket chart. Brussels: IDF 2017. <https://www.idf.org/our-activities/advocacy-aware>.
14. Standards of Medical Care in Diabetes-2017: Summary of Revisions. *Diabetes Care* 2017;40(Suppl 1):S4-5.
15. Craig AB, Strauss MB, Daniller A, et al. Foot sensation testing in the patient with diabetes: introduction of the quick & easy assessment tool. *Wounds* 2014;26(8):221-31.
16. Slater RA, Koren S, Ramot Y, et al. Interpreting the results of the Semmes-Weinstein monofilament test: accounting for false-positive answers in the international consensus on the diabetic foot protocol by a new model. *Diabetes Metab Res Rev* 2014;30(1):77-80.
17. Lavery LA, Lavery DE, Lavery DC, et al. Accuracy and durability of Semmes-Weinstein

- monofilaments: what is the useful service life? *Diabetes Res Clin Pract* 2012;97(3):399-404.
18. Spruce MC, Bowling FL. Diabetic foot screening: new technology versus 10g monofilament. *Int J Low Extrem Wounds* 2012 2012-03-01;11(1):43-8.
19. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. *Diabetes Care* 2011;34(7):1517-8.
20. Vas PR, Sharma S, Rayman G. Distal Sensorimotor Neuropathy: Improvements in Diagnosis. *Rev Diabet Stud* 2015;12(1-2):29-47.
21. Miller JD, Carter E, Shih J, et al. How to do a 3-minute diabetic foot exam. *J Fam Pract* 2014;63(11):646-56.
22. Sharma S, Kerry C, Rosier J, et al. The Ipswich Touch Test (IpTT): Screening for diabetic neuropathy at home. *Diabet Med* 2012;29:20.
23. Sharma S, Kerry C, Atkins H, et al. The Ipswich Touch Test: a simple and novel method to screen patients with diabetes at home for increased risk of foot ulceration. *Diabet Med* 2014;31(9):1100-3.
24. Madanat A, Sheshah E, Badawy E, et al. Utilizing the Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration among diabetics: The Saudi experience. *Prim Care Diabetes* 2015;9(4):304-6.
25. Basir IS, Syam Y, Yusuf S, et al. Accuracy of Ipswich Touch Test (IpTT) to detect small fiber neuropathy and large fiber neuropathy as a risk factor of diabetic foot ulcers in public health centers. *Enferm Clin* 2020;30 Suppl 2:308-12.
26. Dutra L, Moura MC, Do PF, et al. Is it possible to substitute the monofilament test for the Ipswich Touch Test in screening for peripheral diabetic neuropathy? *Diabetol Metab Syndr* 2020;12:27.
27. Schaper NC, van Netten JJ, Apelqvist J, et al. IWGDF Editorial Board. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). *Diabetes Metab Res Rev*. 2020 Mar;36 Suppl 1:e3266. doi: 10.1002/dmrr.3266. PMID: 32176447.
28. Atlantis E, Cochrane B. The association of dietary intake and supplementation of specific polyunsaturated fatty acids with inflammation and functional capacity in chronic obstructive pulmonary disease: a systematic review *Int J Evid Based Healthc* 2016;14(2):53-63.
29. McInnes M, Moher D, Thombs BD, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA* 2018;319(4):388-96.
30. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol*. 2003 Nov 10;3:25. doi: 10.1186/1471-2288-3-25.
31. Foxlee N, Stone JC, Doi SA. A comparison of univariate and bivariate models in meta-analysis of diagnostic accuracy studies. *Int J Evid Based Healthc*. 2015 Mar;13(1):28-34.
32. The Nordic Cochrane Centre (2014) Review manager. Cochrane Collab 1-43.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
33. Doi SA, Barendregt JJ, Khan S, et al. Advances in the meta-analysis of heterogeneous clinical trials II: The quality effects model. *Contemp Clin Trials*. 2015 Nov;45(Pt A):123-9.
34. Doi SAR, Furuya-Kanamori L. Selecting the best meta-analytic estimator for evidence-based practice: a simulation study. *Int J Evid Based Healthc*. 2020 Mar;18(1):86-94.
35. Furuya-Kanamori L, Kostoulas P, Doi SAR. A new method for synthesizing test accuracy data outperformed the bivariate method. *J Clin Epidemiol*. 2021 Apr;132:51-58.
36. Doi SAR, Furuya-Kanamori L, Thalib L, et al. Meta-analysis in evidence-based healthcare: a paradigm shift away from random effects is overdue. *Int J Evid Based Healthc*. 2017 Dec;15(4):152-160.
37. Doi SA. Evidence synthesis for medical decision making and the appropriate use of quality scores. *Clin Med Res*. 2014 Sep;12(1-2):40-6.
38. Stone JC, Glass K, Munn Z, et al. Comparison of bias adjustment methods in meta-analysis suggests that quality effects modeling may have less limitations than other approaches. *J Clin Epidemiol*. 2020 Jan;117:36-45.
39. Wang D, Mou ZY, Zhai JX, et al. Application of Stata software to test heterogeneity in meta-analysis method. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2008 Jul;29(7):726-9.
40. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I² index? *Psychol Methods*. 2006 Jun;11(2):193-206.
41. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int J Evid Based Healthc*. 2018 Dec;16(4):195-203.
42. Furuya-Kanamori L, Xu C, Hasan SS, et al. Quality versus Risk-of-Bias assessment in clinical research. *J Clin Epidemiol*. 2021 Jan;129:172-175.
43. Lo K, Stephenson M, Lockwood C. Analysis of heterogeneity in a systematic review using meta-regression technique. *Int J Evid Based Healthc* 2019 Jun;17(2):131-142.
44. Bowling FL, Abbott CA, Harris WE, et al. A pocket-sized disposable device for testing the integrity of sensation in the outpatient setting. *Diabet Med* 2012;29(12):1550-2.
45. Kempegowda P, Saeed MA. Foot STAMP (Short-burst Teaching Aimed at Medical Professionals): Impact of 'shortburst' teaching on the knowledge regarding the Ipswich Touch Test. *Diabet Med* 2016;33:134.
46. Bailey TS, Yu HM, Rayfield EJ. Patterns of foot examination in a diabetes clinic. *Am Med J* 1985;78(3):371-4.
47. Baker N. An alternative to a 10-g monofilament or tuning fork? Two new, simple, easy-to-use screening tests for determining foot ulcer risk in people with diabetes. *Diabet Med* 2012;29(12):1477-9.
48. O'Loughlin A, Dinneen SF. ACP Journal Club: the Ipswich Touch Test at home had 78% sensitivity and 94% specificity for detecting loss of foot sensation. *Ann Intern Med* 2015;162(4):C10.
49. Kerry C. VPRR. Reduction in the incidence of hospital acquired foot pressure ulcers in people

1
2
3 with diabetes. *Diabetic Med* 2015;SUPPL. 1(32):26.

4 50. Kerry CD, Sharma S, Rayman G. Reduction in hospital-acquired diabetes foot lesions using the
5 Ipswich Touch Test (IpTT). *Diabetic Med* 2013;30:141-2.

6
7 51. Madanat A, Sheshah E, Badawy E, et al.: "P.R. Vas, S. Sharma, G. Rayman, Utilizing the
8 Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration
9 among diabetics: comment on the Saudi experience. *Prim Care Diabetes* 2015;9(5):401-2.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only





Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.



	Q1	Q10	Q11	Q12	Q13	Q14	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
Sharma2012	?	?	?	?	?	?	?	?	?	?	?	?	?	?
Sharma2014a	-	+	+	+	-	?	+	+	+	+	+	+	+	-
Sharma2014b	+	+	+	+	-	?	+	+	+	+	+	+	+	-
Madanat2015	+	?	?	+	?	?	+	+	?	?	?	?	+	-
Basir2020	+	?	?	+	-	?	+	+	?	?	?	+	+	-
Dutra2020	+	?	?	+	?	+	+	+	?	+	+	?	+	+

Figure 2. Quality assessment of the included studies




Figure 3. Sensitivity and specificity of IPTT in the diagnosis of DPN

255x185mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Doi plot and LFK index.

255x185mm (72 x 72 DPI)

Appendix S1

Search Strategy in PubMed, Embase, Cochrane Library, Web of Science, CNKI, CMB, Wanfang database.

PubMed Search Strategy

#1 Search: "Diabetes Mellitus"[Mesh] Sort by: Most Recent

#2 Search: (((Diabetes[Title/Abstract]) OR (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract])

#3 Search: "Diabetic Neuropathies"[Mesh] Sort by: Most Recent

#4 Search: (((((((((((((((((((((((Diabetic Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy, Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicies[Title/Abstract])) OR (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicies, Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR

1
2
3
4 (Simplices, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
5 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
6
7 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract])
8
9

10 #5 Search: "Diabetes Complications"[Mesh] Sort by: Most Recent

11
12
13 #6 Search:

14
15
16 #7 Search: "Diabetic Foot"[Mesh] Sort by: Most Recent

17
18
19 #8 Search: (((Foot, Diabetic[Title/Abstract]) OR (Diabetic Feet[Title/Abstract])) OR (Feet,
20 Diabetic[Title/Abstract])) OR (Foot Ulcer, Diabetic[Title/Abstract])
21
22

23
24 #9 Search: ((ipswich touch test[Title/Abstract]) OR (touch test[Title/Abstract])) OR
25 (IPTT[Title/Abstract])
26
27

28
29 #10 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((((Diabetes[Title/Abstract]) OR
30 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
31 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))))
32 OR ("Diabetic Neuropathies"[Mesh])) OR (((
33 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
34 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
35 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
36 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
37 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
38 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
39 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
40 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR
41 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
42 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
43 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
44 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Mononeuropathies[Title/Abstract]) OR (Mononeuropathies, Diabetic[Title/Abstract]) OR
5 (Mononeuropathy, Diabetic[Title/Abstract]) OR (Diabetic Mononeuropathy
6 Simplex[Title/Abstract]) OR (Diabetic Mononeuropathy Simplicis[Title/Abstract]) OR
7 (Mononeuropathy Simplex, Diabetic[Title/Abstract]) OR (Mononeuropathy Simplicis,
8 Diabetic[Title/Abstract]) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract]) OR
9 (Simplicis, Diabetic Mononeuropathy[Title/Abstract]) OR (Diabetic
10 Polyneuropathy[Title/Abstract]) OR (Diabetic Polyneuropathies[Title/Abstract]) OR
11 (Polyneuropathies, Diabetic[Title/Abstract]) OR (Polyneuropathy, Diabetic[Title/Abstract]))
12 OR ("Diabetes Complications"[Mesh]) OR (((((((Diabetes-Related
13 Complications[Title/Abstract]) OR (Diabetes Related Complications[Title/Abstract]) OR
14 (Diabetes-Related Complication[Title/Abstract]) OR (Diabetic
15 Complications[Title/Abstract]) OR (Diabetic Complication[Title/Abstract]) OR
16 (Complications of Diabetes Mellitus[Title/Abstract]) OR (Diabetes Mellitus
17 Complication[Title/Abstract]) OR (Diabetes Mellitus Complications[Title/Abstract]))) OR
18 ("Diabetic Foot"[Mesh]) OR (((Foot, Diabetic[Title/Abstract]) OR (Diabetic
19 Feet[Title/Abstract]) OR (Feet, Diabetic[Title/Abstract]) OR (Foot Ulcer,
20 Diabetic[Title/Abstract]))

21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 #11 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((((Diabetes[Title/Abstract]) OR
39 (Diabetes, Type 2[Title/Abstract]) OR (Type 2 Diabetes Mellitus[Title/Abstract]) OR
40 (Diabetes Mellitus, Type II[Title/Abstract]) OR (Diabetes Mellitus, Type I[Title/Abstract])))
41 OR ("Diabetic Neuropathies"[Mesh]) OR ((Diabetic
42 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract]) OR (Neuropathy,
43 Diabetic[Title/Abstract]) OR (Diabetic Autonomic Neuropathy[Title/Abstract]) OR
44 (Autonomic Neuropathies, Diabetic[Title/Abstract]) OR (Diabetic Autonomic
45 Neuropathies[Title/Abstract]) OR (Neuropathies, Diabetic Autonomic[Title/Abstract]) OR
46 (Autonomic Neuropathy, Diabetic[Title/Abstract]) OR (Neuropathy, Diabetic
47 Autonomic[Title/Abstract]) OR (Symmetric Diabetic Proximal Motor
48 Neuropathy[Title/Abstract]) OR (Asymmetric Diabetic Proximal Motor
49 Neuropathy[Title/Abstract]) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract]) OR
50
51
52
53
54
55
56
57
58
59
60

1
 2
 3
 4 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
 5 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
 6 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
 7 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 8 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
 9 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
 10 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicies[Title/Abstract])) OR
 11 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicies,
 12 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
 13 (Simplicies, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 14 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
 15 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
 16 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
 17 Complications[Title/Abstract])) OR (Diabetes Related Complications[Title/Abstract])) OR
 18 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
 19 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
 20 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
 21 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
 22 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract])) OR (Diabetic
 23 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
 24 Diabetic[Title/Abstract])) AND (((ipswich touch test[Title/Abstract])) OR (touch
 25 test[Title/Abstract])) OR (IPTT[Title/Abstract]))

Embase Search Strategy

#1 'diabetes mellitus'/exp

#2 'diabetes, type 2':ab,ti OR 'type 2 diabetes mellitus':ab,ti OR 'diabetes mellitus, type
 ii':ab,ti OR 'diabetes mellitus, type 1':ab,ti

#3 #1 OR #2

1
2
3
4 #4 'diabetic neuropathy'/exp
5

6 #5 'diabetic neuropathy':ab,ti OR 'neuropathies, diabetic':ab,ti OR 'neuropathy, diabetic':ab,ti
7
8 OR 'diabetic autonomic neuropathy':ab,ti OR 'autonomic neuropathies, diabetic':ab,ti OR
9
10 'autonomic neuropathy, diabetic':ab,ti OR 'diabetic autonomic neuropathies':ab,ti OR
11
12 'neuropathies, diabetic autonomic':ab,ti OR 'neuropathy, diabetic autonomic':ab,ti OR
13
14 'symmetric diabetic proximal motor neuropathy':ab,ti OR 'asymmetric diabetic proximal
15
16 motor neuropathy':ab,ti OR 'diabetic asymmetric polyneuropathy':ab,ti OR 'asymmetric
17
18 polyneuropathies, diabetic':ab,ti OR 'asymmetric polyneuropathy, diabetic':ab,ti OR 'diabetic
19
20 asymmetric polyneuropathies':ab,ti OR 'polyneuropathies, diabetic asymmetric':ab,ti OR
21
22 'polyneuropathy, diabetic asymmetric':ab,ti OR 'diabetic mononeuropathy':ab,ti OR 'diabetic
23
24 mononeuropathies':ab,ti OR 'mononeuropathies, diabetic':ab,ti OR 'mononeuropathy,
25
26 diabetic':ab,ti OR 'diabetic mononeuropathy simplex':ab,ti OR 'diabetic mononeuropathy
27
28 simplices':ab,ti OR 'mononeuropathy simplex, diabetic':ab,ti OR 'mononeuropathy simplices,
29
30 diabetic':ab,ti OR 'simplex, diabetic mononeuropathy':ab,ti OR 'simplices, diabetic
31
32 mononeuropathy':ab,ti OR 'diabetic polyneuropathy':ab,ti OR 'diabetic polyneuropathies':ab,ti
33
34 OR 'polyneuropathies, diabetic':ab,ti OR 'polyneuropathy, diabetic':ab,ti
35

36 #6 #4 OR #5
37

38
39 #7 'diabetic complication'/exp
40

41
42 #8 'diabetes complication':ab,ti OR 'diabetes-related complications':ab,ti OR 'diabetes
43
44 related complications':ab,ti OR 'diabetes-related complication':ab,ti OR 'diabetic
45
46 complications':ab,ti OR 'diabetic complication':ab,ti OR 'complications of diabetes
47
48 mellitus':ab,ti OR 'diabetes mellitus complication':ab,ti OR 'diabetes mellitus
49
50 complications':ab,ti
51

52
53 #9 #7 OR #8
54

55
56 #10 'diabetic foot'/exp
57

58
59 #11 'diabetic foot':ab,ti OR 'diabetic feet':ab,ti OR 'feet, diabetic':ab,ti OR 'foot ulcer,
60

1
2
3
4 diabetic':ab,ti OR 'foot ulcer':ab,ti
5

6
7 #12 #10 OR #11
8

9
10 #13 #3 OR #6 OR #9 OR #12
11

12
13 #14 'ipswich touch test':ab,ti OR 'touch test':ab,ti OR 'iptt':ab,ti
14

15
16 #15 #13 AND #14
17

18 **Cochrane Library Search Strategy**

19
20
21 #1 MeSH descriptor: [Diabetes Mellitus] explode all trees 31055
22

23
24 #2 (Diabetes):ti,ab,kw OR (Diabetes, Type 2):ti,ab,kw OR (Type 2 Diabetes
25 Mellitus):ti,ab,kw OR (Diabetes Mellitus, Type II):ti,ab,kw OR (Diabetes Mellitus, Type 1)
26

27
28 #3 MeSH descriptor: [Diabetic Neuropathies] explode all trees
29

30
31
32 #4 (Diabetic Neuropathy):ti,ab,kw OR (Neuropathies, Diabetic):ti,ab,kw OR (Neuropathy,
33 Diabetic):ti,ab,kw OR (Diabetic Autonomic Neuropathy):ti,ab,kw OR (Autonomic
34 Neuropathies, Diabetic):ti,ab,kw OR (Autonomic Neuropathy, Diabetic):ti,ab,kw OR
35 (Diabetic Autonomic Neuropathies):ti,ab,kw OR (Neuropathies, Diabetic
36 Autonomic):ti,ab,kw OR (Neuropathy, Diabetic Autonomic):ti,ab,kw OR (Symmetric
37 Diabetic Proximal Motor Neuropathy):ti,ab,kw OR (Asymmetric Diabetic Proximal Motor
38 Neuropathy):ti,ab,kw OR (Diabetic Asymmetric Polyneuropathy):ti,ab,kw OR (Asymmetric
39 Polyneuropathies, Diabetic):ti,ab,kw OR (Asymmetric Polyneuropathy, Diabetic):ti,ab,kw OR
40 (Diabetic Asymmetric Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic
41 Asymmetric):ti,ab,kw OR (Polyneuropathy, Diabetic Asymmetric):ti,ab,kw OR (Diabetic
42 Mononeuropathy):ti,ab,kw OR (Diabetic Mononeuropathies):ti,ab,kw OR
43 (Mononeuropathies, Diabetic):ti,ab,kw OR (Mononeuropathy, Diabetic):ti,ab,kw OR
44 (Diabetic Mononeuropathy Simplex):ti,ab,kw OR (Diabetic Mononeuropathy
45 Simplicis):ti,ab,kw OR (Mononeuropathy Simplex, Diabetic):ti,ab,kw OR (Mononeuropathy
46 Simplicis, Diabetic):ti,ab,kw OR (Simplex, Diabetic Mononeuropathy):ti,ab,kw OR
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(Simplices, Diabetic Mononeuropathy):ti,ab,kw OR (Diabetic Polyneuropathy):ti,ab,kw OR
 (Diabetic Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic):ti,ab,kw OR
 (Polyneuropathy, Diabetic):ti,ab,kw 3653

#5 MeSH descriptor: [Diabetes Complications] explode all trees

#6 (Diabetes-Related Complications):ti,ab,kw OR (Diabetes Related
 Complications):ti,ab,kw OR (Diabetes-Related Complication):ti,ab,kw OR (Diabetic
 Complications):ti,ab,kw OR (Diabetic Complication):ti,ab,kw OR (Complications of Diabetes
 Mellitus):ti,ab,kw OR (Diabetes Mellitus Complication):ti,ab,kw OR (Diabetes Mellitus
 Complications)

#7 MeSH descriptor: [Diabetic Foot] explode all trees

#8 (Diabetic Feet):ti,ab,kw OR (Feet, Diabetic):ti,ab,kw OR (Foot Ulcer, Diabetic)

#9 (ipswich touch test):ti,ab,kw OR (touch test):ti,ab,kw OR (IPTT)

#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

#11 #9 AND #10

Web of Science Search Strategy

#1 TS=(Diabetes Mellitus or Diabetes or Diabetes, Type 2 or Type 2 Diabetes Mellitus or
 Diabetes Mellitus, Type II or Diabetes Mellitus, Type 1)

#2 TS=(Diabetic Neuropathies or Diabetic Neuropathy or Neuropathies, Diabetic or
 Neuropathy, Diabetic or Diabetic Autonomic Neuropathy or Autonomic Neuropathies,
 Diabetic or Autonomic Neuropathy, Diabetic or Diabetic Autonomic Neuropathies or
 Neuropathies, Diabetic Autonomic or Neuropathy, Diabetic Autonomic or Symmetric
 Diabetic Proximal Motor Neuropathy or Asymmetric Diabetic Proximal Motor Neuropathy or
 Diabetic Asymmetric Polyneuropathy or Asymmetric Polyneuropathies, Diabetic or
 Asymmetric Polyneuropathy, Diabetic or Diabetic Asymmetric Polyneuropathies or

1
2
3
4 Polyneuropathies, Diabetic Asymmetric or Polyneuropathy, Diabetic Asymmetric or Diabetic
5 Mononeuropathy or Diabetic Mononeuropathies or Mononeuropathies, Diabetic or
6 Mononeuropathy, Diabetic or Diabetic Mononeuropathy Simplex or Diabetic
7 Mononeuropathy Simplicis or Mononeuropathy Simplex, Diabetic or Mononeuropathy
8 Simplicis, Diabetic or Simplex, Diabetic Mononeuropathy or Simplicis, Diabetic
9 Mononeuropathy or Diabetic Polyneuropathy or Diabetic Polyneuropathies or
10 Polyneuropathies, Diabetic or Polyneuropathy, Diabetic)

11
12
13 #3 TS=(Diabetes Complications or Diabetes Complication or Diabetes-Related
14 Complications or Diabetes Related Complications or Diabetes-Related Complication or
15 Diabetic Complications or Diabetic Complication or Complications of Diabetes Mellitus or
16 Diabetes Mellitus Complication or Diabetes Mellitus Complications)

17
18 #4 TS=(Diabetic Foot or Foot, Diabetic or Diabetic Feet or Feet, Diabetic or Foot Ulcer,
19 Diabetic)

20
21 #5 #4 OR #3 OR #2 OR #1

22
23 #6 TS=(ipswich touch test or touch test or IPTT)

24
25 #7 #6 AND #5

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 **China National Knowledge Infrastructure (CNKI) Search Strategy**

42
43 检索式 A: (((主题=糖尿病 或者 题名=糖尿病 或者 v_subject=中英文扩展(糖尿病)
44 或者 title=中英文扩展(糖尿病)) 或者 (主题=糖尿病足 或者 题名=糖尿病足 或者
45 v_subject=中英文扩展(糖尿病足) 或者 title=中英文扩展(糖尿病足))) 或者 ((主题=糖
46 尿病周围神经病变 或者 题名=糖尿病周围神经病变 或者 v_subject=中英文扩展(糖尿
47 病周围神经病变) 或者 title=中英文扩展(糖尿病周围神经病变)) 或者 (主题=糖尿病并
48 发症 或者 题名=糖尿病并发症 或者 v_subject=中英文扩展(糖尿病并发症) 或者 title=
49 中英文扩展(糖尿病并发症)))) 并且 (((((主题=中英文扩展(touch test) 或者 题名=中
50 英文扩展(touch test) 或者 v_subject=touch test 或者 title=touch test) 或者 (主题=中
51 英文扩展(Ipswich Touch Test) 或者 题名=中英文扩展(Ipswich Touch Test) 或者

v_subject=Ipswich Touch Test 或者 title=Ipswich Touch Test)) 或者 ((主题=伊普斯维奇触摸测试 或者 题名=伊普斯维奇触摸测试 或者 v_subject=中英文扩展(伊普斯维奇触摸测试) 或者 title=中英文扩展(伊普斯维奇触摸测试)) 或者 (主题=中英文扩展(IPTT) 或者 题名=中英文扩展(IPTT) 或者 v_subject=IPTT 或者 title=IPTT))) 或者 ((关键词=轻触 或者 keyword=中英文扩展(轻触)) 或者 (关键词=轻触测试 或者 keyword=中英文扩展(轻触测试)))) 或者 ((题名=触摸 或者 Title=中英文扩展(触摸)) 或者 (题名=触摸测试 或者 Title=中英文扩展(触摸测试)))) (模糊匹配)

Wan Fang Database Search Strategy

主题:((糖尿病)+主题:(糖尿病足)+主题:(糖尿病周围神经病变)+全部:(糖尿病并发症))*主题:((touch test)+主题:(IPTT)+主题:(Ipswich Touch Test)+全部:(伊普斯维奇触摸测试))

China Biology Medicine disc (CBM) Search Strategy

- #1 "糖尿病"[不加权:扩展]
- #2 "糖尿病足"[常用字段:智能]
- #3 "糖尿病神经病变"[常用字段:智能]
- #4 "糖尿病并发症"[常用字段:智能]
- #5 (#4) OR (#3) OR (#2) OR (#1)
- #6 "touch"[常用字段:智能] AND "test"[常用字段:智能]
- #7 "IPTT"[常用字段:智能]
- #8 "Ipswich"[常用字段:智能] AND "Touch"[常用字段:智能] AND "Test"[常用字段:智能]
- #9 "伊普斯维奇触摸测试"[常用字段:智能]
- #10 "轻触"[常用字段:智能]

1
2
3
4 #11 "轻触测试"[常用字段:智能]
5

6 #12 "触摸"[常用字段:智能]
7
8

9 #13 "触摸测试"[常用字段:智能]
10
11

12 #14 (#13) OR (#12) OR (#11) OR (#10) OR (#9) OR (#8) OR (#7) OR (#6)
13
14

15 #15 (#14) AND (#5)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **. diagma tp fp fn tn, qe(qi)**

5
6 Input form: TP FP FN TN assumed
7 Note: Weights are from Doi's quality effects model
8 Studies included: 6
9 Participants included: 1493
10 Prevalence of disease: 19.7%
11 Heterogeneity (I-squared): 40.5%
12 Pub bias (LFK index): -1.7, minor asymmetry
13

	Estimate	95% Conf. Interval	
Sens	.77	.688	.836
Spec	.957	.928	.975
LR+	18.064	10.748	30.358
LR-	.24	.167	.346
DOR	75.239	39.898	141.887
AUC	.897	.863	.923

14
15
16
17
18
19
20
21
22
23
24
25 The results of sensitivity and specificity of IPTT in the diagnosis of DPN
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	2
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	6-7



PRISMA 2009 Checklist

Page 1 of 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6-7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7-8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9-10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12-13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2
For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-046966.R3
Article Type:	Original research
Date Submitted by the Author:	22-Aug-2021
Complete List of Authors:	<p>Zhao, Nan; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Xu, Jing-can; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Qihong; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha</p> <p>Li, Xinyi; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Nursing School of Central South University</p> <p>Chen, Jiarui ; Central South University Xiangya School of Nursing; Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group</p> <p>Zhou, Jing; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing</p> <p>Zhou, Feng; Xiangya Hospital Central South University, Teaching and Research Section of Clinical Nursing; Xiangya Hospital Central South University, Department of Emergency</p> <p>Liang , Jinghong; Sun Yat-Sen University, 6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Neurology, Public health, Diabetes and endocrinology
Keywords:	Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, Diabetic foot < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

AUTHORS' INFORMATION

Zhao Nan^{1,2}, Xu Jingcan^{1,2}, Zhou Qihong^{1,4}, Li Xinyi^{1,3}, Chen Jiarui^{2,3}, Zhou Jing¹, Zhou Feng^{1,5}, Liang Jinghong⁶

Zhao Nan 187811023@csu.edu.cn

Xu Jingcan 983556951@qq.com

Zhou Qihong 928555448@qq.com

Li Xinyi 905492390@qq.com

Chen Jiarui chenjr@csu.edu.cn

Zhou Jing zhou-jing62@hotmail.com

Zhou Feng 316925782@qq.com

Liang Jinghong liangjh78@mail2.sysu.edu.cn

1. Teaching and Research Section of Clinical Nursing, Xiangya Hospital of Central South University, Changsha, 410008, China

2. Xiangya center for Evidence-Based Practice & Healthcare Innovation: A Joanna Briggs Institute Affiliated Group, Changsha, 410013, China

3. Xiangya Nursing School of Central South University, Changsha, 410013, China

4. Diabetic Foot Prevention Center, Xiangya Hospital, Central South University, Changsha, 410008, China

5. Department of Emergency, Xiangya Hospital, Central South University, Changsha, 410008, China

6. Department of Maternal and Child Health, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China

Corresponding author: Xu Jingcan, 983556951@qq.com; Zhou Qihong, 928555448@qq.com

Application of the Ipswich Touch Test for Diabetic Peripheral Neuropathy Screening: A Systematic Review and Meta-Analysis

ABSTRACT

Objective: Diabetic peripheral neuropathy (DPN) is one of the most important risk factors of diabetic foot ulcers (DFU), and early screening and treatment of DPN are crucial. The Ipswich Touch Test (IPTT) is a new method for screening for DPN and, compared with traditional methods, is more simple to operate and requires no equipment. However, the screening accuracy of IPTT in DPN patients has not been well characterized. We aim to conduct a systematic review and meta-analysis to characterize the sensitivity and specificity of IPTT compared to traditional methods and to understand the potential screening value of IPTT.

Design: Systematic review and meta-analysis.

Data sources: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, Chinese Biomedical Literature Database (CBM) up to April 16, 2020.

Methods: Stata version 15.1 software was used for analysis, and the screening value of IPTT in DPN was described using 10g-MF, NDS, Pin prick, 128Hz tuning fork, and ankle reflex as reference standards. Sensitivity, specificity, and other measures of accuracy of IPTT for screening DPN were pooled based on a quality effects model. The protocol was registered with PROSPERO (42020168420).

Results: Of the 441 records retrieved, seven studies were evaluated for the screening value of IPTT. Five studies with 10g-MF as the reference standard were included in the meta-analysis, and the pooled sensitivity and specificity were 0.78 (95 % CI 0.65–0.87) and 0.95(95 % CI 0.89–0.98), respectively, and AUC was 0.93. Compared with VPT, IPTT showed a sensitivity between 0.76 and 1, and a specificity between 0.90 and 0.97. Compared with NDS, IPTT showed a sensitivity between 0.53 and 1, and a specificity between 0.90 and 0.97. Compared with Pin prick, IPTT showed a

1
2
3 sensitivity and specificity of 0.8 and 0.88, respectively. Compared with 128Hz tuning fork, IPTT
4 showed a sensitivity and specificity of 0.4 and 0.27, respectively. Compared with ankle reflex, IPTT
5 had a sensitivity of 0.2 and a specificity of 0.97.
6
7
8
9

10 **Conclusions:** IPTT shows a high degree of agreement with other commonly used screening tools
11 for DPN screening. It can be used clinically, especially in remote areas and in primary medical
12 institutions, and by self-monitoring patients. More high-quality studies are needed to assess and
13 promote more effective screening practices.
14
15
16
17
18

19 **Prospero:** Registration Number is CRD (42020168420)
20
21

22 **Strengths and limitations of this study**

23

- 24 • This is the first meta-analysis to explore the potential screening value of IPTT in DPN.
- 25 • A quality effects model was used to achieve optimal error estimation in the data analysis.
- 26 • A Doi plots and Luis Furuya-Kanamori (LFK) index were used to assess publication bias.
- 27 • Although we systematically and comprehensively studied the current evidence of IPTT screening
28 in DPN screening, the number of original studies was very limited, and the existing conclusions
29 were based on these 7 original studies. Therefore, readers should therefore proceed with caution.
30
31
32
33
34
35
36
37
38
39
40
41

42 **Keywords:** Ipswich Touch Test, Diabetic peripheral neuropathy, Meta-analysis
43
44

45 **INTRODUCTION**

46

47
48 Diabetic peripheral neuropathy (DPN) is a common long-term complication and the most important
49 risk factor for the occurrence of diabetic foot ulcers (DFU).¹⁻⁴ DPN affects up to 50% of people with
50 diabetes,^{5,6} with chronic painful neuropathy affecting up to 26%.⁷ In the early stage of DPN, the
51 symptoms lack specificity, and about half of patients with diabetes cannot recognize the injury to
52 the lower extremities.^{8,9} Once the patient has symptoms such as limb numbness and pain, it signals
53 that pathological changes have occurred in the peripheral nerves and have advanced into the
54
55
56
57
58
59
60

1
2
3 irreversible stage. If not treated promptly, serious tissue damage, such as foot ulcers, amputation,
4 and even death, may occur.^{10,11} Studies have shown that early screening and detection of peripheral
5 neuropathy can not only slow down the DPN process, but also effectively prevent DFU.¹² Therefore,
6
7 early screening and treatment of DPN is very important.
8
9

10
11
12 At present, the screening value of 10g monofilament (10g-MF), Vibration perception threshold
13 (VPT), and 128Hz tuning fork in DPN has been widely recognized.¹³ Compared with VPT and
14 128Hz tuning forks, 10g-MF is the most widely used screening tool because it is more simple,
15 objective, and easy to carry, although it requires a calibration facility to confirm that the vertical
16 pressure of the monofilament used when bending is 10g.¹⁴⁻¹⁶ Commercially available 10g-MF
17 devices exhibit significant variability within and between devices of different manufacturers and
18 their actual bending force varies widely from their designated 10g value. When used they have a
19 short service life where the instrument is within 10% of their initial bending force which is not
20 usually the stated 10g of force.^{17,18} Meanwhile, medical personnel are required to be trained before
21 using the device, and screening is limited to hospitals or clinics. For clinics and communities in
22 remote areas, medical personnel may lack the device or the training to screen patients for DPN,
23 resulting in a missed opportunity for patients to receive the best treatment. In recent years, Dr.
24 Rayman proposed the Ipswich Touch Test (IPTT), which only requires the physician's index finger.
25 During this test, the patient is required to close their eyes while the physician lightly rests their finger
26 on each of the patient's first, third, and fifth toes for 1 to 2 seconds. Patients are instructed to respond
27 with a "yes" when they feel the physician's touch. Compared with the current methods, IPTT
28 requires no equipment, is more convenient and effective, and can be performed by doctors, nurses,
29 and even family caregivers after training.¹⁹ IPTT can be applied to inpatients, outpatients,
30 community patients, self-monitoring patients at home, and to areas lacking more advanced
31 equipment.^{20,21} Currently, IPTT has been applied in the United Kingdom, Spain, Brazil, and Saudi
32 Arabia,^{19,22-26} and was approved by the American Diabetes Association in 2015.²⁰ The 2019
33 guidelines of the International Working Group on the Diabetic Foot also suggest that IPTT should
34 be used for DPN screening in patients with diabetes in the absence of 10g-MF.²⁷ Although these
35 studies have achieved satisfactory results, they have not been widely promoted and applied globally.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Previous studies have reported differences in the results of the screening value of DPN. However,
4
5 neither a meta-analysis nor a systematic review has been conducted on the screening value of IPTT.
6
7

8 In this study, we aimed to conduct a comprehensive and systematic literature review to
9
10 systematically evaluate the potential screening value of IPTT in DPN, and provide evidence and
11
12 guidance for the clinical application value of IPTT.
13
14

15 **METHODS**

16
17
18 The Joanna Briggs Institute (JBI) protocol²⁸ has been registered with PROSPERO, the International
19
20 Prospective Register of Systematic Reviews hosted by the Centre for Reviews and Dissemination
21
22 (Registration Number is CRD (42020168420). We followed the Preferred Reporting Items for
23
24 Systematic Reviews and Meta-Analyses (PRISMA)²⁹.
25
26

27 **Data Sources and Searches**

28
29 We systematically searched PubMed, Embase, Cochrane Library, Web of Science, China National
30
31 Knowledge Infrastructure (CNKI), Wanfang Data, Chinese Biomedical Literature Database (CBM)
32
33 for reports published before April 16, 2020. For included studies with insufficient data, we emailed
34
35 the authors to ask if they would provide data for our study. With this strategy, we combined search
36
37 terms for applied technique (Ipswich touch test, touch test, IPTT) and disease (Diabetic peripheral
38
39 neuropathy, diabetic foot, diabetic foot ulcer, Diabetes Mellitus, diabetic complications). The study
40
41 design and published language were not limited. In addition, we conducted a manual search,
42
43 including searching through conference papers and gray literature, and the references of all included
44
45 studies were examined. All search strategies were determined by multiple pre-searches, and the
46
47 search formulas were adjusted according to the characteristics of each database. A detailed search
48
49 strategy is provided in “Supplementary files 1”. All analyses were based on previously published
50
51 studies; thus, no ethical approval and patient consent were required.
52
53

54 **Inclusion and Exclusion Criteria**

55
56
57 Previously published studies were included in this meta-analysis if: (1) the study examined the
58
59 screening accuracy of the IPTT test for detecting DPN; (2) all the research subjects were patients
60

1
2
3 with diabetes, and; (3) IPTT was included as an index test. Studies were excluded from the meta-
4 analysis if the studies had incomplete data sets or were other than original reports
5 (commentaries/reviews). The age, sex, region, and race of the subjects were not restricted. The
6 published language was not limited.
7
8
9

10 11 12 **Data Extraction and Quality Assessment**

13
14
15 We imported initial search records from databases into NoteExpress V3.2.0.7535 literature
16 management software. Two reviewers independently screened titles and abstracts of all the included
17 literature, following the inclusion and exclusion criteria. After screening the abstract, the full text
18 was read in detail. Any discrepancies were resolved by discussion. The following information was
19 extracted from the eligible studies: study characteristics (author, publication year, study period,
20 country, reference standard, setting, operators), participant characteristics (sample number, range),
21 and outcome indicators (sensitivity, specificity, true positive number (TP), false positive number
22 (FP), false negative number (FN), true negative number (TN)). Missing data were supplemented by
23 contacting authors wherever possible.
24
25
26
27
28
29
30
31
32
33

34 The quality of the included studies was assessed using the Quality Assessment of Diagnostic
35 Accuracy Studies (QUADAS), it is a methodological quality assessment scale, and includes 14
36 items³⁰. Quality items were weighted equally with 1 point awarded for each of the 14 items. The
37 quality score was then calculated by summing the points awarded for each question (maximum sum
38 14). This score was then normalized by dividing the sum by the highest score of the listed studies,
39 thereby ranking the studies from 1 down to a minimum of 0.³¹ Data extraction and quality assessment
40 was performed independently by two reviewers. Differences were reconciled through discussion
41 until a consensus was reached on the item in question.
42
43
44
45
46
47
48
49
50

51 **Data Synthesis**

52
53
54 We calculated sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio
55 (NLR) and DOR, a value of pooled PLR greater than 10 and of pooled NLR less than 0.1 were noted
56 as providing convincing diagnostic evidence. For each summary statistic, a 95% confidence interval
57
58
59
60

(95% CI) was computed, and the sensitivity, specificity, PLR, NLR, DOR and corresponding 95% CI were obtained using the quality effects model under the split component synthesis method framework.^{32,33} Relevant studies have proven that the quality effects model is superior to the traditional random effects model.³⁴⁻³⁶ The quality scores were used to redistribute inverse variance weights based on study deficiencies via the quality effects model,^{37,38} and analyses were conducted using Stata, version 15.1 (Stata Corp, College Station, TX).

Since the number of studies included affects the Q test, we used the I^2 statistic to evaluate the magnitude of heterogeneity since the value of the I^2 statistic will not change with the number of studies included and the results of heterogeneity test are more reliable, An $I^2 \geq 50\%$ indicates the existence of significant heterogeneity.^{39,40} Publication bias was assessed with Doi plots and Luis Furuya-Kanamori (LFK) index, the Doi plot uses a rank-based measure (Z score) of precision (instead of the standard error) and plots it against the effect size, it can visualize asymmetry, and the LFK index quantifies the extent of Doi plot asymmetry by averaging half of the sum of the Z score plus the normalized effect size across the meta-analysis, which can detect and quantify the asymmetry in the Doi plots. The closer the value of the LFK index is to zero, the more symmetrical the Doi plot.⁴¹ LFK index values outside the interval of -1 and +1 are deemed consistent with asymmetry.⁴¹ Related studies have shown that these methods can markedly improve the ability of researchers to detect bias in a meta-analysis.⁴¹

Patient and public involvement

Since the data in this study were all from previously published studies, patients and the public were not involved in this research.

RESULTS

Study Selection

Our initial search resulted in a total of 441 records: 437 from database searching and four records from manual searches of references. After duplicates were removed, 242 records were identified, and 220 records were excluded as irrelevant. After reading the full-text articles, 7 studies met the

1
2
3 inclusion criteria (Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses
4 (PRISMA) flow diagram.). Two studies were excluded for lacking necessary data for meta-analysis.
5
6 Finally, five studies with 6 datasets were included in the final meta-analysis, involving a total of
7
8 1162 patients.²²⁻²⁶
9
10

11 12 **Characteristics and Quality of the Included Studies** 13

14
15 The characteristics of the included studies are presented in Table 1. The 7 studies included a total of
16
17 1,510 participants with diabetes and were published between 2011 and 2020.^{19,22-27} To explore the
18
19 accuracy of IPTT in DPN screening, 10g-MF, VPT, NDS, pin prick, 128Hz tuning fork, and ankle
20
21 reflex were used as the reference standard. The research setting included homes of patients, clinics,
22
23 care centers, and outpatient centers, and the assessors included doctors, nurses, and family
24
25 caregivers.
26

27
28 We assessed the methodological quality of the studies using QUADAS. The assessment results
29
30 of the research methodological quality of each study are presented in Figures 2.⁴²
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Basic characteristics of the included studies.

Study	Year	Country	n	Setting	Operators	Quality score(Qi)	Reference standard	TP	FP	FN	TN	Se(%)	Sp (%)
Sharma ²²	2012	UK	130	home	families	0.074	10g-MF	24	4	6	96	80.0	96.0
Sharma ²³	2014	UK	331	home	families	0.714	10g-MF	65	15	18	233	78.3	93.9
				clinic	doctors/ nurses	0.786	10g-MF	67	9	16	239	81.2	96.4
Amal Madanat ²⁴	2015	Saudi Arabia	351	care centers	doctors/ nurses	0.357	10g-MF	29	6	28	288	51.0	98.0
							VPT	48	24	9	270	85	92
							NDS	30	9	27	285	53	97
							10g- MF	4	30	1	65	80.0	68.0
I.S, Basir ²⁵	2020	Spain	100	care centers	doctors/ nurses	0.429	Pin prick	4	1	11	84	80.0	88.0
							Tuning fork 128Hz	2	3	69	26	40.0	27.0
							Ankle reflex	1	4	2	93	20.0	97.0
Dutra ²⁶	2020	Brasilia	250	outpatient centre	doctors/ nurses	0.643	10g-MF	30	5	6	209	83.3	97.7
Rayman ¹⁹	2011	UK	265	clinic	-	-	VPT	-	-	-	-	76.0	90.0
Bowling ²⁷	2012	UK	83	clinic	doctors/ nurses	-	VPT	-	-	-	-	100	96.6
							NDS	-	-	-	-	100	90.3

Se, Sensitivity; Sp, Specificity

Screening Accuracy

In the included studies, the researchers used a variety of different test methods as the standard to observe the sensitivity and specificity of IPTT for screening for DPN, such as 10g-MF, VPT, NDS, tuning fork 128Hz, and ankle reflex. The differences in the sensitivity and specificity of IPTT obtained by using different test methods as reference standards are presented. In general, when 10g-MF and VPT were used as reference standards, the sensitivity and specificity of IPTT were relatively high. For the 5 studies comprising 6 data pools that used 10g-MF as the reference standard, the sensitivity ranged from 51.0% - 83.3%, and the specificity ranged from 68.0 - 98.0%.²²⁻²⁶ For the 3 studies that used VPT as a reference standard, the sensitivity ranged from 76.0 - 100.0%, and the specificity ranged from 90.0 - 96.6%. Using neuropathy disability scores (NDS) as the reference standard, the sensitivity of IPTT to be 0.53, and the specificity to be 0.97. Compared with the pin prick, the sensitivity and specificity of IPTT were 0.8 and 0.88, respectively.²⁴ Compared with 128Hz tuning fork, the sensitivity and specificity of IPTT were only 0.4 and 0.27, respectively.²⁵ Compared with ankle reflex, IPTT had a sensitivity of 0.2 and a specificity of 0.97 (Table 1).²⁵

Meta-analysis Results Using 10g-MF as the Reference Standard

Screening Accuracy

In the literature we retrieved, there were a total of five studies with IPTT as the target test and 10g-MF as the reference standard.²²⁻²⁶ Among these five studies, one study contained two datasets because it was conducted at the patient's homes and in the clinic.²² Therefore, six datasets were included to evaluate the overall effect of IPTT in the screening of DPN.²²⁻²⁶ The combined sensitivity and specificity were 0.77 (95% CI 0.69–0.84) and 0.96 (95% CI 0.93–0.98), respectively.

The results show I - squared is 40.5%. In addition, the DOR was 75.24(39.90-141.89). The SROC analysis for the studies yielded an overall weighted area under the curve of 0.897(0.86-0.92) (Figure 3; Supplementary Files 2; Table 2).

Table 2. Meta-analysis of screening accuracy under the quality effect model

Variables	Se (95% CI)	Sp (95% CI)	PLR (95% CI)	NLR (95% CI)	DOR (95% CI)	AUC (95% CI)
Pooled value	0.77(0.69-0.84)	0.96(0.93-0.98)	18.06 (10.75-30.36)	0.24(0.17-0.35)	75.24(39.90-141.89)	0.897(0.86-0.93)

Se, Sensitivity; Sp, Specificity; CI: Confidence Interval.

Publication Bias

Minor asymmetry was present in the Doi plot and the results of the LFK index also suggested minor negative asymmetry of the Doi plot (LFK index =-1.68). The findings might provide unequivocal evidence for publication bias, implying that studies with negative or equal outcomes are lacking. However, these findings might also be attributable to chance, given the few number of studies included in the analyses (Figure 4).

DISCUSSION

DPN is the most important risk factor for the occurrence of DFU and one of the more common chronic complications associated with diabetes. However, it is often ignored. Once the patient develops DPN, it is likely to cause diabetic foot ulcers, gangrene, and even amputation, and many patients experience numbness and tingling in their limbs. Early identification of DPN can greatly reduce the burden of chronic diseases on society. In this study, we systematically reviewed the relevant literature on the identification of DPN by IPTT. A total of 7 studies were included, involving 1,510 participants with diabetes to explore the value of IPTT screening. Previous studies have disputed the diagnostic value of IPTT, mainly due to the use of different test methods, such as VPT, NDS, pinprick, tuning fork 128Hz, and ankle reflex, as the reference standard, compared with NDS, acupuncture, 128Hz tuning fork, and ankle reflex, IPTT has higher screening accuracy when 10g-MF and VPT were used as the reference standard.^{10,19,20} Basir et al. observed that when the 128Hz tuning fork was used as a reference standard, the sensitivity and specificity of IPTT were only 40% and 27%, respectively. This may be due to the lower predictive level of the tuning fork compared to the monofilament. However, Miller et al observed that combining a tuning fork with a monofilament would result in a more effective evaluation.²¹ Regarding the quality of the current

1
2
3 studies, some studies lacked rigor in study design, such as the interval between target tests and
4 unclear reference standard tests, and most studies failed to describe the reference methods in detail.
5
6
7 The overall quality of the included studies was rated as low to medium quality.
8
9

10 Compared with 10g-MF, the results of the meta-analysis found the combined sensitivity and
11 specificity of IPTT to be 0.77(95%CI 0.69-0.84) and 0.96(95%CI 0.93-0.98), respectively, and the
12
13 AUC to be 0.897(95%CI 0.86-0.93). The results indicated that IPTT cannot well rule out DPN, but
14
15 can confirm DPN effectively. In our study, the PLR and the NLR were 18.06 (95% CI 10.75-30.36)
16
17 and 0.24(95% CI 0.17-0.35), respectively, it means that the ratio of the true positive rate to the false
18
19 positive rate of IPTT screening for DPN is 18.06, and the ratio of false negative rate to true negative
20
21 rate is 0.24. A DOR equal to 1 indicated that a test was unable to distinguish between patients with
22
23 or without the disease. Our study yielded a DOR value of 75.24(95%CI 39.90-141.89), indicating
24
25 that IPTT had good discrimination in patients with DPN. We also found that when VPT is used as
26
27 a reference standard, IPTT shows a higher sensitivity and specificity. At present, 10g-MF and VPT
28
29 are the most widely used clinical screening methods for DPN. Basir et al. explored the accuracy of
30
31 using IPTT in detecting neuropathy in patients with small fiber and large fiber neuropathy, and
32
33 found that there was no difference between IPTT and the gold standard, indicating that IPTT can be
34
35 used as an alternative assessment method.²⁵ Therefore, the current evidence shows that IPTT has a
36
37 high screening value for DPN and can be used for preliminary screening of DPN in areas lacking
38
39 more advanced equipment.
40
41
42
43
44
45

46 Heterogeneity is an important factor of this meta-analysis.⁴³ In this study, we chose the quality
47
48 effects model because it has been proven to be significantly better than the traditional random effects
49
50 model and fixed effects model and attempts bias adjustment. When 10g-MF was used as the
51
52 reference standard, the I^2 was only 40.5%, indicating there was good consistency among the five
53
54 studies included in the meta-analysis. In addition, the existence of heterogeneity may be related to
55
56 other factors, such as differences in research methodology, operators, or other factors. Due to the
57
58 limited number of included studies, we did not analyze the heterogeneity through subgroup analysis
59
60

1
2
3 in this study. In terms of methodology, although we systematically and comprehensively studied the
4 current evidence of using IPTT for DPN screening, the number of original studies is very limited,
5 and the current conclusions are based only on these seven studies. Therefore, caution should be
6 taken when generalizing these results. About using other test methods as the reference standard
7 (except 10g-MF), we only described the relevant indicators as there were too few related studies to
8 merge data. In addition, despite our efforts to conduct a thorough search for eligible studies,
9 symmetry was detected. Thus, the pooled effect may have been overstated, this was also one of the
10 limitations of our study.
11
12
13
14
15
16
17
18
19

20 Studies have shown that routine foot examinations and rapid risk stratification are often difficult
21 to implement in busy primary care institutions. Additionally, the lack of awareness of standardized
22 testing for DPN amongst healthcare professionals is a concern, which may be due to a shortage of
23 material and personnel resources in primary care institutions. This is concerning because identifying
24 foot neuropathy and the patients at risk for ulceration has been shown to prevent the incidence of
25 foot ulcers.⁴⁴⁻⁴⁶ IPTT is a new method for screening DPN that does not require any tools and can be
26 carried out after minimal training. It is not affected by time, venue, or its operators.²⁰ The
27 advancement of IPTT is of great significance for the early screening of DPN to impede the
28 progression of diabetic foot ulcers, as it can be used to quickly and reliably screen and manage
29 patients at high risk for ulceration, especially in remote areas or places lacking screening tools.^{47,48}
30 Kerry et al. reported that in the first year IPTT was introduced as a screening tool, the relative risk
31 reduction (RRR) of DFU was 64%, and in the second year, the RRR was 70%, thereby reducing
32 hospital-acquired foot ulcers in patients with diabetes by two-thirds and negating the excess risk
33 associated with diabetes.^{20,49-51} Meanwhile, it can effectively improve patients' disease-related
34 knowledge, which plays a positive role in promoting the self-management of patients and their
35 families. At the same time, IPTT has a predictive effect on diabetic foot ulcers and reduces delays
36 in patient visits.²¹ However, more thorough studies are needed for verification.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Most of the literature on IPTT is focused on screening tests and some commentary-type studies,
56 and the number of studies is small. These studies were carried out in the United Kingdom, Spain,
57 Brazil, and Saudi Arabia, and although they achieved satisfactory results, have not been carried out
58
59
60

1
2
3 globally. However, it has not been applied in developing countries such as China. China is a country
4 with a large population and a relatively small number of medical personnel, especially in some
5 remote areas where the medical allocation is in short supply. In these areas, the application and
6 promotion of IPTT can effectively alleviate the challenges associated with the allocation of medical
7 resources and play an important role in the management of patients with diabetes. IPTT has also
8 recently been approved for use in a number of countries.^{21,24-26} However, Kempegowda et al.
9 reported that 88.4% of physicians are not familiar with IPTT. Therefore, we suggest that IPTT be
10 further promoted amongst physicians and medical staff, especially in remote areas and areas lacking
11 screening tools.³⁶ Future large-scale, high-quality, and multi-center studies on populations of
12 different ethnicities will verify the potential applicability of IPTT alone or in combination with other
13 DPN screening methods.
14
15
16
17
18
19
20
21
22
23
24
25

26 CONCLUSIONS

27
28
29 In summary, IPTT shows a high degree of agreement with commonly used screening tools for DPN,
30 it can be used clinically, especially in remote areas and primary medical institutions, and self-
31 monitoring patients. This is also the first meta-analysis of the accuracy of IPTT identification of
32 DPN, and a systematic quantitative evaluation of its screening value, which can provide evidence
33 for the clinical application of IPTT in the future. However, due to a limited number of studies of
34 low or medium quality from limited geographical areas, more high-quality studies are needed to
35 promote more effective screening practices.
36
37
38
39
40
41
42
43
44

45 Acknowledgments

46
47
48 Thanks all authors and patients of the previous research for providing data for our article.
49
50

51 Funding sources

52
53
54 This research was supported by the Natural Science Foundation of Hunan Province (Grant No.
55 2019JJ80087)
56
57
58

59 Author contributions

1
2
3 ZN conducted the database search, screened and extracted data for the meta-analysis, prepared
4 extracted data for the procedures, and had primary responsibility in writing this article. LXY, ZJ
5 and ZF performed statistical analysis and contributed to article screening, data collection and
6 extraction. XJC, ZQH, and LJH contributed to the discussion and editing. XJC and CJR critically
7 revised the draft manuscript. All authors contributed toward data analysis, drafting and critically
8 revising the paper and agree to be accountable for all aspects of the work.
9
10
11
12
13
14

15 16 **Competing interests**

17
18
19 The authors state that they have no conflict of interest.
20
21

22 **Patient consent for publication**

23
24
25 Not required. All analyses were conducted based on previously published studies. Accordingly,
26 there was no patient or public involvement in this study. Ethical approval was not required since it
27 was a systematic review of the published literature.
28
29
30
31

32 **Data availability statement**

33
34
35 Data are available in a public, open access repository. There are no data in this work. Data are
36 available on reasonable request. Data can be obtained from a third party and are not publicly
37 available. All data relevant to the study are included in the article or uploaded as supplementary
38 information.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Cho NH, Shaw JE, Karuranga S et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018;138:271-281.
2. Armstrong DG, Boulton A, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* 2017;376(24):2367-2375.
3. Banik PC, Barua L, Moniruzzaman M et al. Risk of diabetic foot ulcer and its associated factors among Bangladeshi subjects: a multicentric cross-sectional study. *BMJ Open*. 2020 Feb 28;10(2):e034058.
4. Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. *Curr Neurol Neurosci Rep*. 2014;14(8):473.
5. Strachan MW, Reynolds RM, Marioni RE, et al. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. *Nat Rev Endocrinol*. 2011;7(2):108-14.
6. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep* 2019;19(10):86.
7. Hicks CW, Selvarajah S, Mathioudakis N, et al. Trends and determinants of costs associated with the inpatient care of diabetic foot ulcers. *J Vasc Surg* 2014;60(5):1247-54.
8. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017;40(1):136-154.
9. Javed S, Hayat T, Menon L, et al. Diabetic peripheral neuropathy in people with type 2 diabetes: too little too late. *Diabet Med* 2020;37(4):573-579.
10. Feldman EL, Nave KA, Jensen TS, et al. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. *Neuron* 2017;93(6):1296-1313.
11. Zhang Y, Li N, Zhao Y, Fan D. Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnts (PDN-SCOPE): protocol for a multicentre cross-sectional registry study of clinical characteristics and treatment in China. *BMJ Open*. 2019 Apr 8;9(4):e025722.
12. Carls GS, Gibson TB, Driver VR, et al. The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. *J Am Podiatr Med Assoc* 2011;101(2):93-115.
13. International Diabetes Federation. Diabetic foot screening pocket chart. Brussels: IDF 2017. <https://www.idf.org/our-activities/advocacy-aware>.
14. Standards of Medical Care in Diabetes-2017: Summary of Revisions. *Diabetes Care* 2017;40(Suppl 1):S4-5.
15. Craig AB, Strauss MB, Daniller A, et al. Foot sensation testing in the patient with diabetes: introduction of the quick & easy assessment tool. *Wounds* 2014;26(8):221-31.
16. Slater RA, Koren S, Ramot Y, et al. Interpreting the results of the Semmes-Weinstein monofilament test: accounting for false-positive answers in the international consensus on the diabetic foot protocol by a new model. *Diabetes Metab Res Rev* 2014;30(1):77-80.
17. Lavery LA, Lavery DE, Lavery DC, et al. Accuracy and durability of Semmes-Weinstein

- 1
2
3 monofilaments: what is the useful service life? *Diabetes Res Clin Pract* 2012;97(3):399-404.
- 4
5 18. Spruce MC, Bowling FL. Diabetic foot screening: new technology versus 10g monofilament.
6 *Int J Low Extrem Wounds* 2012 2012-03-01;11(1):43-8.
- 7
8 19. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to
9 identify inpatients with diabetes at risk of foot ulceration. *Diabetes Care* 2011;34(7):1517-8.
- 10
11 20. Vas PR, Sharma S, Rayman G. Distal Sensorimotor Neuropathy: Improvements in Diagnosis.
12 *Rev Diabet Stud* 2015;12(1-2):29-47.
- 13
14 21. Miller JD, Carter E, Shih J, et al. How to do a 3-minute diabetic foot exam. *J Fam Pract*
15 2014;63(11):646-56.
- 16
17 22. Sharma S, Kerry C, Rosier J, et al. The Ipswich Touch Test (IpTT): Screening for diabetic
18 neuropathy at home. *Diabet Med* 2012;29:20.
- 19
20 23. Sharma S, Kerry C, Atkins H, et al. The Ipswich Touch Test: a simple and novel method to
21 screen patients with diabetes at home for increased risk of foot ulceration. *Diabet Med*
22 2014;31(9):1100-3.
- 23
24 24. Madanat A, Sheshah E, Badawy E, et al. Utilizing the Ipswich Touch Test to simplify screening
25 methods for identifying the risk of foot ulceration among diabetics: The Saudi experience. *Prim*
26 *Care Diabetes* 2015;9(4):304-6.
- 27
28 25. Basir IS, Syam Y, Yusuf S, et al. Accuracy of Ipswich Touch Test (IpTT) to detect small fiber
29 neuropathy and large fiber neuropathy as a risk factor of diabetic foot ulcers in public health
30 centers. *Enferm Clin* 2020;30 Suppl 2:308-12.
- 31
32 26. Dutra L, Moura MC, Do PF, et al. Is it possible to substitute the monofilament test for the
33 Ipswich Touch Test in screening for peripheral diabetic neuropathy? *Diabetol Metab Syndr*
34 2020;12:27.
- 35
36 27. Schaper NC, van Netten JJ, Apelqvist J, et al. IWGDF Editorial Board. Practical Guidelines on
37 the prevention and management of diabetic foot disease (IWGDF 2019 update). *Diabetes Metab*
38 *Res Rev.* 2020 Mar;36 Suppl 1:e3266. doi: 10.1002/dmrr.3266. PMID: 32176447.
- 39
40 28. Atlantis E, Cochrane B. The association of dietary intake and supplementation of specific
41 polyunsaturated fatty acids with inflammation and functional capacity in chronic obstructive
42 pulmonary disease: a systematic review *Int J Evid Based Healthc* 2016;14(2):53-63.
- 43
44 29. McInnes M, Moher D, Thombs BD, et al. Preferred Reporting Items for a Systematic Review
45 and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. *JAMA*
46 2018;319(4):388-96.
- 47
48 30. Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality
49 assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res*
50 *Methodol.* 2003 Nov 10;3:25. doi: 10.1186/1471-2288-3-25.
- 51
52 31. Foxlee N, Stone JC, Doi SA. A comparison of univariate and bivariate models in meta-analysis
53 of diagnostic accuracy studies. *Int J Evid Based Healthc.* 2015 Mar;13(1):28-34.
- 54
55 32. The Nordic Cochrane Centre (2014) Review manager. Cochrane Collab 1-43.
- 56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
33. Doi SA, Barendregt JJ, Khan S, et al. Advances in the meta-analysis of heterogeneous clinical trials II: The quality effects model. *Contemp Clin Trials*. 2015 Nov;45(Pt A):123-9.
34. Doi SAR, Furuya-Kanamori L. Selecting the best meta-analytic estimator for evidence-based practice: a simulation study. *Int J Evid Based Healthc*. 2020 Mar;18(1):86-94.
35. Furuya-Kanamori L, Kostoulas P, Doi SAR. A new method for synthesizing test accuracy data outperformed the bivariate method. *J Clin Epidemiol*. 2021 Apr;132:51-58.
36. Doi SAR, Furuya-Kanamori L, Thalib L, et al. Meta-analysis in evidence-based healthcare: a paradigm shift away from random effects is overdue. *Int J Evid Based Healthc*. 2017 Dec;15(4):152-160.
37. Doi SA. Evidence synthesis for medical decision making and the appropriate use of quality scores. *Clin Med Res*. 2014 Sep;12(1-2):40-6.
38. Stone JC, Glass K, Munn Z, et al. Comparison of bias adjustment methods in meta-analysis suggests that quality effects modeling may have less limitations than other approaches. *J Clin Epidemiol*. 2020 Jan;117:36-45.
39. Wang D, Mou ZY, Zhai JX, et al. Application of Stata software to test heterogeneity in meta-analysis method. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2008 Jul;29(7):726-9.
40. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I² index? *Psychol Methods*. 2006 Jun;11(2):193-206.
41. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. *Int J Evid Based Healthc*. 2018 Dec;16(4):195-203.
42. Furuya-Kanamori L, Xu C, Hasan SS, et al. Quality versus Risk-of-Bias assessment in clinical research. *J Clin Epidemiol*. 2021 Jan;129:172-175.
43. Lo K, Stephenson M, Lockwood C. Analysis of heterogeneity in a systematic review using meta-regression technique. *Int J Evid Based Healthc* 2019 Jun;17(2):131-142.
44. Bowling FL, Abbott CA, Harris WE, et al. A pocket-sized disposable device for testing the integrity of sensation in the outpatient setting. *Diabet Med* 2012;29(12):1550-2.
45. Kempegowda P, Saeed MA. Foot STAMP (Short-burst Teaching Aimed at Medical Professionals): Impact of 'shortburst' teaching on the knowledge regarding the Ipswich Touch Test. *Diabet Med* 2016;33:134.
46. Bailey TS, Yu HM, Rayfield EJ. Patterns of foot examination in a diabetes clinic. *Am Med J* 1985;78(3):371-4.
47. Baker N. An alternative to a 10-g monofilament or tuning fork? Two new, simple, easy-to-use screening tests for determining foot ulcer risk in people with diabetes. *Diabet Med* 2012;29(12):1477-9.
48. O'Loughlin A, Dinneen SF. ACP Journal Club: the Ipswich Touch Test at home had 78% sensitivity and 94% specificity for detecting loss of foot sensation. *Ann Intern Med* 2015;162(4):C10.
49. Kerry C. VPRR. Reduction in the incidence of hospital acquired foot pressure ulcers in people

1
2
3 with diabetes. *Diabetic Med* 2015;SUPPL. 1(32):26.

4 50. Kerry CD, Sharma S, Rayman G. Reduction in hospital-acquired diabetes foot lesions using the
5 Ipswich Touch Test (IpTT). *Diabetic Med* 2013;30:141-2.

6
7 51. Madanat A, Sheshah E, Badawy E, et al.: "P.R. Vas, S. Sharma, G. Rayman, Utilizing the
8 Ipswich Touch Test to simplify screening methods for identifying the risk of foot ulceration
9 among diabetics: comment on the Saudi experience. *Prim Care Diabetes* 2015;9(5):401-2.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only





Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.



	Q1	Q10	Q11	Q12	Q13	Q14	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9
Sharma2012	?	?	?	?	?	?	?	?	?	?	?	?	?	?
Sharma2014a	-	+	+	+	-	?	+	+	+	+	+	+	+	-
Sharma2014b	+	+	+	+	-	?	+	+	+	+	+	+	+	-
Madanat2015	+	?	?	+	?	?	+	+	?	?	?	?	+	-
Basir2020	+	?	?	+	-	?	+	+	?	?	?	+	+	-
Dutra2020	+	?	?	+	?	+	+	+	?	+	+	?	+	+

Figure 2. Quality assessment of the included studies




Figure 3. Sensitivity and specificity of IPTT in the diagnosis of DPN

255x185mm (72 x 72 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Doi plot and LFK index.

255x185mm (72 x 72 DPI)

1
2
3
4 (Simplices, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
5 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
6
7 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract])
8
9

10 #5 Search: "Diabetes Complications"[Mesh] Sort by: Most Recent

11
12
13 #6 Search:

14
15
16 #7 Search: "Diabetic Foot"[Mesh] Sort by: Most Recent

17
18
19 #8 Search: (((Foot, Diabetic[Title/Abstract]) OR (Diabetic Feet[Title/Abstract])) OR (Feet,
20 Diabetic[Title/Abstract])) OR (Foot Ulcer, Diabetic[Title/Abstract])
21
22

23
24 #9 Search: ((ipswich touch test[Title/Abstract]) OR (touch test[Title/Abstract])) OR
25 (IPTT[Title/Abstract])
26
27

28
29 #10 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((((Diabetes[Title/Abstract]) OR
30 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
31 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))))
32 OR ("Diabetic Neuropathies"[Mesh])) OR (((
33 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
34 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
35 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
36 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
37 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
38 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
39 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
40 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR
41 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
42 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
43 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
44 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
5
6 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
7
8 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicis[Title/Abstract])) OR
9
10 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicis,
11
12 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
13
14 (Simplicis, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
15
16 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
17
18 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
19
20 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
21
22 Complications[Title/Abstract]) OR (Diabetes Related Complications[Title/Abstract])) OR
23
24 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
25
26 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
27
28 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
29
30 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
31
32 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract]) OR (Diabetic
33
34 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
35
36 Diabetic[Title/Abstract]))

37
38 #11 Search: (((((((("Diabetes Mellitus"[Mesh]) OR (((Diabetes[Title/Abstract]) OR
39
40 (Diabetes, Type 2[Title/Abstract])) OR (Type 2 Diabetes Mellitus[Title/Abstract])) OR
41
42 (Diabetes Mellitus, Type II[Title/Abstract])) OR (Diabetes Mellitus, Type I[Title/Abstract]))
43
44 OR ("Diabetic Neuropathies"[Mesh])) OR (((((((((((((((((((((((((((((((((((((((Diabetic
45
46 Neuropathy[Title/Abstract]) OR (Neuropathies, Diabetic[Title/Abstract])) OR (Neuropathy,
47
48 Diabetic[Title/Abstract])) OR (Diabetic Autonomic Neuropathy[Title/Abstract])) OR
49
50 (Autonomic Neuropathies, Diabetic[Title/Abstract])) OR (Diabetic Autonomic
51
52 Neuropathies[Title/Abstract])) OR (Neuropathies, Diabetic Autonomic[Title/Abstract])) OR
53
54 (Autonomic Neuropathy, Diabetic[Title/Abstract])) OR (Neuropathy, Diabetic
55
56 Autonomic[Title/Abstract])) OR (Symmetric Diabetic Proximal Motor
57
58 Neuropathy[Title/Abstract])) OR (Asymmetric Diabetic Proximal Motor
59
60 Neuropathy[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathy[Title/Abstract])) OR

1
 2
 3
 4 (Asymmetric Polyneuropathies, Diabetic[Title/Abstract])) OR (Asymmetric Polyneuropathy,
 5 Diabetic[Title/Abstract])) OR (Diabetic Asymmetric Polyneuropathies[Title/Abstract])) OR
 6 (Polyneuropathies, Diabetic Asymmetric[Title/Abstract])) OR (Polyneuropathy, Diabetic
 7 Asymmetric[Title/Abstract])) OR (Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 8 Mononeuropathies[Title/Abstract])) OR (Mononeuropathies, Diabetic[Title/Abstract])) OR
 9 (Mononeuropathy, Diabetic[Title/Abstract])) OR (Diabetic Mononeuropathy
 10 Simplex[Title/Abstract])) OR (Diabetic Mononeuropathy Simplicies[Title/Abstract])) OR
 11 (Mononeuropathy Simplex, Diabetic[Title/Abstract])) OR (Mononeuropathy Simplicies,
 12 Diabetic[Title/Abstract])) OR (Simplex, Diabetic Mononeuropathy[Title/Abstract])) OR
 13 (Simplicies, Diabetic Mononeuropathy[Title/Abstract])) OR (Diabetic
 14 Polyneuropathy[Title/Abstract])) OR (Diabetic Polyneuropathies[Title/Abstract])) OR
 15 (Polyneuropathies, Diabetic[Title/Abstract])) OR (Polyneuropathy, Diabetic[Title/Abstract]))
 16 OR ("Diabetes Complications"[Mesh])) OR (((((((Diabetes-Related
 17 Complications[Title/Abstract])) OR (Diabetes Related Complications[Title/Abstract])) OR
 18 (Diabetes-Related Complication[Title/Abstract])) OR (Diabetic
 19 Complications[Title/Abstract])) OR (Diabetic Complication[Title/Abstract])) OR
 20 (Complications of Diabetes Mellitus[Title/Abstract])) OR (Diabetes Mellitus
 21 Complication[Title/Abstract])) OR (Diabetes Mellitus Complications[Title/Abstract])) OR
 22 ("Diabetic Foot"[Mesh])) OR (((Foot, Diabetic[Title/Abstract])) OR (Diabetic
 23 Feet[Title/Abstract])) OR (Feet, Diabetic[Title/Abstract])) OR (Foot Ulcer,
 24 Diabetic[Title/Abstract])) AND (((ipswich touch test[Title/Abstract])) OR (touch
 25 test[Title/Abstract])) OR (IPTT[Title/Abstract]))

Embase Search Strategy

#1 'diabetes mellitus'/exp

#2 'diabetes, type 2':ab,ti OR 'type 2 diabetes mellitus':ab,ti OR 'diabetes mellitus, type ii':ab,ti OR 'diabetes mellitus, type 1':ab,ti

#3 #1 OR #2

1
2
3
4 #4 'diabetic neuropathy'/exp
5

6 #5 'diabetic neuropathy':ab,ti OR 'neuropathies, diabetic':ab,ti OR 'neuropathy, diabetic':ab,ti
7
8 OR 'diabetic autonomic neuropathy':ab,ti OR 'autonomic neuropathies, diabetic':ab,ti OR
9
10 'autonomic neuropathy, diabetic':ab,ti OR 'diabetic autonomic neuropathies':ab,ti OR
11
12 'neuropathies, diabetic autonomic':ab,ti OR 'neuropathy, diabetic autonomic':ab,ti OR
13
14 'symmetric diabetic proximal motor neuropathy':ab,ti OR 'asymmetric diabetic proximal
15
16 motor neuropathy':ab,ti OR 'diabetic asymmetric polyneuropathy':ab,ti OR 'asymmetric
17
18 polyneuropathies, diabetic':ab,ti OR 'asymmetric polyneuropathy, diabetic':ab,ti OR 'diabetic
19
20 asymmetric polyneuropathies':ab,ti OR 'polyneuropathies, diabetic asymmetric':ab,ti OR
21
22 'polyneuropathy, diabetic asymmetric':ab,ti OR 'diabetic mononeuropathy':ab,ti OR 'diabetic
23
24 mononeuropathies':ab,ti OR 'mononeuropathies, diabetic':ab,ti OR 'mononeuropathy,
25
26 diabetic':ab,ti OR 'diabetic mononeuropathy simplex':ab,ti OR 'diabetic mononeuropathy
27
28 simplices':ab,ti OR 'mononeuropathy simplex, diabetic':ab,ti OR 'mononeuropathy simplices,
29
30 diabetic':ab,ti OR 'simplex, diabetic mononeuropathy':ab,ti OR 'simplices, diabetic
31
32 mononeuropathy':ab,ti OR 'diabetic polyneuropathy':ab,ti OR 'diabetic polyneuropathies':ab,ti
33
34 OR 'polyneuropathies, diabetic':ab,ti OR 'polyneuropathy, diabetic':ab,ti
35

36 #6 #4 OR #5
37

38
39 #7 'diabetic complication'/exp
40

41
42 #8 'diabetes complication':ab,ti OR 'diabetes-related complications':ab,ti OR 'diabetes
43
44 related complications':ab,ti OR 'diabetes-related complication':ab,ti OR 'diabetic
45
46 complications':ab,ti OR 'diabetic complication':ab,ti OR 'complications of diabetes
47
48 mellitus':ab,ti OR 'diabetes mellitus complication':ab,ti OR 'diabetes mellitus
49
50 complications':ab,ti
51

52
53 #9 #7 OR #8
54

55
56 #10 'diabetic foot'/exp
57

58
59 #11 'diabetic foot':ab,ti OR 'diabetic feet':ab,ti OR 'feet, diabetic':ab,ti OR 'foot ulcer,
60

1
2
3
4 diabetic':ab,ti OR 'foot ulcer':ab,ti
5

6
7 #12 #10 OR #11
8

9
10 #13 #3 OR #6 OR #9 OR #12
11

12
13 #14 'ipswich touch test':ab,ti OR 'touch test':ab,ti OR 'iptt':ab,ti
14

15
16 #15 #13 AND #14
17

18 **Cochrane Library Search Strategy**

19
20
21 #1 MeSH descriptor: [Diabetes Mellitus] explode all trees 31055
22

23
24 #2 (Diabetes):ti,ab,kw OR (Diabetes, Type 2):ti,ab,kw OR (Type 2 Diabetes
25 Mellitus):ti,ab,kw OR (Diabetes Mellitus, Type II):ti,ab,kw OR (Diabetes Mellitus, Type 1)

26
27 #3 MeSH descriptor: [Diabetic Neuropathies] explode all trees
28

29
30
31 #4 (Diabetic Neuropathy):ti,ab,kw OR (Neuropathies, Diabetic):ti,ab,kw OR (Neuropathy,
32 Diabetic):ti,ab,kw OR (Diabetic Autonomic Neuropathy):ti,ab,kw OR (Autonomic
33 Neuropathies, Diabetic):ti,ab,kw OR (Autonomic Neuropathy, Diabetic):ti,ab,kw OR
34 (Diabetic Autonomic Neuropathies):ti,ab,kw OR (Neuropathies, Diabetic
35 Autonomic):ti,ab,kw OR (Neuropathy, Diabetic Autonomic):ti,ab,kw OR (Symmetric
36 Diabetic Proximal Motor Neuropathy):ti,ab,kw OR (Asymmetric Diabetic Proximal Motor
37 Neuropathy):ti,ab,kw OR (Diabetic Asymmetric Polyneuropathy):ti,ab,kw OR (Asymmetric
38 Polyneuropathies, Diabetic):ti,ab,kw OR (Asymmetric Polyneuropathy, Diabetic):ti,ab,kw OR
39 (Diabetic Asymmetric Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic
40 Asymmetric):ti,ab,kw OR (Polyneuropathy, Diabetic Asymmetric):ti,ab,kw OR (Diabetic
41 Mononeuropathy):ti,ab,kw OR (Diabetic Mononeuropathies):ti,ab,kw OR
42 (Mononeuropathies, Diabetic):ti,ab,kw OR (Mononeuropathy, Diabetic):ti,ab,kw OR
43 (Diabetic Mononeuropathy Simplex):ti,ab,kw OR (Diabetic Mononeuropathy
44 Simplicis):ti,ab,kw OR (Mononeuropathy Simplex, Diabetic):ti,ab,kw OR (Mononeuropathy
45 Simplicis, Diabetic):ti,ab,kw OR (Simplex, Diabetic Mononeuropathy):ti,ab,kw OR
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(Simplices, Diabetic Mononeuropathy):ti,ab,kw OR (Diabetic Polyneuropathy):ti,ab,kw OR
 (Diabetic Polyneuropathies):ti,ab,kw OR (Polyneuropathies, Diabetic):ti,ab,kw OR
 (Polyneuropathy, Diabetic):ti,ab,kw 3653

#5 MeSH descriptor: [Diabetes Complications] explode all trees

#6 (Diabetes-Related Complications):ti,ab,kw OR (Diabetes Related
 Complications):ti,ab,kw OR (Diabetes-Related Complication):ti,ab,kw OR (Diabetic
 Complications):ti,ab,kw OR (Diabetic Complication):ti,ab,kw OR (Complications of Diabetes
 Mellitus):ti,ab,kw OR (Diabetes Mellitus Complication):ti,ab,kw OR (Diabetes Mellitus
 Complications)

#7 MeSH descriptor: [Diabetic Foot] explode all trees

#8 (Diabetic Feet):ti,ab,kw OR (Feet, Diabetic):ti,ab,kw OR (Foot Ulcer, Diabetic)

#9 (ipswich touch test):ti,ab,kw OR (touch test):ti,ab,kw OR (IPTT)

#10 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8

#11 #9 AND #10

Web of Science Search Strategy

#1 TS=(Diabetes Mellitus or Diabetes or Diabetes, Type 2 or Type 2 Diabetes Mellitus or
 Diabetes Mellitus, Type II or Diabetes Mellitus, Type 1)

#2 TS=(Diabetic Neuropathies or Diabetic Neuropathy or Neuropathies, Diabetic or
 Neuropathy, Diabetic or Diabetic Autonomic Neuropathy or Autonomic Neuropathies,
 Diabetic or Autonomic Neuropathy, Diabetic or Diabetic Autonomic Neuropathies or
 Neuropathies, Diabetic Autonomic or Neuropathy, Diabetic Autonomic or Symmetric
 Diabetic Proximal Motor Neuropathy or Asymmetric Diabetic Proximal Motor Neuropathy or
 Diabetic Asymmetric Polyneuropathy or Asymmetric Polyneuropathies, Diabetic or
 Asymmetric Polyneuropathy, Diabetic or Diabetic Asymmetric Polyneuropathies or

1
2
3
4 Polyneuropathies, Diabetic Asymmetric or Polyneuropathy, Diabetic Asymmetric or Diabetic
5 Mononeuropathy or Diabetic Mononeuropathies or Mononeuropathies, Diabetic or
6 Mononeuropathy, Diabetic or Diabetic Mononeuropathy Simplex or Diabetic
7 Mononeuropathy Simplicis or Mononeuropathy Simplex, Diabetic or Mononeuropathy
8 Simplicis, Diabetic or Simplex, Diabetic Mononeuropathy or Simplicis, Diabetic
9 Mononeuropathy or Diabetic Polyneuropathy or Diabetic Polyneuropathies or
10 Polyneuropathies, Diabetic or Polyneuropathy, Diabetic)

11
12
13 #3 TS=(Diabetes Complications or Diabetes Complication or Diabetes-Related
14 Complications or Diabetes Related Complications or Diabetes-Related Complication or
15 Diabetic Complications or Diabetic Complication or Complications of Diabetes Mellitus or
16 Diabetes Mellitus Complication or Diabetes Mellitus Complications)

17
18 #4 TS=(Diabetic Foot or Foot, Diabetic or Diabetic Feet or Feet, Diabetic or Foot Ulcer,
19 Diabetic)

20
21 #5 #4 OR #3 OR #2 OR #1

22
23 #6 TS=(ipswich touch test or touch test or IPTT)

24
25 #7 #6 AND #5

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 **China National Knowledge Infrastructure (CNKI) Search Strategy**

42
43 检索式 A: (((主题=糖尿病 或者 题名=糖尿病 或者 v_subject=中英文扩展(糖尿病)
44 或者 title=中英文扩展(糖尿病)) 或者 (主题=糖尿病足 或者 题名=糖尿病足 或者
45 v_subject=中英文扩展(糖尿病足) 或者 title=中英文扩展(糖尿病足))) 或者 ((主题=糖
46 尿病周围神经病变 或者 题名=糖尿病周围神经病变 或者 v_subject=中英文扩展(糖尿
47 病周围神经病变) 或者 title=中英文扩展(糖尿病周围神经病变)) 或者 (主题=糖尿病并
48 发症 或者 题名=糖尿病并发症 或者 v_subject=中英文扩展(糖尿病并发症) 或者 title=
49 中英文扩展(糖尿病并发症)))) 并且 (((((主题=中英文扩展(touch test) 或者 题名=中
50 英文扩展(touch test) 或者 v_subject=touch test 或者 title=touch test) 或者 (主题=中
51 英文扩展(Ipswich Touch Test) 或者 题名=中英文扩展(Ipswich Touch Test) 或者

v_subject=Ipswich Touch Test 或者 title=Ipswich Touch Test)) 或者 ((主题=伊普斯维奇触摸测试 或者 题名=伊普斯维奇触摸测试 或者 v_subject=中英文扩展(伊普斯维奇触摸测试) 或者 title=中英文扩展(伊普斯维奇触摸测试)) 或者 (主题=中英文扩展(IPTT) 或者 题名=中英文扩展(IPTT) 或者 v_subject=IPTT 或者 title=IPTT))) 或者 ((关键词=轻触 或者 keyword=中英文扩展(轻触)) 或者 (关键词=轻触测试 或者 keyword=中英文扩展(轻触测试)))) 或者 ((题名=触摸 或者 Title=中英文扩展(触摸)) 或者 (题名=触摸测试 或者 Title=中英文扩展(触摸测试)))) (模糊匹配)

Wan Fang Database Search Strategy

主题:((糖尿病)+主题:(糖尿病足)+主题:(糖尿病周围神经病变)+全部:(糖尿病并发症))*主题:((touch test)+主题:(IPTT)+主题:(Ipswich Touch Test)+全部:(伊普斯维奇触摸测试))

China Biology Medicine disc (CBM) Search Strategy

- #1 "糖尿病"[不加权:扩展]
- #2 "糖尿病足"[常用字段:智能]
- #3 "糖尿病神经病变"[常用字段:智能]
- #4 "糖尿病并发症"[常用字段:智能]
- #5 (#4) OR (#3) OR (#2) OR (#1)
- #6 "touch"[常用字段:智能] AND "test"[常用字段:智能]
- #7 "IPTT"[常用字段:智能]
- #8 "Ipswich"[常用字段:智能] AND "Touch"[常用字段:智能] AND "Test"[常用字段:智能]
- #9 "伊普斯维奇触摸测试"[常用字段:智能]
- #10 "轻触"[常用字段:智能]

1
2
3
4 #11 "轻触测试"[常用字段:智能]
5

6 #12 "触摸"[常用字段:智能]
7
8

9 #13 "触摸测试"[常用字段:智能]
10
11

12 #14 (#13) OR (#12) OR (#11) OR (#10) OR (#9) OR (#8) OR (#7) OR (#6)
13
14

15 #15 (#14) AND (#5)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 . diagma tp fp fn tn, qe(qi)

5
6 Input form: TP FP FN TN assumed
7 Note: Weights are from Doi's quality effects model
8 Studies included: 6
9 Participants included: 1493
10 Prevalence of disease: 19.7%
11 Heterogeneity (I-squared): 40.5%
12 Pub bias (LFK index): -1.7, minor asymmetry
13

	Estimate	95% Conf. Interval	
Sens	.77	.688	.836
Spec	.957	.928	.975
LR+	18.064	10.748	30.358
LR-	.24	.167	.346
DOR	75.239	39.898	141.887
AUC	.897	.863	.923

14
15
16
17
18
19
20
21
22
23
24
25 The results of sensitivity and specificity of IPTT in the diagnosis of DPN
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	2
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6-7
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	6-7



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6-7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6-7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7-8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7,9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9-10
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10-12
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12-13
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2
For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>